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Abstract 
 
While many studies have looked at the role of the high-risk E6 and E7 proteins in the 
development of cancer, few have looked at their role in the progression from productive 
infection to LSIL and HSIL+, which can occur soon after infection in the absence of 
integration.  
I analyze isogenic NIKS lines containing HPV16 episomes, which have previously been 
shown to have LSIL- or HSIL-like phenotypes in raft culture. In monolayer culture, the 
HSIL-like cells proliferate more than the LSIL-like cells, and I have found that this 
appears to be due to the activity of the E6 protein. In contrast, the E7 protein is only 
able to drive proliferation when the cells are cultured without serum. At confluence, the 
HSIL-like cells divide to form increasingly small cells in a monolayer, whilst the LSIL-
like cells tend to stratify, like the parental line. This indicates that the LSIL- and HSIL-
like cells respond differently to cell density. Furthermore I see a similar fast-growing 
phenotype with an E6 mutant that is unable to bind p53, suggesting that the effect on 
proliferation is independent of p53 degradation. Increasing or decreasing the levels of 
E6 leads to LSIL-like cells now having a more HSIL-like growth phenotype or vice 
versa, respectively. Analysis of contact inhibition signaling pathways shows that the 
levels of active Notch are significantly higher in the LSIL-like cells. Additionally, I 
have observed what may be a novel truncated form of active Notch. 
My results suggest that in productive infections any elevation in cell proliferation in the 
basal cells may be dependent on E6, while E7-stimulated cell cycle entry may be 
limited to the suprabasal cells. Aberrant expression of E6 level can then further promote 
proliferation by overcoming cellular contact inhibition pathways and this contributes to 
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Chapter 1: Introduction 
 
1.1 Introduction to papillomaviruses 
Papillomaviruses (PVs) are small, non-enveloped viruses, consisting of a circular 
double-stranded DNA genome within an icosahedral capsid of approximately 55 nm in 
diameter (Howley, 1996). They infect many mammals, including ungulates and 
cetaceans, birds (de Villiers et al., 2004, Bernard et al., 2010) and some reptiles (Herbst 
et al., 2009). PVs are very host-tropic with interspecies transmissions being rare, 
suggesting that these viruses have been co-evolving with their specific hosts through 
time (Bernard et al., 2006). PVs infect mucosal and cutaneous epithelial tissues, through 
abrasions or microwounds (Roberts et al., 2007), and the viral life cycle is tightly linked 
to the differentiation program of host cells and utilizes the entire epithelium (Favre et 
al., 1997). The production of new virions is restricted to the most apical layers of the 
tissue (reviewed in (Doorbar et al., 2012)) where cells are most differentiated.  Infection 
by PVs can cause a whole spectrum of diseases in their hosts, ranging from 
asymptomatic infections to skin warts, including Verruca vulgaris (common wart), 
Verruca plantaris (plantar wart) and Verruca plana (flat wart), Condyloma acuminata 
(genital wart) and cancers (reviewed in (Mammas et al., 2009)). The vast majority of 
infections in humans are sub-clinical and for this reason it has been estimated that the 
rate of incidence is much higher than the reporting rate 
(http://virus.stanford.edu/papova/HPV.html). 
 
1.2 Classification of papillomaviruses 
Papillomaviruses are a member of the Papillomaviridae family, which consists of about 
200 different types of viruses (Bernard et al., 2010). When PVs were first discovered 
they were classified into the family of Papoviridae, with polyomaviruses, due to their 
structural similarities and small, double-stranded DNA genome. However, it was found 
that PVs are quite different in terms of the organization of their genomes and also 
transcriptional regulation, leading to the categorization into their own taxonomic family. 
 
The organization of PVs into their respective genera is based on the homology of the L1 
open reading frame (ORF). L1 is the major capsid protein of the virus and is the most 
conserved of all PV ORFs. All virus types within one genus generally share more than 
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60 % nucleotide sequence identity within the L1 gene, while types within the same 
species have 71-89 % identity to each other (de Villiers et al., 2004).  
 
1.3 Human papillomaviruses (HPVs) 
Over 160 different types of HPVs have been described in 5 out of 24 PV genera (Alpha, 
Beta, Gamma, Mu and Nu). HPVs can infect a variety of epithelial tissues of the cervix, 
vulva, anus, penis and the oral cavity, larynx, esophagus, tonsils and tracheobronchial 
tree (reviewed in (zur Hausen, 2009, Graham, 2010)). HPVs are additionally sub-
divided into two broad categories; low-risk viruses are associated with predominantly 
benign disease while high-risk types can cause cancer (Laimins, 1993, Favre et al., 
1997, Walboomers et al., 1999). 
 
The genus that is most medically significant is Alpha as it comprises the high-risk HPV 
types that are implicated in, among other things, genital cancers (zur Hausen, 2009), 
such as HPV16 and 18. Additionally, this genus also encompasses some low-risk types, 
for instance HPV6 and 11, which cause genital warts (Longworth and Laimins, 2004) 
and HPV2 and 4, which are associated with common warts. Beta HPVs, for example 
HPV5 and 8, infect cutaneous epithelia and are generally associated with mild skin 
lesions. HPVs of the Gamma, Mu and Nu genera, including HPV65, 1 and 41, 
respectively, also infect mainly cutaneous sites and cause benign lesions such as 
verrucas (Pfister, 1992). 
 
1.4 HPVs and disease 
Studies have shown that there is a correlation between the severity of disease caused by 
different types of HPV and the degree to which they can immortalize cells in culture. 
Many low-risk types such as HPV6 and 11 are unable to immortalize primary epithelial 
cells while several high-risk types, such as HPV16, 18 and 31 can (Schlegel et al., 1988) 
(Pecoraro et al., 1989) (Woodworth et al., 1989).  
 
1.4.1 Low-risk HPVs  
As mentioned, low risk-HPVs are generally not linked to cancer but can cause a range 
of different warts and benign symptoms. However, in individuals that have autoimmune 
disorders, are immunosuppressed or suffer from the inherited disease epidermodysplasia 
verruciformis (EV) (Harwood and Proby, 2002, Pfister, 2003), low-risk 
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papillomaviruses can cause more severe disease or cancer. In the case of EV patients, 
HPVs of type 5 and 8 from the beta genus can cause non-melanoma skin cancer. Some 
low-risk HPVs of the alpha genus, predominantly HPV6 and 11 (Gissmann et al., 1982, 
Mounts et al., 1982), are also implicated in the development of recurrent respiratory 
papillomatosis (RRP) (Major et al., 2005). This rare condition, found mainly in 
children, is brought about by HPV infection in the larynx. Without treatment it can be 
potentially fatal as papillomas can spread to the lungs and obstruct airways (Derkay, 
1995, Hsueh, 2009). 
 
1.4.2 High-risk HPVs 
Twelve HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) are categorized in 
the high-risk category. Additionally, there are other types that are classed as high-risk 
due to sequence similarities with the cancer-causing types (Schiffman et al., 2005) 
although for many there is no clinical data as of yet to prove that they promote 
malignancy. One such type for which some data exist is cutaneous HPV8, which has 
been linked to carcinogenesis in immunosuppressed patients (O'Shaughnessy et al., 
2007a) and also shown to increase the rate of tumorigenesis in transgenic mice (Schaper 
et al., 2005).  
 
The cancer type most often associated with these high-risk HPVs is that of the cervix, 
with over 99 % of all cervical cancer cases being brought about by the virus (zur 
Hausen, 2002). There are about 530000 new cervical cancer cases worldwide every year 
with about 275000 deaths (WHO/ICO Information Centre on Human Papilloma Virus 
(HPV) and Cervical Cancer; http://www.who.int/hpvcentre/en/), making it the second 
most common cancer associated with women worldwide. HPV16 and 18 alone are 
involved in bringing about over 70 % of these (Schiffman et al., 2007), with the other 
high-risk HPV types accounting for the rest (Bosch et al., 1995, Walboomers et al., 
1999).  
 
HPV is predominantly transmitted sexually, though it can also be spread through casual 
physical contact and perinatal vertical transmission (Mammas et al., 2009). When 
transmitted sexually, infection generally occurs soon after sexual activity is initiated, 
with the highest prevalence associated with women below the age of 25. However it has 
been shown that while HPV prevalence decreases with age, there seems to be a second 
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peak after the age of 55 (Herrero et al., 2000), which may be caused by the reactivation 
of latent viral infections. The vast majority of infections are cleared rapidly, with one 
study showing that 70 % of women in their late teens and early 20s showed no signs of 
HPV DNA within 12 months after the first detection (Ho et al., 1998) and 80 % of 
women after 18 months. Most cervical cancer cases occur in women that are in their late 
40s or early 50s (reviewed in (Baseman and Koutsky, 2005)), and it is thought that they 
arise from persistent viral infection for years or even decades. Although the mechanism 
is not yet clearly understood, high-risk HPVs associated with cancer have evolved the 
ability to persist at some sites of infection, with the development of disease requiring 
the prolonged aberrant expression of the viral oncogenes E6 and E7 (Schiffman and 
Kjaer, 2003). 
 
The majority of cervical cancers occur in the transformation zone of the cervix (Arends 
et al., 1998, Herfs et al., 2013). This is where the ectocervical squamous epithelium and 
the endocervical columnar cells meet to form the squamo-columnar junction (Burghardt 
and Ostor, 1983) and is an area of metaplastic change. It is thought that the reason why 
this zone is highly susceptible to HPV infection is because the basal layer of the 
epithelium is more easily accessible to the virus and also because immunosurveillance 
may be perturbed compared to other areas of the cervix (Giannini et al., 2002). 
 
1.4.3 Cervical screening 
The lag-phase between infection with HPV and progression to cancer allows for screening 
of the cervix for HPV-associated lesions. George Papanicolaou first described the cervical 
smear, or Papanicolaou (Pap) smear test, in 1941 and it involves swabbing the surface of 
the cervix to remove cells that can be assessed for signs of neoplasia. Many developed 
countries have population-wide screening programs where women are tested on a regular 
basis for the presence of HPV and dysplasia. These programs are highly effective which 
means that over 80 % of all cervical cancer cases arise in the developing world (Jones, 
1999), where such programs are not commonly in place. However, the Pap smear test is not 
100 % efficient, predominantly because its overall format has not changed in the last 70 
years and evaluation of cervical cells still relies on DNA testing and also subjective 
cytopathological analysis. New screening methods are being developed at the moment with 
some approaches using multiparameter testing that makes use of a whole panel of 
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biomarkers associated with neoplastic progression (Baldwin et al., 2003, Middleton et al., 
2003, Doorbar, 2007).  
 
1.4.4 Prophylactic vaccines against HPVs 
In recent years, two prophylactic vaccines have been developed, based on work using 
virus-like particles (VLPs) expressing only the main structural L1 protein of HPV 
(Zhou et al., 1991, Kirnbauer et al., 1992) that stimulated high levels of neutralizing 
antibodies (Brown et al., 2001, Evans et al., 2001, Harro et al., 2001) and T-cell 
responses (Emeny et al., 2002) upon injection in human volunteers. Cervarix 
(GlaxoSmithKline Biologicals) is a bivalent vaccine and protects against HPV16 and 
18, associated with 70 % of cervical cancers (Schiffman et al., 2007), while Gardasil 
(Merck & Co. Inc.) is quadrivalent and protects additionally against HPV6 and 11, 
which are the two types associated with 90 % of genital warts (Schiffman et al., 2007). 
While these vaccines have 98 and 100 % efficacy in clinical trials, respectively 
(Garland et al., 2007, Paavonen et al., 2009), they do not protect against any other high-
risk HPV types associated with cancer. Moreover, the lag in the onset of cervical cancer 
after HPV infection means that it is likely that the reduction in mortality rates will not 
be significant for 30-50 years (reviewed in (Stanley, 2012)). Furthermore, a recent study 
in Scotland has shown that public knowledge of HPV and its precise link to cervical 
cancer, which is essential for good coverage of the UK vaccination program, is low in 
educated young males and females (McCusker et al., 2013). Hence, further public 
health campaigns may be necessary to promote the vaccine in the general population. 
Additionally, due to the high cost of both vaccines, and also the fact that both involve 
multiple vaccinations, the coverage across developing countries will likely be very low 
(Agosti and Goldie, 2007). 	  
1.5 Morphological classification of HPV-associated lesions 
The development of cervical cancer is preceded by a number of well-defined neoplastic 
stages. There are two grading systems; one was developed in 1960 and is based on 
histological analysis of a lesion and uses the cervical intraepithelial neoplasia (CIN) 
nomenclature. The second one, the Bethesda system, was devised in 1988 (Solomon, 
1989) and refers to the risk of the lesion progressing to cancer. 
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According to the first system, a CIN1 is the mildest form of a lesion, with only one third 
of the epithelium considered dysplastic, a CIN2 is more severe with up to two-thirds of 
the epithelium showing signs of dysplasia while in a CIN3 the epithelium is fully 
dysplastic (Richart, 1973, Woodman et al., 2007). In the newer Bethesda system a low-
grade squamous intraepithelial lesion (LSIL) is equivalent to a CIN1 while a high-grade 
squamous intraepithelial lesion (HSIL) comprises both CIN2 and 3. 
 
In normal cervical tissue, cells within the basal layer are small and uniformly sized and 
can undergo normal stratification and differentiation within the suprabasal layers. In 
low-grade lesions (LSILs), cells in the lower third are generally disorganized and lack 
polarity. Additionally, in the basal layer nuclei are variable in terms of their shape and 
size, and the presence of koilocytes is common in the upper parts of the epithelium. This 
is associated with a delay in the onset of the normal differentiation program of cells. In 
high-grade lesions (HSILs), nuclear abnormalities are more widespread and many more 
cells have lost polarity. Moreover, differentiation is even further delayed. Within the 
HSIL classification, a CIN2 lesion will show overall less abnormality than a CIN3. 
Generally in a CIN3 lesion, cells have completely lost their potential to differentiate. 
 
1.6 HPV16 genome 
HPV16 contains an 8 kb double-stranded DNA genome encoding eight ORFs (Fig 1.1). 
The genome is divided into three major regions separated by two polyadenylation, or 
poly(A), sites; the early, late and long control regions (LCR) (Zheng and Baker, 2006). 
The early promoter (PE), also called p97, lies within the LCR and controls expression of 
the E1, E2, E4, E5, E6 and E7 genes. The L1 and L2 structural proteins are expressed 
from the late, differentiation-dependent promoter (PL), or p670, which lies within the E7 
ORF (Smotkin and Wettstein, 1986, Hummel et al., 1992, Grassmann et al., 1996). This 
promoter can also be used to express E1, E2, E4 and E5 in certain stages of 
differentiation due to its precise location within the genome (Wang et al., 2009, 
Johansson and Schwartz, 2013). The LCR of the viral genome lies immediately 
upstream of the E6 ORF and, in addition to the p97 promoter, also contains several cis-
acting regulatory elements that are involved in viral genome replication and 
transcription. The binding sites for several cellular transcription factors have been 
identified, including Sp1, AP-1, Oct-1 and YY1 (Gloss and Bernard, 1990, Chong et al., 
1991, Morris et al., 1993, Lace et al., 2009) which can up- and down-regulate 
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transcription. There are also glucocorticoid responsive elements (GREs) that, upon 
binding glucocorticoid, can bring about an increase in replication (Piccini et al., 1997). 
 
The LCR also contains four viral E2 protein binding sites (E2BS1-4) (Androphy et al., 
1987). E2 can have both positive and negative regulatory effects on viral transcription 
(Spalholz et al., 1985, Phelps and Howley, 1987, Bernard et al., 1989, Romanczuk et 
al., 1990, Bouvard et al., 1994) and it has been suggested that these differential effects 
may be determined by the physical state of the viral genome within the cells (Bechtold 
et al., 2003, Schmidt et al., 2005) and also the exact levels of the E2 protein (Steger and 
Corbach, 1997). Additionally, the E2BS3 is located next to viral origin of replication, 
which is also found in the LCR (Chiang et al., 1992). When E2 binds to this site it can 
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Figure 1.1: The HPV16 genome 
The HPV16 genome is a circular, double-stranded DNA genome approximately 8 kb in 
size and consists of eight ORFs. These encode for six non-structural early proteins, E1, 
E2, E4, E5, E6 and E7, and two structural late proteins, L1 and L2. The early proteins 
are expressed from the early promoter, p97, and a subset of these (E1, E2, E4 and E5) 
along with the two late genes are expressed from the late promoter, p670. There are also 
two polyadenylation sites, PAE and PAL. The LCR, long control region, is located 
upstream of the first early ORF and contains not only the viral origin of replication but 
also cis-acting regulatory elements, such as binding sites for cellular transcription 
factors and the viral E2 protein, that are involved in regulating viral transcription and 




Chapter	  1:	  Introduction	  
	   27	  
1.7 HPV16 transcription 
The study of HPV16 transcripts has been done mostly in W12 cells (Doorbar et al., 
1990, Milligan et al., 2007), which are keratinocytes isolated from a LSIL cervical 
lesion containing HPV16 episomes (Stanley et al., 1989). Due to the episomal nature of 
the viral genomes, these cells are much more suited to studying viral transcripts than 
cervical cancer cell lines such as CaSki and SiHa, which contain only integrated 
genomes and do not support the viral life cycle.  
 
All HPV16 genes are transcribed as polycistronic messages from either p97 or p670. 
The p97 early promoter is regulated by cellular transcription factors binding to their 
respective sites and also by E2 (Zheng and Baker, 2006). It has been suggested that 
transcription from the early promoter is quite constant throughout the viral life cycle 
while the p670 late promoter controls transcription within a certain window of time and 
relies on cellular differentiation to be activated (Grassmann et al., 1996, Spink and 
Laimins, 2005). The activation of the late promoter in addition to the early one leads to 
high levels of E2 transcripts. This causes an inhibition of p97 (McBride, 2008, Thierry, 
2009) leading to abrogation of E6 and E7 expression, which allows cells to commit to 
their terminal differentiation program and thereby enables the virus to finish the late 
stages of its life cycle (Johansson and Schwartz, 2013).  
 
In addition to these two well-characterized HPV16 promoters, evidence suggests that 
other promoters exist throughout the genome. One study reported the location of a 
promoter upstream of p97, within the E6 ORF at nucleotide 542, that controls 
transcription of a monocistronic E7 message (Glahder et al., 2003). While this specific 
E7 mRNA is not plentiful, translation initiation from this message is very abundant. 
Another group (Hansen et al., 2010) has found an additional promoter within the E6 
ORF, even further upstream at nucleotide 441. These authors reported that both of these 
lesser-known promoters (at nucleotides 542 and 441) are involved in regulating gene 
expression in differentiaing cells. A different study has suggested that another HPV16 
promoter can be found at the start of the E1 ORF, however more evidence for this is 
needed (Milligan et al., 2007). This same group and two others (Doorbar et al., 1990, 
Ozbun and Meyers, 1997) have also found a promoter at the start of the E4 ORF. It has 
been suggested that L1 is the first mRNA transcribed from this promoter. This may 
allow efficient accumulation of the L1 capsid protein and hence packaging of the new 
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virions (Graham, 2010). A further promoter at the start of the E5 ORF, involved in 
transcribing L2 mRNA (Milligan et al., 2007), may complement the function of the 
promoter described above. 
 
The viral polycistronic messages are heavily regulated by constitutive and alternative 
splicing which give rise to various different mRNA products (Zheng and Baker, 2006). 
One example of this is the E6/E7 polycistronic or bicistronic transcripts. E6 from high-
risk HPVs, such as HPV16, contains an intron and several alternative splice sites to 
generate various E6 products. In addition to full-length E6 there are at least two 
truncated species, E6*I and II, that share the N-terminal sequence until the splice 
junction, lack the intron and have distinct C-terminal truncations (Schneider-Gadicke 
and Schwarz, 1986, Smotkin et al., 1989). It has been suggested that E6* mRNAs are 
more abundant than full-length E6 in cervical carcinoma cells (Smotkin et al., 1989, 
Cornelissen et al., 1990) as this favors the expression of E7 (Zheng et al., 2004, Tang et 
al., 2006). The mechanism regulating E6 splicing to bring about the alternate transcripts 
has not been well characterized. A recent study has shown that the presence of 
epidermal growth factor (EGF) promotes full-length E6 while its absence brings about 
higher levels of E6* and E7 (Rosenberger et al., 2010). This suggests a mechanism that 
regulates splicing in differentiating cells, as EGF, also shown by Rosenberger et al., is 
generally only present at very low levels in areas of the epithelium where differentiation 
occurs. The E6*I species can be translated into a truncated protein (Schneider-Gadicke 
et al., 1988) although its exact role and function remains to be elucidated.  
 
1.8 HPV16 viral life cycle 
Due to their clinical importance, a big proportion of work on HPV has been carried out 
using the high-risk types. As mentioned earlier, the virus utilizes the full epithelium to 
complete its life cycle (Fig 1.2). This means that not only the precise levels but also the 
exact patterns of viral gene expression are tightly regulated. They are very different in 
the basal layer, where HPVs first infect and cells are actively cycling, as compared to 
the upper layers where cells are differentiating. The life cycle is divided into early and 
late events; early events include mainly viral infection and the establishment of 
episomes within the host cell nucleus while late events include genome amplification, 
expression of the structural capsid proteins, assembly of new virions and their 
subsequent release from the cell. 
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Figure 1.2: The HPV life cycle 
HPVs infect the basal layer of the epithelium through microwounds. In basal cells the 
virus is established within the nucleus in an episomal form at a low copy number. The 
p97 early promoter brings about expression of E1, E2, E6 and E7, which are required 
for early life cycle events. As cells are pushed out of the basal layer they remain in 
cycle, where they normally do not cycle, due to the activities of the E6 and E7 
oncoproteins. As cells are pushed further up the epithelium they exit the cell cycle and 
begin to differentiate which leads to activation of the p670 late promoter. At this point 
expression of E1, E2, E4 and E5 is augmented to enable viral genome amplification. 
Once this is completed, L1 and L2 are expressed and package the viral DNA to make 
new infectious virions that are released from cells when the surface of the epithelium is 













Figure 2 Organization of the HPV genome and the virus life cycle
(A) The HPV16 genome (7904 bp) is shown as a black circle with the early (p97) and late (p670) promoters marked by arrows. The six early ORFs [E1, E2, E4 and
E5 (in green) and E6 and E7 (in red)] are expressed from either p97 or p670 at differ nt stages during epithelial cell differentiati n. The late ORFs [L1 a d L2
(in yellow)] are also expressed from p670, following a change in splicing patterns, and a shift in polyadenylation site usage [from early polyadenylation site (PAE)
to late polyadenylation site (PAL)]. All the viral genes are encoded on one strand of the double-stranded circular DNA genome. The long control region (LCR from
7156–7184) is enlarged to allow visualization of the E2-binding sites and the TATA element of the p97 promoter. The location of the E1- and SP1-binding sites is
also shown. (B) The key events that occur following infection are shown diagrammatically on the left. The epidermis is shown in colour with the underlying dermis
being shown in grey. The different cell layers present in the epithelium are indicated on the left. Cells in the epidermis expressing cell cycle markers are shown with
red nuclei. The appearance of such cells above the basal layer is a consequence of virus infection, and in particular, the expression of the viral oncogenes, E6 and
E7. The expression of viral proteins necessary for genome replication occurs in cells expressing E6 and E7 following activation of p670 in the upper epithelial layers
(cells shown in green with red nuclei). The L1 and L2 genes (yellow) are expressed in a subset of the cells that contain amplified viral DNA in the upper epithelial
C© 2006 The Biochemical Society
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1.8.1 Infection of the basal layer of the epithelium 
HPVs must gain entry into basal cells of the epithelium. The cervical transformation 
zone is the place must commonly associated with HPV16-dependent neoplasia as this 
area is where ectocervical squamous epithelium and the endocervical columnar cells 
meet (Burghardt and Ostor, 1983). It seems that this area is highly prone to infection 
due to the basal layer of the epithelium being easily accessible to the virus and also 
because immunosurveillance may be low (Giannini et al., 2002). 
 
Within a normal epithelium, cells in the basal layer are the only cells that are mitotically 
active. It is generally accepted that there are two types of cells within the basal and 
adjacent suprabasal layers; epidermal stem cells and transit amplifying cells. Stem cells 
in the basal layer divide and exit their compartment to enter the first suprabasal layer, 
giving rise to transit amplifying cells (Watt, 2001, Fuchs et al., 2004). These stem cell 
daughter cells can then undergo a finite number of cell divisions before exiting the cell 
cycle and committing to the cellular terminal differentiation program (Kolly et al., 
2005). It is thought that the virus must gain entry into a stem cell so that the infection 
can persist (Schmitt et al., 1996, Egawa, 2003) but conclusive proof as to whether this is 
true does not exist. 
 
The proposed mechanism of HPV infection implicates the two capsid proteins, L1 and 
L2, in the process (Schiller et al., 2010). L1 binds to heparan sulfate proteoglycans 
located on the basement membrane that become accessible to the virus via 
microwounds in the tissue (Joyce et al., 1999). This leads to the cleavage of L2 by 
enzymes such as furin (Richards et al., 2006), which in turn allows L1 to bind to 
receptors, such as alpha-6 integrin (Evander et al., 1997), on the surface of 
keratinocytes. Subsequently the virus is internalized by endocytosis, which may involve 
both clathrin- and cavelolae-mediated pathways depending on the specific HPV type 
(Bousarghin et al., 2003).  
 
1.8.2 Early events 
 
1.8.2.1 Establishment and maintenance of HPV episomes  
After infection, the virus is uncoated and the viral genomes are established as episomes 
within the nucleus of the cell. The virus must first undergo a transient replication phase 
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to increase its own copy number before replicating along with cellular DNA and 
dividing equally into two daughter cells with every cell division (Kadaja et al., 2009). It 
is thought that the virus is maintained at a fairly constant copy number, of between 10-
200 copies (De Geest et al., 1993), in basal cells. 
 
1.8.2.2 Early proteins 
The two viral replications proteins, E1 and E2, are expressed from the early p97 
promoter to enable viral DNA replication. E2 can bind to the viral origin of replication 
and recruit the E1 helicase (Masterson et al., 1998), which in turn promotes binding of 
cellular replication proteins (Kadaja et al., 2009). It has been suggested that HPV must 
infect cells that can undergo mitosis (Pyeon et al., 2009) and that phosphorylation of 
cyclin E/CDK2 (cyclin dependent kinase 2) and cyclin A/CDK2 complexes are 
important for nuclear localization of E1 (Deng et al., 2004). Another role of E2 is to 
anchor viral genomes to mitotic chromosomes during cell division, to promote their 
equal segregation amongst daughter cells and localization to the nucleus (You et al., 
2004, Feeney and Parish, 2009). 
 
Due to the lack of sensitive detection methods it is not entirely clear which other viral 
proteins are expressed in basal cells. However, several studies in monolayer cell culture 
have shown that E6 and E7 (Thomas et al., 1999), or even just E7 (Flores et al., 2000, 
Laurson et al., 2010) or just E6 (Nicolaides et al., 2011), are important for the 
persistence of viral episomes. Therefore it seems likely that the viral oncoproteins are 
expressed from the early p97 promoter in the basal layer.  
 
1.8.2.3 Cell proliferation 
As mentioned above, in an uninfected epithelium only basal cells are mitotically active 
and when they are pushed out of the basal layer, they exit the cell cycle and commit to 
terminal differentiation. However, this is detrimental to the virus, as it relies on the host 
replication machinery to copy its own genome. Therefore, in an infected epithelium, the 
virus can bring about a delay in the onset of differentiation and push cells to cycle, even 
in suprabasal layers. This involves the expression of the viral E6 and E7 proteins, which 
can push cells into S phase (Dollard et al., 1992, Cheng et al., 1995). The most well 
characterized function of the E7 protein to enable DNA replication, is its ability to bind 
to and degrade the Rb protein (Dyson et al., 1989, Boyer et al., 1996), which causes 
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release of E2F and in turn promotes G1/S phase transition (Zerfass et al., 1995, Black 
and Azizkhan-Clifford, 1999). E6 can bind to and bring about degradation of the p53 
protein to inhibit apoptosis (Scheffner et al., 1990, Werness et al., 1990). Additionally 
high-risk E6 can also bind to and promote degradation of PDZ proteins to bring about 
epidermal hyperproliferation (Nguyen et al., 2003, Lee and Laimins, 2004).  
 
1.8.3 Late events  
While the combined activities of E6 and E7 push suprabasal cells into S phase, these 
cells must eventually stop dividing and begin their terminal differentiation program. 
This is necessary for activation of the late differentiation-dependent p670 promoter, and 
subsequent expression of the late proteins (Grassmann et al., 1996). 
 
1.8.3.1 Genome amplification 
As cells migrate closer to surface of the epithelium, the virus must amplify its own 
genome, up to several 1000-fold (Bedell et al., 1991), in preparation for packaging new 
virions. The expression of E1, E2 (Klumpp and Laimins, 1999), E4 and E5 (Hummel et 
al., 1992) from the p670 promoter is necessary to allow genome amplification to take 
place. Additionally, it has been suggested that in this stage of the life cycle, the virus 
switches to rolling circle replication that requires only a single initiation event, and that 
this mechanism contributes to the high levels of viral DNA observed (Flores and 
Lambert, 1997). 
 
In the upper layers it is known that E4 is expressed abundantly. It is first detected in the 
apical most cell layers of the epithelium that express E7 and are in S phase, and hence 
this is where the switch from early to late gene expression is proposed to occur (Peh et 
al., 2002, Middleton et al., 2003, Peh and Doorbar, 2005). Additionally, this is also 
where the first amplified viral genomes may arise (Doorbar et al., 1997). E4 has been 
shown to arrest cells in G2 phase, preventing mitotic entry (Davy et al., 2002, Davy et 
al., 2005). This is hypothesized to keep the cells in a pseudo-S phase state that enables 
amplification of the viral genomes. E7 is thought to aid in this process by inducing 
expression of the host cell replication machinery that is essential for amplifying 
genomes (Flores et al., 2000). The precise role of E5 is not entirely clear. It seems that 
E5 can promote an environment that is conducive to viral DNA replication, as well as 
increase transcription from the late promoter (Fehrmann et al., 2003). 
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1.8.3.2 Virus assembly and release 
The last stage of the viral life cycle involves packaging new infectious virions that can 
then be shed and go on to infect other cells. L1 and L2 capsid proteins are expressed, 
typically in cells that also express E4 (Peh et al., 2002), and localize to the nucleus 
(Doorbar and Gallimore, 1987, Day et al., 1998) where encapsidation of the new 
amplified viral genomes occurs. The encapsidation process may be enhanced by E2 
(Day et al., 1998, Zhao et al., 2000). As HPV is a non-lytic virus, new progeny virions 
are only released when cells at the very surface of the epithelium are shed (Bryan and 
Brown, 2001). However, the E4 protein may contribute to viral release as it can disrupt 
the keratin network of cells and make the whole epithelium more fragile (Doorbar et al., 
1991, Wang et al., 2009, McIntosh et al., 2010). To do this, E4 can bring about the 
phosphorylation and subsequent ubiquitylation of keratin in cells, in much the same 
way that is observed in response to a stress stimulus (McIntosh et al., 2010). 
 
1.8.4 Abortive infections 
As mentioned previously, HPVs can cause both high- and low-grade disease. Generally 
a low-grade squamous intraepithelial lesion (LSIL) constitutes a productive HPV 
infection, where new infectious virions are produced (reviewed in (Doorbar et al., 
2012)). In sites where a productive infection is inefficiently supported, such as in the 
cervical transformation zone, the virus can cause an abortive infection, which is 
associated with a high-grade squamous intraepithelial lesion (HSIL) (reviewed in 
(Doorbar, 2006)). In these types of lesions, progeny virions are not produced and if left 
untreated they can progress to cancer. An example of site-specific PV malignancy is the 
cottontail rabbit papillomavirus (CRPV), which can cause productive infections in its 
natural cottontail rabbit host but is associated with tumor outgrowth and cancer 
development in domestic rabbits (Hu et al., 2007). 
 
Within the HSIL classification a CIN3 describes a lesion that is more severely 
deregulated in terms of viral gene expression patterns than a CIN2 (reviewed in 
(Doorbar et al., 2012)). As a lesion becomes more high-grade, the differentiation 
program of cells is further delayed and this is associated with less, or even no, 
expression of the late proteins such as E4, L1 and L2 (Middleton et al., 2003). 
Moreover, there are high levels of the viral E6 and E7 oncoproteins. This allows cells in 
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the upper layers of the epithelium (which would be differentiating in a productive 
infection) to stay in cycle and retain their pseudo-S phase state. Aberrant expression of 
E6 and E7 predisposes cells to the accumulation of genetic changes, which further 
contribute to neoplastic progression (reviewed in (Doorbar et al., 2012)). High-grade 
disease is also associated with the integration into host chromosomes of the viral 
genomes, which is promoted by viral deregulation but at the same time promotes further 
deregulation. In vulval intraepithelial lesions (VINs) it seems that integration of HPV16 
genomes is generally associated with high levels of E7 and also AKT1 (Ekeowa-
Anderson et al., 2012). Integrated genomes usually do not express any E1 and E2 and 
hence at least some of the negative regulation of the early p97 promoter that is normally 
brought about by E2, is lost, which leads to aberrant E6 and E7 expression (Steger and 
Corbach, 1997). Integration has also been shown to correlate with an increase in E6 and 
E7 mRNA stability and higher E6 and/or E7 protein levels (Jeon and Lambert, 1995, 
Dong et al., 1994, Alazawi et al., 2002).  
 
1.9 Immune response and clearance of HPV infection 
One of the main reasons why, in some situations, an HPV infection can persist for so 
many years without being cleared by the immune system is because the virus is non-
lytic and therefore does not cause inflammation at the site of infection. Moreover, due 
to the fact that PVs infect the epithelium, neither the site of infection nor that of viral 
release are close to blood vessels or the lympathic system (Stanley, 2009). Furthermore, 
both E6 and E7 have been shown to interfere interferon (INF) signaling (Barnard and 
McMillan, 1999, Park et al., 2000, Ronco et al., 1998) and hence repress IFN-inducible 
genes (Chang and Laimins, 2000, Nees et al., 2001). 
 
Moreover both E6 and E7 can bring about a reduction in the levels of E-cadherin 
(Matthews et al., 2003, Laurson et al., 2010) which correlates with a decrease in 
antigen-presenting Langerhans cells (Hubert et al., 2005), leading to a reduction of the 
anti-viral immune response. Interestingly, several other tumor viruses including 
Hepatitis B (Liu et al., 2006) and C (Iso et al., 2005) and Epstein-Barr viruses (Fahraeus 
et al., 1992) also share this ability to suppress E-cadherin. 
 
Although the virus seems to be have evolved a number of mechanisms to avoid the 
immune system it remains to be said (as mentioned earlier) that most infections are 
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cleared rapidly, with up to 80 % of women in their late teens and early 20s showing no 
signs of HPV DNA after 18 months of initial detection (Ho et al., 1998). Additionally, 
the fact that many low-risk viruses can cause malignant disease in immunocompromised 
or immunosuppressed patients or people that have EV, shows that the immune system 
does play a pivotal role in the clearance of infection. Moreover in response to lesions of 
different grades (Coleman and Stanley, 1994) and even just the presence of the viral 
proteins E2 and E6 (Welters et al., 2003), T-cell responses have been observed. 
 
1.10 Papillomavirus models 
Studying the full HPV life cycle has proved challenging due to its dependence on the 
full stratified, differentiating epithelium. This means that although vast amounts of 
work have been done in monolayer cell cultures, from these it has not always been easy 
to infer the function of the viral proteins in the late stages of the life cycle in the upper 
layers. This means that most monolayer cultures can only be used to study the virus in 
its basal cell environment. A lot of this work has been done in keratinocytes, including 
primary foreskin keratinocytes (Thomas and Banks, 1999), immortalized foreskin 
keratinocytes (NIKS) (Flores et al., 1999) and the W12 line. To study the late stages of 
the life cycle a lot of clinical samples are used but these are not easy to come to and 
they are generally removed from patients with high-grade disease, so studying the 
productive viral life cycle is difficult. 
 
Another challenge of studying HPV is the fact that it very host-tropic and does not have 
the same effect in other species as humans. The first PV to be identified in animals was 
the cottontail rabbit PV (CRPV) (Shope and Hurst, 1933), which means that these 
rabbits have been used to study the virus for many years. CRPV can cause cutaneous 
lesions that sometimes have the capacity to progress to malignancy. Although mice 
have been used extensively to study PVs, including HPVs, it was only recently that the 
first murine papillomavirus was discovered (Ingle et al., 2011). The fact that the genetic 
backgrounds in mice can be controlled so precisely and that they have very well 
characterized immune systems, for which an extensive range of reagents are available, 
means, that now that murine PVs have been described, this laboratory model will prove 
even more useful in the coming years.  
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1.10.1 The organotypic raft culture model system 
Over the past decade the organotypic raft culture system has further facilitated the study 
of the full life cycle of PVs (Lambert et al., 2005, Wilson and Laimins, 2005). Raft 
cultures are a three-dimensional cell culture system in which keratinocytes can form a 
fully stratified and differentiated epithelium. To achieve this, keratinocytes are seeded 
on a dermal equivalent support structure made of mainly collagen and fibroblasts, thus 
mimicking a real dermis. Upon seeding on the dermal equivalent, cells are first allowed 
to grow to confluence to form a confluent basal layer and then exposed to the air and 
fed with high calcium medium to promote differentiation and stratification. After the 
rafts are harvested they can by sectioned and stained, like clinical biopsies, allowing for 
the visualization of viral and cellular gene expression patterns. Although other methods 
to induce differentiation in keratinocytes do exist, including the use of high-calcium 
medium (Hennings et al., 1980) or methylcellulose (Ruesch et al., 1998), only rafts 
enable the production of a stratified epithelium, and they have proven to be a very 
useful tool. Additionally, raft cultures have also been used for producing virions for 
infectivity studies (McLaughlin-Drubin et al., 2004). 
 
1.11 The E7 protein 
E7 is one of the viral oncoproteins and for HPV16, it is approximately 11 kDa in size. It 
can bind to several cellular proteins and its main functions are brought about by these 
interactions. E7 has been shown to immortalize keratinocytes in culture (Halbert et al., 
1991) and can cause hyperplasia in mouse epithelium (Herber et al., 1996). 
 
As described in more detail above, only cells within the basal layer of the epithelium are 
mitotically active. However, to complete its life cycle the virus needs to extend the 
S phase compartment to allow replication of its genome. The major role of E7 is to keep 
cells in cycle and delay the onset of terminal differentiation to allow the virus to 
replicate (McLaughlin-Drubin and Munger, 2009). A summary of the oncogenic 
activities of the E7 protein is shown in Figure 1.3. 
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Figure 1.3: Oncogenic activities of the HPV E7 protein 
The major mechanisms used by E7 (white boxes) to bring about cellular characteristics 
commonly associated with human tumors (black boxes) as described by Hanahan and 
Weinberg in 2000.  
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1.11.1 Association with Rb and effects on cell cycle regulators  
The most well established role of high-risk E7 is its ability to bind to primarily Rb but 
also p107 and p130, which together comprise the pocket protein family (Cobrinik, 
2005), and target them for proteasomal degradation (Dyson et al., 1989, Munger et al., 
1989, Davies et al., 1993, Boyer et al., 1996, Jones and Munger, 1996). The main role 
of phosphorylated Rb is to bind to the transcription factor E2F (Chellappan et al., 1991) 
and thereby prevent it from carrying out its cell cycle progression promoting role 
(reviewed in (Donjerkovic and Scott, 2000)). E7 targets preferentially these 
phosphorylated forms of Rb (Boyer et al., 1996), bringing about the release of E2F. 
This allows E2F to activate its downstream targets that include cyclin A and E, 
minichromosome maintenance proteins (MCMs) and the proliferating cell nuclear 
antigen (PCNA) (Cheng et al., 1995, Leone et al., 1998, Chien et al., 2000). 
 
E7 from low-risk viruses can also bind to Rb, though with a much lower efficiency than 
high-risk E7. This might explain why low-risk E7 cannot bring about the transformation 
of cells (Gage et al., 1990, Heck et al., 1992), yet can still extend the S phase 
compartment and cause hyperproliferation in the suprabasal layers of the epithelium. It 
has also been shown that while high-risk E7 can bring about degradation of all three 
members of the pocket protein family, low-risk E7 can only destabilize p130 (Zhang et 
al., 2006). Both p107 and p130 share the role of Rb to modulate E2F levels. Rb 
degradation by E7 is more abundant in undifferentiated cells, such as those found in the 
basal layer, than p130 degradation which has been observed predominantly in 
differentiating suprabasal cells (Collins et al., 2005). Hence, inefficient Rb degradation 
in favor of p130 destabilization may also contribute to the lack of transformation 
potential of low-risk E7. 
 
The ability of HPV E7 to interact with Rb seems to be a function that is shared with 
other tumor viruses as both SV40 large T antigen (DeCaprio et al., 1988) and also the 
adenovirus E1A protein (Whyte et al., 1988) have been attributed this role. 
 
Furthermore, E7 from both high- and low-risk HPVs have been show to increase the 
activity of CDK complexes. This has been observed for both the cyclin E/CDK2 
complex, involved in G1/S transition, and also the cyclin A/CDK2 complex, which 
plays a role in pushing cells from G2 phase into mitosis (Arroyo et al., 1993, 
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Tommasino et al., 1993, He et al., 2003, Nguyen and Munger, 2008). Moreover, E7 can 
repress the function of the CDK inhibitors p21 and p27, thereby further promoting cell 
cycle progression (Zerfass-Thome et al., 1996, Funk et al., 1997). 
 
1.11.2 Association with other cellular binding partners 
Another role of E7 is its ability to bind to histone deacetylase 1 (HDAC1) (Brehm et al., 
1999). HDACs normally repress transcription, as they allow histones to wrap DNA 
tightly, thus hindering access of transcription co-activators to DNA (de Ruijter et al., 
2003). The interaction of E7 with HDAC1 brings about further transcriptional activation 
by E2F (Longworth et al., 2005). Additionally, E7 can also bind and augment the 
activity of members of the AP-1 family of transcription factors, such as c-Jun and c-Fos 
(Antinore et al., 1996). The AP-1 family can regulate several important cellular 
processes that include proliferation and differentiation (Hess et al., 2004). 
 
1.12 The E6 protein 
E6 is one of the viral oncoproteins and is just over 150 amino acids long (Foster et al., 
1994) and approximately 18 kDa in size for HPV16. Like E7, E6 can bind to many 
different cellular proteins and additionally bind directly to DNA (Ristriani et al., 2000). 
Both low- and high-risk E6 can bind to the cellular E3 ubiquitin ligase, E6-associated 
protein (E6AP). It is through this interaction that E6 can bring about many of its 
functions, including the degradation of p53 and some PDZ proteins. However, it seems 
that the relationship between E6 and E6AP is very complex as their binding has been 
shown to lead to the degradation of E6AP via the proteasome (Kao et al., 2000). At the 
same time E6AP can stabilize the E6 protein itself to protect it from degradation 
(Tomaic et al., 2009). Hence it appears that the association of E6 and E6AP is 
controlled by several factors, including their precise levels and localization within the 
cell and signal transduction pathways that are active at different stages in the viral life 
cycle and throughout neoplastic progression. 
 
E6 can interfere with a number of important cellular pathways to modulate apoptosis, 
proliferation and immune evasion. The presence of this oncoprotein alone has been 
shown to induce hyperplasia and also to transform epithelial cells in transgenic mice 
(Song et al., 1999, Nguyen et al., 2003). The oncogenic activities of the E6 protein and 
cellular interaction partners are summarized in Figure 1.4 and 1.5, respectively. 
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Figure 1.4: Oncogenic activities of the HPV E6 protein 
The major processes targeted by E6 (white boxes) to bring about cellular characteristics 
commonly associated with human tumors (black boxes) as described by Hanahan and 


















Figure 1.5: A summary of cellular proteins affected by high-risk E6 
Proteins marked with an asterisk are affected by E6 at a transcriptional level while all others 
are directly bound by E6. These include the E3 ubiquitin ligase E6AP, transcriptional 
regulators, mediators of apoptosis, immune recognition, chromosomal stability, epithelial 
organization and differentiation and those involved in cell-cell adhesion, polarity and 
proliferation.  
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1.12.1 Association with p53 
The most well characterized activity of E6 is its ability to bind to and degrade p53 
(Scheffner et al., 1990, Werness et al., 1990), mediated by E6AP (Huibregtse et al., 
1991, Scheffner et al., 1993). The transcription factor p53 is a key tumor suppressor in 
cells and in response to stress it can initiate DNA repair, bring about growth arrest of 
cells and initiate apoptosis if DNA damage is irreparable (Gottlieb and Oren, 1996). 
When E6 is not present, E6AP does not bind to p53 (Huibregtse et al., 1991). Due to the 
important role of p53 in signal transduction, its mutation in cancers is widespread, with 
more than 50 % of all cancers being shown to have them (Vogelstein et al., 2000). As 
E6 can efficiently degrade p53, cervical cancers are usually not associated with 
mutations in this protein. Additionally, other tumor viruses such as the Simian viruses 
40 (SV40), a type of polyomavirus, and adenoviruses have proteins that share the ability 
of E6 to bind to p53 (Lane and Crawford, 1979, Sarnow et al., 1982). 
 
In normal cells, when p53 does not have to fulfill its role, its levels are regulated by the 
cellular E3 ubiquitin ligase Mdm2 (Haupt et al., 1997). At times when p53 needs to be 
stabilized, for example in instances of DNA damage or abnormal cell cycle activity, 
Mdm2 is phosphorylated resulting in the loss of its ability to bind to p53. As mentioned 
earlier, E7 can drive keratinocytes to cycle actively at times when they should not be. 
Thus, in cells expressing only E7 this results in the up-regulation of p53 levels (Demers 
et al., 1994, Laurson et al., 2010). However, during normal HPV infection E6 can 
circumvent this and bring about degradation of p53 thus allowing cells to stay in cycle 
and the virus to replicate its genomes. 
 
Both high- and low-risk E6 proteins can bind to p53, however only the high-risk variety 
can bring about its degradation (Foster et al., 1994). This difference is brought about by 
the ability of high-risk E6 to associate with the main DNA-binding region of p53 (Li 
and Coffino, 1996), which is a requirement of E6-mediated p53 degradation. In 
contrast, low-risk E6 is associated with binding to the C-terminal region of p53. 
Additionally, in low-risk HPV E6-expressing cells, p53 is sequestered to the cytoplasm 
(Sun et al., 2008), where it cannot carry out its normal function. This shows that 
irrespective of its ability to degrade p53, low-risk E6 can still impact on the function of 
this protein. 
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1.12.2 Inhibition of apoptosis 
While degradation of p53 by E6 can bring about inhibition of apoptosis, E6 can 
interfere directly with the extrinsic and intrinsic apoptosis pathways independently of 
p53. E6 can bring about the degradation of the Fas-associated death domain (FADD) 
and procaspase 8 (Filippova et al., 2004, Garnett et al., 2006), which are involved in the 
extrinsic pathway, in response to viral infection. Additionally, E6 can target Bak for 
proteasomal degradation (Thomas and Banks, 1998, Jackson et al., 2000), which is part 
of the intrinsic apoptosis pathway that is activated in response to cellular stress and 
DNA damage. 
 
1.12.3 Degradation of PDZ proteins by E6 and disruption of cell-cell adhesion and 
polarity 
The stratified epithelium consists of several cell layers, each with highly regulated gene 
expression patterns. In order for each cell to fulfill its appropriate role, it needs to be 
sent correct signals from neighboring cells and also from the extracellular matrix 
(ECM). For this reason both cell-cell adhesion and apico-basal polarity of cells need to 
be very tightly regulated (Bilder, 2004). In uninfected epithelium only basal cells are 
mitotically active. This is due to their attachment to the basement membrane and 
receiving appropriate proliferation signals. When HPV is present cells are driven to 
cycle in suprabasal layers by E7 (as outlined above) but also by E6, in part by its ability 
to disrupt cell adhesion and polarity. 
 
PDZ-domain proteins are a large group of proteins that all have one or more PDZ 
domains involved in the interaction with other proteins. PDZ proteins derive their name 
from the first letter of the three proteins in which the domain was first discovered: post 
synaptic density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1), and 
Zonula occludens-1 protein (ZO-1) (Kennedy, 1995). The high-risk E6 protein can bind 
to and bring about the degradation of certain cellular PDZ proteins due to a PDZ-
binding motif located on its extreme carboxy terminus. The degradation mediated by E6 
can occur in both E6AP-dependent (Nakagawa and Huibregtse, 2000) and -independent 
(Pim et al., 2000, Storrs and Silverstein, 2007) manners. E6 from low-risk viruses do 
not have a PDZ motif and are unable to bind to PDZ proteins (Kiyono et al., 1997). The 
PDZ proteins that have been studied most with respect to their interaction with E6 are 
hScrib, hDlg and MAGI-1, -2 and -3, and these are all involved in epithelial polarity 
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and scaffolding (Kiyono et al., 1997, Gardiol et al., 1999, Lee et al., 1997, Nakagawa 
and Huibregtse, 2000, Thomas et al., 2002).  
 
The hScrib and hDlg genes are the human homologues of the Drosophila melanogaster 
scribble and disc large genes, respectively (Lue et al., 1994, Dow et al., 2003). The 
resulting gene products are involved in several important functions in the cell, including 
signal transduction, cell polarity and proliferation, and they have been classified as 
tumor suppressors (Woods and Bryant, 1989, Bilder et al., 2000, Dow et al., 2003). 
They can localize to adherens junctions, in an E-cadherin-dependent manner (Navarro 
et al., 2005), as part of the Scribble polarity complex and as such have been attributed a 
role in the formation of these cell-cell junctions (Bilder et al., 2000, Firestein and 
Rongo, 2001). Moreover, non-membrane-associated forms of these proteins have been 
described (McLaughlin et al., 2002, Garcia-Mata et al., 2007) and in the case of hDlg its 
precise localization to the nucleus or cytoplasm seems to be regulated by 
phosphorylation (Mantovani et al., 2001). Interestingly, highly phosphorylated forms of 
the protein seem to be most susceptible to degradation by E6 (Massimi et al., 2006, 
Narayan et al., 2009). Additionally, both hDlg and hScrib can bind to the adenomatous 
polyposis coli (APC) protein (Matsumine et al., 1996, Takizawa et al., 2006), via the 
PDZ-binding motif of the latter. APC forms part of the destruction complex of the 
canonical Wnt pathway that actively degrades β-catenin in the absence of Wnt ligands, 
to prevent activation of β-catenin transcriptional targets (Logan and Nusse, 2004). 
Binding of both hDlg and hScrib to APC has been shown to be involved in this cell 
cycle inhibitory function (Ishidate et al., 2000, Nagasaka et al., 2006). Hence, 
degradation of these two PDZ proteins by E6 may lead to malignancy by several 
different mechanisms. (A recent study has been shown that E6 can also augment Wnt 
signaling in an E6AP and PDZ-motif independent manner (Lichtig et al., 2009).) 
 
The various MAGI PDZ-domain proteins are primarily involved in regulation of cell 
proliferation and differentiation due to their role in the formation of tight junctions 
(Balda and Matter, 2003). Additionally, MAGI can also stabilize the tumor suppressor 
Phosphatase and tensin homolog (PTEN) (Wu et al., 2000b) and thus facilitate its role 
of inhibiting growth-promoting signaling (Stambolic et al., 1998). Based on these roles 
of the MAGI proteins it seems feasible that their disruption by E6 can promote 
neoplastic progression. 
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Studies looking at the PDZ motif of E6 have shown that different types of HPV bind to 
PDZ proteins with varying affinity. In the case of HPV16 and 18, this is brought about 
by a slight amino acid variation within their PDZ motifs (Thomas et al., 2005). While 
MAGI is targeted equally well by both types, it seems that 18E6 binds predominantly to 
hDlg with only minor effects on hScrib, while 16E6 can bring about degradation of 
mainly hScrib (Pim et al., 2000, Thomas et al., 2001).  
 
While the interaction of E6 with PDZ proteins has been studied predominantly in terms 
of progression to malignancy, a role of PDZ proteins in the productive viral life cycle, 
although not well characterized, has also been suggested. It seems that PDZ proteins are 
involved in the persistence of viral episomes (Lee and Laimins, 2004), and that this may 
rely on the ability of E6 to bind hScrib and other PDZ-domain proteins (Nicolaides et 
al., 2011).  
 
Cellular PDZ proteins have been shown to interact with proteins from other viruses, 
including the Tax protein of Human T-lymphotropic virus Type 1 (HTLV-1) and the 
Adenovirus 9 E4ORF1 protein (Lee et al., 1997, Glaunsinger et al., 2000). These two 
proteins and also the influenza virus protein NS1, also have a PDZ motif (Obenauer et 
al., 2006). 
 
1.12.4 Induction of telomerase activity  
One mechanism by which E6 can bring about immortalization of cells (Band et al., 
1991), is through activation of telomerase. Telomerase is a ribonucleoprotein that adds 
specific DNA sequence repeats to telomeres at the end of chromosomes to avoid loss of 
important coding DNA with each replication event (reviewed in (Wai, 2004)). In 
normal somatic cells, unlike stem cells, telomerase is expressed at very low levels and 
this contributes to the finite life-span of a cell (Hayflick, 1965). Telomerase is made up 
of two components, the catalytic subunit (hTERT) and the RNA template (TERC). E6 
can bring about an increase in hTERT transcription (Veldman et al., 2001) and also 
interact directly with the enzyme and with telomeres (Liu et al., 2009). Targeting of 
telomerase has been shown to occur independently of p53 (Klingelhutz et al., 1996) and 
through both E6AP-dependent (Liu et al., 2005) and -independent (Sekaric et al., 2008) 
mechanisms. 
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1.12.5 Association with other cellular binding partners 
The functions of E6 described so far are the most well studied and characterized ones. 
In addition to the proteins already mentioned, E6 can interact with a variety of other 
cellular proteins and these associations correlate with neoplastic progression. One such 
target is E6-targeted protein 1 (E6TP1), a GTPase-activating protein. High-risk E6 can 
bring about its degradation (Gao et al., 1999) in an E6AP-dependent manner (Gao et al., 
2002). Furthermore, E6 from both low- and high-risk HPVs have been shown to bind to 
(Kukimoto et al., 1998) and, in the case of HPV18 E6, degrade MCM7 (Kuhne and 
Banks, 1998). One of the functions of MCM7 is to allow DNA to replicate only once 
per cycle (Chong et al., 1996), hence its interaction with E6 contributes to genomic 
instability. The association of E6 with several proteins involved in DNA repair such as 
XRCC1 (Iftner et al., 2002) and O(6)-methylguanine DNA methyl-transferase (MGMT) 
(Srivenugopal and Ali-Osman, 2002) further contributes to genomic instability. 
Additionally, E6 can bring about the degradation of TIP60 (Jha et al., 2010), a histone 
acetyltransferase involved in regulation of transcription and the DNA damage response 
(Gorrini et al., 2007), one of its main targets being p53. TIP60 can repress the viral p97 
early promoter (Jha et al., 2010) and its degradation, mediated by E6, may counteract 
this. 
 
1.13 E6 and E7 interaction with adherens junction proteins 
E6 and E7 together have transforming potential through their interactions with adherens 
junction proteins. Adherens junctions are important adhesive junctions found at specific 
cell-cell contact sites in the epithelium and allow adjacent cells to bind to each other and 
form connections (reviewed in (Balda and Matter, 2003)). They play essential roles in 
cell adhesion, recognition and motility, epithelial polarity, contact inhibition and 
differentiation. The main component of the junction is the cell adhesion receptor 
E-cadherin and it associates with β-catenin, and also indirectly with α-catenin through 
β-catenin. Increasing grades of HPV-dependent neoplasia have been linked to a 
reduction of E-cadherin expression (Vessey et al., 1995). Both E6 and E7 have been 
shown to not only associate directly with the E-cadherin receptor (Wilding et al., 1996, 
Caberg et al., 2008) but also reduce its levels (Matthews et al., 2003, Yuan et al., 2009, 
Laurson et al., 2010). This leads to loss of adherens junctions-mediated cell-cell 
adhesion and polarity.  
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Another role of E-cadherin is to sequester β-catenin out of the nucleus to the cell 
membrane (reviewed in (Balda and Matter, 2003)). β-catenin is a transcription factor 
that is the key downstream effector of the Wnt pathway (reviewed in (Huelsken and 
Behrens, 2002)). It forms a complex with LEF/TCF transcription factors to transactivate 
proteins such as cyclin D and c-Myc, which promote cell cycle progression. Hence loss 
of E-cadherin, through E6 and E7, can lead to hyperproliferation of cells. 
 
Moreover, hDlg and hScrib, discussed in more detail earlier, are recruited to adherens 
junctions in an E-cadherin-dependent manner (Navarro et al., 2005), as part of the 
Scribble polarity complex. The PDZ proteins can stabilize the linkage between 
E-cadherin and the catenins (Qin et al., 2005) and also seem to have a role in the 
formation of the junction (Bilder et al., 2000, Firestein and Rongo, 2001). E6 can bind 
to and degrade both hDlg and hScrib thereby destabilizing adherens junctions. 
 
1.14 Cellular contact inhibition 
Contact inhibition of proliferation refers to the inherent ability of cells to stop growing 
in a density-dependent manner. The concept first came about 50 years ago to explain 
why cells in monolayer culture stop growing upon reaching confluence. As the term 
“contact inhibition” suggests, growth arrest is brought about by contact between cells. It 
involves the association of cell surface receptors on adjacent cells and subsequent 
repression of growth promoting pathways that are affected by the receptors (reviewed in 
(McClatchey and Yap, 2012)). One such cell receptor is E-cadherin, which is an 
essential component of adherens junctions, discussed in more detail above. It has been 
shown that in cancer cell lines, the ability of cells to grow past confluence is mediated 
by an absence of E-cadherin (St Croix et al., 1998). Moreover, expressing E-cadherin in 
E-cadherin deficient skin cancer cells reduces tumor formation upon implantation into 
mice (Navarro et al., 1991).  
 
The Hippo signal transduction system is a major pathway involved in regulating growth 
and also apoptosis. Its key effector of proliferation is Yes-associated protein (YAP) 1, 
which, in its unphosphorylated form, is a transcriptional co-activator of growth-
promoting genes such as c-Myc (Zhao et al., 2011). The Hippo pathway has been 
implicated in contact inhibition due the observation that YAP1 is phosphorylated and 
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relocates to the cytoplasm, and is thus unable to fulfill its role, when monolayer cultures 
reach confluence (Kim et al., 2011, Schlegelmilch et al., 2011). This nuclear exclusion 
of YAP1 is dependent on the presence of α-catenin (Schlegelmilch et al., 2011, Silvis et 
al., 2011), which is another component of adherens junctions.  
Another key regulatory pathway of growth, and hence in contact inhibition, is the Notch 
signal transduction pathway which will be discussed in more detail in the next section. 
 
Generally, transformed keratinocytes, such as those expressing the HPV oncoproteins 
E6 and E7, can present with a pattern of proliferation where cells have the tendency to 
grow past the point of confluence. Additionally, it has been shown that both proteins 
can repress E-cadherin (Matthews et al., 2003, Yuan et al., 2009, Laurson et al., 2010). 
Hence, it is highly likely that in these cells normal contact inhibition pathways are 
attenuated.  
 
1.15 Notch signal transduction pathway 
The Notch signaling pathway (Figure 1.6) is a highly conserved signal transduction 
system that is present in most multi-cellular organisms (Artavanis-Tsakonas et al., 
1999) and is involved in regulating cellular proliferation and differentiation. The Notch 
gene was originally discovered in Drosophila melanogaster, when it was observed that 
those individuals with a mutant Notch allele had “notches” at the margin of their wings 
(Morgan, 1917). The Notch family consists of four single spanning cell-surface 
receptors (Notch1-4) and five Notch ligands of the delta and jagged family: 
Delta-like-1, -3 and -4 and Jagged-1 and -2 (reviewed in (Dotto, 2008, Watt et al., 2008, 
Borggrefe and Liefke, 2012)). A simplified schematic of the Notch receptor is shown in 
Figure 1.7. When an appropriate ligand binds to its receptor, activation of Notch is 
brought about by two sequential cleavages. The first one is mediated by ADAM 
metalloproteinase and occurs extracellularly. NICD subsequently gets cleaved 
intracellularly by the gamma secretase complex, consisting of, among other proteins, 
presenillin (PS), anterior pharynx-defective 1 (APH-1) and nicastrin. The released 
NICD can then translocate to the nucleus where it associates with DNA-bound RBPJ 
(Recombining binding protein suppressor of hairless). The interaction with RBPJ is 
brought about by the RAM domain (RBPJ Associated Molecule) and ankyrin repeat 
region, or ANK domain, of NICD (Johnson and Barrick, 2012). In the absence of 
Notch, RBPJ is a repressor complex (Dou et al., 1994) and can inhibit transcription of 
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its target genes through the recruitment of the histone deacetylase HDAC1 (Kao et al., 
1998). However when NICD is bound, other proteins such as MAML1 (Mastermind-
like protein 1) (Petcherski and Kimble, 2000, Wu et al., 2000a)and p300 (E1A binding 
protein p300) (Oswald et al., 2001) are recruited to the, now, activator complex and this 
enables transcriptional regulation of Notch targets including, amongst many others, 
HES1 (Iso et al., 2003), p21, p27 and AP-1 (reviewed in (Borggrefe and Liefke, 2012)). 
 
In mammals, Notch signaling is regulated on another level by three Fringe 
N-acetylglucosamine-transferases, called lunatic, manic or radical fringe. These 
enzymes can bring about a so-called “fringe” effect whereby Notch signaling through 
the Delta-like ligands is promoted while Jagged ligands can not bring about Notch 
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Figure 1.6: Simplified schematic of the Notch pathway 
Upon binding of an active ligand, the Notch receptor is cleaved extracellularly by 
ADAM metalloproteinase (S2 cleavage) and then intracellularly by the gamma 
secretase complex (S3 cleavage). The released NICD can then translocate to the nucleus 
where it associates with DNA-bound CSL (CBF1, Su(H), Lag-1), also known as RBPJ 
(Recombining binding protein suppressor of hairless). When NICD is bound, other 
proteins such as MAML1 (Mastermind-like protein 1) are recruited and this enables 
transcriptional regulation of Notch target genes including, amongst many others, 
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Figure 1.7: Simplified schematic of the Notch receptor 
The Notch receptor is comprised of two main portions; the Notch ExtraCellular (NEC) 
subunit and Notch TransMembrane (NTM) subunit, located within the cell. Notch 
ligands on adjacent cells bind to the EGF-like repeats which leads to the activation of 
Notch by two sequential cleavages (C1 and C2, respectively). C1 is mediated by 
ADAM metalloproteinase and brings about a membrane-tethered form of Notch 
IntraCellular Domain (NICD). NICD subsequently gets cleaved (C2) in the 
transmembrane-spanning segment (TM) by the gamma secretase complex. NICD is then 
free to translocate to the nucleus, using two nuclear localization signals (NLS), where it 
associates with Recombining binding protein suppressor of hairless (RBPJ). The 
interaction with RBPJ is brought about by the RBPJ Associated Molecule (RAM) 
domain and ankyrin repeat region (ANK) of NICD. Notch regulatory region (NRR), 
which is composed of three Lin12/Notch repeats and the heterodimerization domain 
(HD), is involved in regulating the activation of the receptor. The transactivation 
domain (TAD) and proline, glutamate, serine, and threonine (PEST) domain are 
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1.15.1 Role of Notch in stem cell maintenance and cell fate determination 
Stem cells are characterized by their inherent ability to differentiate into multiple 
lineages and undergo self-renewal (Weissman, 2000), allowing them to produce 
differentiated daughter cells without depleting the stem cell pool. It is important to 
understand the pathways that control stem cell function, not only because they are 
instrumental during development but also because their deregulation has been 
implicated in carcinogenesis (Reya et al., 2001).  Signal transduction pathways, such as 
Notch (Austin and Kimble, 1987, Henrique et al., 1997, Varnum-Finney et al., 2000), 
Hedgehog (Wechsler-Reya and Scott, 1999) and Wnt (Korinek et al., 1998) are 
considered to be the core stem cell signaling pathways and are involved in regulating 
the capacity of stem cells to self-renew. For Notch specifically this was originally 
shown in hematopoietic stem cells (Karanu et al., 2000, Varnum-Finney et al., 2000).  
 
These signal transduction pathways, including Notch, have been found to be defective 
in a variety of tumors, allowing cancer cells to undergo self-renewing cell divisions 
similar to those of stem cells (Ellisen et al., 1991, Chan et al., 1999, Gailani and Bale, 
1999). In the majority of cancers this is associated with aberrant, uncontrolled Notch 
activation, resulting in high Notch levels. However, in some cases even a lack of Notch 
can have oncogenic effects, including in the epidermis and head and neck squamous cell 
carcinomas (Nicolas et al., 2003, Restivo et al., 2011). 
 
Notch signaling occurs between adjacent cells and hence the fate of any given cell in 
response to Notch is dependent on its neighbors and precise physiological context 
(reviewed in (Hori et al., 2013)). This means that the consequence of any given level of 
Notch being present in a cell is strictly context dependent, with it promoting 
proliferation in one tissue and differentiation in another. One hallmark of Notch-
regulated cell fate is lateral specification (Greenwald, 1998). This refers to the ability of 
a cell that has adopted a specific lineage, for example to differentiate into a neuroblast 
in a developing embryo, to inhibit its cellular neighbors from adopting the same cell 
fate. High levels of expression of the Notch ligand Delta1 from an epidermal stem cell 
have been shown to induce neighboring cells to become transit amplifying cells, with a 
limited number of cell divisions (Lowell et al., 2000). This example of lateral 
specification has a differentiation-promoting effect. This means that Notch signaling 
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allows one cell to distinguish itself from a group of developmentally identical cells and 
also to segregate two populations of cells (Bray, 2006). 
 
1.15.2 Role of Notch in the epithelium  
In the epidermis, Notch is implicated mainly in cell cycle withdrawal and keratinocyte 
differentiation (reviewed in (Watt et al., 2008, Dotto, 2008)), though some of its targets 
are involved in actively promoting cell growth. Calcium is one of main regulators of 
differentiation (reviewed in (Bikle et al., 2012)). The calcium gradient within the 
stratified epithelium is involved in the sequential differentiation of keratinocytes. 
Hence, it has been suggested that the calcium receptors of cells are the main initiators of 
differentiation in response to extracellular calcium in suprabasal layers. Notch 
activation has also been shown to be a requirement of epithelial cells to commit to their 
cellular differentiation program. This is brought about by the ability of NICD to activate 
p21 and p27 (Rangarajan et al., 2001b), which are potent suppressors of c-Myc 
(Horiguchi-Yamada et al., 2002), and can bring about cell cycle arrest, in a 
p63-dependent manner (Wu et al., 2012). However, a recent study has shown that cell 
density rather than high calcium levels in keratinocyte cell medium are determinants of 
Notch activation (Kolly et al., 2005). Once initiated, calcium is necessary to bring 
terminal differentiation to completion but it does not control the beginning of the 
process. This study suggests that Notch is activated in response to cell-cell contact and 
can bring about growth arrest and contact inhibition. It seems plausible that Notch 
receptor activation generally requires cell-cell contact because its ligands (Delta-like1, -
3, -4 and Jagged-1, -2) are cell surface anchored molecules (Mumm and Kopan, 2000, 
Baron, 2003).  
 
1.15.3 Notch in cervical carcinogenesis 
Notch1 expression was originally shown to correlate with the progression from low-
grade disease to invasive carcinoma (Zagouras et al., 1995, Daniel et al., 1997). 
Thereafter it was postulated that Notch activation cooperates with HPV-dependent 
malignant transformation of cells to induce cell survival, as Notch1 was found to be 
elevated in cervical carcinoma (Rangarajan et al., 2001b, Nair et al., 2003). 
Additionally, the down-regulation of Notch1 was shown to lead to a reduction of 
anchorage independent growth of cervical cancer cells (Weijzen et al., 2002). 
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However, it has also been suggested that high levels of Notch in cervical carcinoma, 
could be reflective of more highly differentiated parts of the tumor (that have abundant 
Notch) (Dotto, 2008) rather than represent the overall levels of Notch in the whole 
tumor. Furthermore, it has been shown that primary keratinocytes containing HPV, 
express lower levels of Notch than uninfected cells (Yugawa et al., 2007) and that the 
growth potential of these cells is suppressed when Notch activity is high (Lowell et al., 
2000, Lefort et al., 2007). Additionally, Notch1 was shown to suppress viral protein 
expression through its ability to activate of AP-1 (Talora et al., 2002), which has a role 
in the transcriptional regulation of HPV due to the presence of AP-1 binding sites 
within the LCR of the viral genome (Thierry et al., 1992, Soto et al., 1999). 
 
The studies outlined above represent the tip of the iceberg in terms of the vast amount 
of work that has been done to characterize the involvement of Notch in neoplasia and 
cervical cancer. However, they are representative of the current divide in the HPV field 
concerning the function of Notch and whether this signal transduction pathway 
promotes or represses neoplastic progression. Based on this, it is conceivable that the 
effect of Notch in cells infected with HPV may depend on not only the exact type of 
virus and levels of viral proteins but also the precise location of the cell within the 
epithelium and the activity of other signaling pathways. 
 
1.15.4 Notch and E6 
Several groups have shown that E6 from low-risk HPV8 and also bovine 
papillomaviruses (BPVs) can suppress Notch activation through a mechanism that 
inhibits the formation of the RBPJ/NICD/MAML1 complex (Brimer et al., 2012, Tan et 
al., 2012, Meyers et al., 2013). Furthermore, a study using HPV16 E6 and E7 has 
suggested that their repression leads to a significant activation of the Notch pathway in 
oropharyngeal cancer cell lines (Rampias et al., 2008). Additionally, further work using 
both HPV16- and -18 positive cervical cancer cell lines has demonstrated that Notch1 
expression is reduced by a mechanism involving inactivation of p53 by E6 (Yugawa et 
al., 2007). 
 
In contrast it has also been postulated that both HPV16 oncoproteins can cooperate with 
Notch1 to promote malignant transformation of HaCaT keratinocytes (Rangarajan et al., 
2001a). Moreover, both HPV16 E6 and E7 independently can up-regulate Notch1 
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expression, with inhibition of Notch1 resulting in the loss of the tumorigenic phenotype 
of cells (Weijzen et al., 2003). Another study has shown that HPV16 E6 can activate the 
Notch ligand Jagged-1 and bring about the activation of both Notch1 and 2 
(Veeraraghavalu et al., 2005). 
 
This shows that even when it comes to the effects of just one viral protein on Notch 
signaling, in this case E6, there is disagreement in the field. While the exact mechanism 
by which E6 affects Notch has yet to be determined, it seems that depending on the 
precise expression levels and cellular environment (Henken et al., 2012), Notch, as 
deregulated by E6, can have both growth inhibitory and promoting effects.  
 
1.16 Gamma secretase complex 
Gamma secretase is a membrane complex with unusual aspartyl protease activity, 
consisting of various subunits, that is involved in cleaving single-pass type I 
transmembrane proteins (reviewed in (Strooper and Annaert, 2001)). It is has been 
highly conserved throughout evolution and is found in essentially all animal species. Its 
substrates include proteins such as Notch, amyloid precursor protein (APP), E-cadherin, 
N-cadherin, Nectin-1 and the ErbB4 receptor tyrosine kinase. Interestingly, target 
specificity and proteolytic activity of the gamma secretase complex is not critically 
dependent on a specific sequence that is recognized but on the size of the extracellular 
domain of its targets, with smaller domains resulting in more efficient cleavage (Struhl 
and Adachi, 2000). The gamma secretase complex was first described through its role in 
the production of amyloid beta (Aβ), which is brought about through cleavage of 
Amyloid precursor protein (APP) (Selkoe, 2001). In patients with Alzheimer’s disease, 
Aβ is processed abnormally and this is associated with amyloid plaques in the brain 
(Hardy and Allsop, 1991). 
 
Though not yet fully characterized, the gamma secretase complex consists of four 
essential proteins; presenilin (PS), presenilin enhancer-2 (PEN-2), nicastrin (Nct) and 
anterior pharynx-defective-1 (APH-1) (reviewed in (Kaether et al., 2006)). Additionally, 
the complex may also comprise a fifth non-essential protein, CD147, which is a 
negative regulator of its activity (Zhou et al., 2005, Zhou et al., 2006). Presenilin is 
encoded by two genes giving rise to two homologues, presenilin-1 and -2 (PS-1 and -2) 
(Levy-Lahad et al., 1995, Sherrington et al., 1995). Moreover, in mammalian cells two 
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homologues of APH-1 have been found, APH-1α and APH-1β, with APH-1α having 
two additional splice variants that differ in their C-termini (Francis et al., 2002). It has 
been shown that PS-1 and -2 and APH-1α and APH-1β can all assemble into different 
gamma secretase complexes (Steiner et al., 2002, Shirotani et al., 2004). This suggests 
that the exact components of the complex and thus its precise activity are likely to 
reflect the tissue-specific expression of the various subunits (Kaether et al., 2006). 
 
In addition to a role in proteolytic activity, APH-1 promotes the assembly of all the 
components into the gamma secretase complex (Lee et al., 2004). Once it is fully 
formed the complex is activated through autocatalytic processing of PS-1, which is the 
main proteolytic component. This involves its cleavage into an N- and a C-terminal 
fragment that are both retained within the complex (Thinakaran et al., 1996, Capell et 
al., 1998). The main role of Nct is to stabilize the whole complex (Zhang et al., 2005) 
while additionally PEN-2 is also involved in complex stabilization after the two 
fragments of PS-1 have been formed (Prokop et al., 2004). 
 
1.16.1 Inhibition of gamma secretase 
Much of the characterization of the gamma secretase complex and also identification of 
its core components has been done using protein inhibitors (reviewed in (Wolfe, 2001)). 
By doing this it was discovered that the absence of even just one of the four essential 
subunits brings with it loss of function of the whole complex (Pardossi-Piquard et al., 
2009). As PS-1 is the active site of the complex, a lot of work has focused on the study 
of this protein and it has been shown that PS-1 knock-out mice are embryonically lethal 
(Herreman et al., 1999). PS-1 on its own was first described to be involved in 
Alzheimer’s disease (Levy-Lahad et al., 1995, Rogaev et al., 1995, Sherrington et al., 
1995) and then gradually over several years it was discovered that, to bring about 
cleavage of APP, it associates with other proteins to form the gamma secretase complex 
(reviewed in (Smolarkiewicz et al., 2013)). Alzheimer’s is a widespread type of 
dementia and the most common neurological disorder in the developed world. It has 
been predicted that by 2050, 1 in 85 people on a global scale will be affected by the 
disease (Brookmeyer et al., 2007). Due to it being so widespread a lot of work has been 
done on developing drugs and inhibitors against the gamma secretase complex to 
prevent the formation of amyloid plaques. This means that they are readily available for 
research purposes. Many of them do not distinguish between APP and other gamma 
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secretase substrates, such as Notch, and therefore they can be used for studying 
signaling pathways that are not necessarily involved in Alzheimer’s disease.  
 
1.17 The PI3K/AKT pathway 
The serine/threonine kinase AKT (Jones et al., 1991, Bellacosa et al., 1991, Coffer and 
Woodgett, 1991), also known as Protein Kinase B (PKB), is a downstream mediator of 
the phosphatidylinositol 3-kinase (PI3K) pathway (Figure 1.8) (reviewed in (Brazil and 
Hemmings, 2001, Hemmings and Restuccia, 2012)) and as such an important cellular 
regulator of the fine balance between cell survival and apoptosis. As the PI3K/AKT 
pathway is activated by members of the insulin-like growth factor (IGF) protein family, 
AKT is also considered to be a key regulator of growth factor responsiveness. When 
receptor tyrosine kinases (RTKs) are activated by appropriate growth factors, such as 
IGF, this leads to activation of PI3K, bound directly to RTK via its regulatory subunit 
or indirectly through insulin receptor substrate (IRS) proteins. Upon activation PI3K is 
catalytically converted to PIP3. AKT binds to PIP3, leading to subsequent partial 
activation of AKT by 3-phosphoinositide-dependent protein kinase 1 (PDK1). This 
allows AKT to activate mTORC1. Two of the main substrates of mTORC1 include the 
eukaryotic translation initiation factor 4E binding protein 1 (4EBP1), and ribosomal 
protein S6 kinase 1 (S6K1). These can, when activated, bring about protein synthesis 
and cellular proliferation. Inhibitors of the PI3K pathway include protein phosphatase 2 
(PP2A) (Andjelkovic et al., 1996), phosphatase and tensin homolog (PTEN) (Stambolic 
et al., 1998), and the PH-domain leucine-rich-repeat-containing protein phosphatases 
(PHLPP1/2) (Brognard et al., 2007).  
 
The AKT pathway is involved in the normal cellular differentiation program of 
keratinocytes (Janes et al., 2004, Calautti et al., 2005, Thrash et al., 2006, 
O'Shaughnessy et al., 2007b) and mice deficient in both AKT1 and 2 isoforms have 
been found to die neonatally (Peng et al., 2003). In cancers of many cell types, 
including keratinocytes (Segrelles et al., 2002, Mao et al., 2004), the PI3K pathway has 
been shown to be attenuated, leading to dysregulation of apoptosis and proliferation. In 
instances where the pathway is too active, the functional inactivation of PTEN is often 
involved. PTEN is one of the most commonly inactivated tumor suppressors associated 
with human cancers (Chen et al., 2005). 
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1.17.1 HPV and AKT 
Increased AKT activity has been linked to anogenital HPV infection (Pim et al., 2005, 
Menges et al., 2006). Current literature suggests that AKT can be deregulated by E7. A 
recent study with vulval intraepithelial lesions (VINs) has suggested that in the presence 
of HPV, AKT levels correlate with E7 expression (Ekeowa-Anderson et al., 2012). 
When the virus first infects and is maintained episomally, with low E7 levels due to 
heavy regulation by E2, patient tissue sections are negative for AKT expression. 
However, after integration, when E2 regulation is lost, E7 levels are much higher and 
AKT can be readily detected. Furthermore, when E7 is expressed in human foreskin 
keratinocytes (HFKs) this leads not only to enhanced cell proliferation and inhibition of 
differentiation but also increased AKT activity in raft culture (Menges et al., 2006). 
This seems to be dependent on the ability of E7 to bring about the degradation of Rb. 
Additional it has been suggested that HFKs expressing HPV16 E7 have to ability to 
promote the cytoplasmic retention of the cyclin-dependent kinase inhibitor p27 via the 
PI3K/AKT pathway. This not only removes normal cellular restrictions on cell cycle 
progression but also allows cells to migrate more rapidly (Charette and McCance, 
2007).  
 
Although generally high levels of the AKT1 isoform are associated with malignancy, 
especially in head and neck squamous cell carcinoma (SCC) (Amornphimoltham et al., 
2005, Lim et al., 2005, Moral and Paramio, 2008) it has been shown that upon infection 
with a cutaneous HPV, specifically HPV8, AKT1 is downregulated while high AKT2 
levels are correlated with tumor progression (O'Shaughnessy et al., 2007a).  
 
All in all, current literature suggests that AKT may be an important prognostic marker 
for disease and also a good target for therapeutic intervention in treating cervical and 
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Figure 1.8: Simplified schematic of the PI3K/AKT pathway 
When a tyrosine kinase receptor is activated by an appropriate growth factor, such as 
insulin-like growth factor (IGF), this leads to activation of PI3K. Upon activation PI3K 
is able to bind to and bring about the partial activation of AKT. This allows AKT to 
activate mTORC1. Two of the main substrates of mTORC1 include the eukaryotic 
translation initiation factor 4E binding protein 1 (4EBP1), and ribosomal protein S6 
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1.18 Rationale and aims of this study 
The overall aim of this study was to increase the understanding of neoplastic 
progression resulting from HPV infection by characterizing viral gene expression and 
the effects of the E6 and E7 viral oncoproteins.  
 
This was addressed primarily using HPV16-expressing, episomal NIKS cell lines that 
had previously been shown to give rise to LSIL- and HSIL-like rafting phenotypes and 
also corresponding growth patterns in monolayer culture (Isaacson Wechsler et al., 
2012). Once this unique model of viral deregulation was fully established I used it to 
understand how HPV16 can cause different grades of neoplasia and how pathology is 
regulated by gene expression patterns.  
 
HPV research has been carried out for several decades and a lot is known about the 
virus, its mechanism of infection and how it causes diseases. Nevertheless, to date it is 
often difficult to say with 100 % certainty whether a lesion, detected during a routine 
cervical smear test, has to be treated or not. It is generally accepted that, if detected, a 
LSIL is monitored while an advanced HSIL is removed. However, the stage in between 
(equating to a CIN2) seems to be a grey area and there have been recent debates as to 
whether treating this type of lesion is good or bad (Mosicki et al., 2012). On the one 
hand, treatment is essential to prevent the lesion from progressing to an advanced HSIL 
or even cervical carcinoma. On the other hand, it is important not to treat unnecessarily 
as treatment can be invasive and may bring with it the risk of premature births. Hence, 
the age of the affected woman is an important consideration in this decision. In younger 
individuals, of childbearing age, the tendency is to monitor as oppose to treat while in 
older women, no longer wishing to or able to have children, treatment is more common. 
In light of this, it is important to further describe the molecular differences between 
low- and high-grade lesions (as shown in this report) so that physicians can say with 
more certainty whether treatment is required.  
 
My overall hypothesis was that differences in the expression levels and precise 
expression patterns of E6 and/or E7, and the resulting differential deregulation of 
certain molecular pathways, are involved in giving rise to the LSIL- and HSIL-like 
phenotypes. To test this, I decided to break the hypothesis down into three smaller more 
easily testable ones to be addressed one after the other. 
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1)  Hypothesis: Differences in E6 and/or E7 are involved in regulating the 
LSIL- and HSIL-like phenotypes. 
Aims/Objectives:  a) Test the reproducibility of the previously published 
LSIL- and HSIL-like rafting and growth patterns. 
  b) Determine whether the LSIL- and HSIL-like 
phenotypes arise as a consequence of the way experiments 
are routinely carried out. 
c) Find out whether E6 and/or E7 mRNA and/or protein 
levels differ between the LSIL- and HSIL-like cell lines. 
d) Investigate whether the role of E6 and/or E7 is 
dependent on where in the stratified epithelium the 
proteins are expressed. 
 
 
2)  Hypothesis: Modulating E6 and/or E7 levels will lead to a corresponding effect 
on the proliferation of cells and alter the LSIL- and HSIL-like phenotypes. 
Aims /Objectives: a) Test various previously published siRNA sequences or 
shRNA vectors to achieve the best possible knock-down 
of E6 and/or E7 in highly transfectable cells. 
 b) Use the sequences/vectors identified and tested in a) to 
achieve knock-down of E6 and/or E7 in NIKS HPV16-
expressing clonal cells. 
 c) Determine whether knock-down of E6 and/or E7 has an 
effect on the LSIL- and HSIL-like growth patterns. 
 d) Use a plasmid(s) to overexpress E6 and/or E7 in the 
clonal HPV16-expressing NIKS cell lines. 
 e) Find out whether the overexpression of E6 and/or E7 
has an effect on the proliferation of the LSIL- and HSIL-
like cell lines. 
 
 
3) Hypothesis: E6 can deregulate a pathway(s) involved in cell proliferation and/or 
contact inhibition to bring about the LSIL- and HSIL-like phenotypes. 
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Aims/Objectives: a) Determine whether E6 can interfere with contact 
inhibition by binding to and degrading PDZ proteins. 
 b) Investigate whether E6 can attenuate normal growth 
pathways through its ability to degrade the p53 protein. 
 c) Test whether the deregulation of the Notch and/or 
Hippo pathway(s) by E6 gives rise to the LSIL- and HSIL-
like growth patterns. 
 d) Challenge the findings in c) by using siRNA and/or 
shRNA or chemical agonists and/or antagonists specific to 
the pathway(s) identified. 
 e) Find out whether the pathway(s) involved in 
deregulating proliferation of the HPV16-expressing NIKS 
cell lines are also involved in giving rise to LSIL- and 
HSIL-like rafting phenotypes. 
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Chapter 2: Materials and Methods 
 
2.1 Suppliers of reagents 
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich (UK), BDH 
Laboratory Supplies (UK), Fisher Scientific (UK) or VWR International Ltd. (UK). 
 
2.1.1 Commonly used buffers and reagents 
Commonly used buffers and reagents were made according to Table 2.1. All buffers 
listed were prepared by the NIMR media facility. 
 
Table 2.1: Buffers and reagents 
Name Components 
Penicillin/Streptomycin 
(for cell culture) 
0.6 % (v/v) penicillin, 1 % (v/v) streptomycin 
Trypsin-versene  
(for cell culture) 
0.8 % NaCl, 0.02 % KCl, 0.12 % Na2HPO4, 0.02 % 
KH2PO4, 0.01 % EDTA, 0.13 % trypsin, 0.001 % phenol 
red; pH 7.8 1X Phosphate buffered 
saline (PBS) 
1 % NaCl, 0.025 % KCl, 0.14 % Na2HPO, 0.025 % 
KH2PO4 
1X Tris-buffered saline 
(TBS) 
2.42 g Tris base, 8 g NaCl; pH 7.6 
(for 1L) 
Lysogeny broth (LB) 1 % Bacto-Tryptone, 0.5 % Bacto-yeast extract, 1 % NaCl 
LB agar LB medium plus 2 % Bacto agar 
50X Tris acetate EDTA 
(TAE) 




25 mM Tris base, 200 mM glycine, 0.1 % sodium dodecyl 
sulfate (SDS); pH 8.3 
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2.2 Basic monolayer cell culture methods 
 
2.2.1 Cell lines 
 
2.2.1.1 J2-3T3 mouse fibroblasts 
J2-3T3 is an immortalized fibroblast cell line that was originally isolated from Swiss 
albino mouse embryos (Todaro and Green, 1963). J2-3T3 cells were γ-irradiated and 
used as a bed of feeder cells for culturing NIKS. 
 
2.2.1.2 SiHa cells 
SiHa are an HPV16-positive squamous cell carcinoma (SCC) cell line isolated from the 
cervix of a 55 year old patient (Friedl et al., 1970). The viral DNA in these cells is fully 
integrated with at least 11 chromosomal sites of HPV16 integration having been 
described (Mincheva et al., 1987). 
 
2.2.1.3 EF-1F human foreskin fibroblasts 
EF-1F cells were originally isolated from human foreskin epithelium. The cell line was 
used for preparing dermal equivalents as part of the rafting process. 
 
2.2.1.4 Normal Immortalized Human Keratinocytes (NIKS)  
NIKS are a spontaneously immortalized HPV-negative human foreskin keratinocyte cell 
line. These cells arose originally from their parental BC-1-Ep cell line, isolated from 
neonatal foreskin, through serial passaging (Allen-Hoffmann et al., 2000). All HPV16 
and the vast majority of other experiments used NIKS cells.  
 
2.2.1.5 NIKS HPV16-positive cells  
HPV16 clonal cell lines were established from two independent transfection events by 
Kenneth Raj; NIMR, London, UK and Qian Wang; NIMR, London, UK. This process 
involved cotransfecting NIKS with recircularized replication competent HPV16 wild 
type (WI2) genomes and a pcDNA6 vector containing a blasticidin resistance gene. 
Clonal cell lines were recovered after selection with 6 µg/ml of blasticidin. After 
individual colonies became visible, cells were first cultured in single wells of 60 mm 
6-well plates (Thermo Scientific; 140675) and subsequently expanded to make cell 
stock. 
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2.2.2 Media and supplements 
The various media used for culturing the cell lines as well as for freezing of cells for 
long-term storage are described in Table 2.2. The supplements used in the FI medium 
for NIKS were prepared either as 100 or 1000X stock, filter sterilized using a 0.2 µM 
filter unit (Sartorius; 16534) and frozen at -20 °C in 5 ml aliquots. 
Table 2.2 Cell culture and freeze media 
Cell type Medium type Medium components 
NIKS, HPV16 
clones and other 
NIKS-derived 
cell populations 
FI medium 500 ml F Medium (3 part F12-Hams + 1 part 
high glucose DMEM) (PAA; T15-355), 5 % 
(v/v) FBS (Biosera; S1900-500), 24 µg/ml 
adenine (Sigma-Aldrich; A2786), 8.4 ng/ml 
cholera toxin (Sigma-Aldrich; C8052), 
0.4 µg/ml hydrocortisone (Calbiochem; CAS 
50-23-7), 5 µg/ml insulin (Sigma-Aldrich; 
I4011) and 1 % (v/v) pen/strep 
NIKS, HPV16 
clones and other 
NIKS-derived 
cell populations 
FC medium FI medium with Epidermal Growth Factor 
(EGF) added prior to use at a concentration of 
10 ng/ml (R&D Systems; 236-EG) 
NIKS, HPV16 





90 % (v/v) FBS, 10 % (v/v) DMSO (Sigma-
Aldrich; D2650) 
NIKS, HPV16 





500 ml FI Medium with 0.5 % (v/v) FBS and 
610 µl CaCl2 (Ca2+ final concentration of 
1.88 mM) 
 
 NIKS, HPV16 





500 ml FI medium with 5 % (v/v) FBS and 
610 µl CaCl2 (Ca2+ final concentration of 
1.88 mM).  
N 1,2-dioctanoyl-sn-glycerol (C8:0) 
(Calbiochem; 317505) was added fresh to a 
final concentration of 10 µM 
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J2-3T3, SiHa DMEM complete 500 ml high glucose DMEM (Sigma-Aldrich; 
D6429), 10 % (v/v) FBS and 1 % (v/v) 
pen/strep 
EF-1F F12 medium 500 ml F12-Ham’s (Gibco; 21765-029), 10 % 
(v/v) FBS and 1 % (v/v) pen/strep 
J2-3T3, EF-1F, 
SiHa 
J2-3T3 / EF-1F / 
SiHa freezing 
medium 
95 % (v/v) FBS, 5 % (v/v) DMSO 
 
2.2.3 Maintenance of monolayer cells 
All cells were cultured in 5 % CO2 at 37 °C. 
 
2.2.3.1 J2 3T3 and SiHa 
J2-3T3 fibroblasts and SiHa cells were cultured in 10 ml of DMEM complete medium 
in T75 flasks (Fisher Scientific; TKV-123-013L). Cells were split between 1:10 and 
1:40 as needed. To harvest, cells were washed with 7 ml of PBS and then incubated 
with 2 ml of trypsin-versene for 2 minutes at 37 °C. Thereafter, 8 ml of fresh medium 
was added, cells were resuspended into a single cell suspension and a small aliquot 
transferred to a new flask for further culturing. Cells were given fresh medium every 
3-4 days. For long-term storage, a confluent flask of low passage cells was harvested, 
spun down at 1500 rpm using a MSE Mistral 1000 centrifuge for 5 minutes, 
resuspended in 2 ml of J2-3T3/SiHa freezing medium, transferred to 2 cryovials 
(Thermo Scientific; 5000-1012) and frozen down at -80 °C or in liquid nitrogen. J2 3T3 
cells above passage 25 were not used for experimental purposes. 
 
2.2.3.2 EF-1F 
 EF-1F fibroblasts were cultured in 10 ml of F12 medium in T75 flasks and split 1:3 or 
1:5, as needed. To harvest, cells were washed with 7 ml of PBS and then incubated with 
2 ml of trypsin-versene for 5-10 minutes at 37 °C. Thereafter, 8 ml of fresh DMEM 
complete medium was added, cells were resuspended into a single cell suspension and a 
small aliquot transferred to a new flask for further culturing. Cells were given fresh 
medium every 2-3 days. For long-term storage, a confluent flask of cells was harvested, 
spun down at 1500 rpm for 5 minutes, resuspended in 1 ml of EF-1F freezing medium, 
transferred to a cryovial and frozen down at -80 °C or in liquid nitrogen. 
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2.2.3.3 Routine passaging of NIKS, NIKS HPV16 clones and other NIKS-derived 
cell populations 
NIKS, and variations thereof, were cultured on a layer of γ-irradiated J2-3T3 cells 
(feeders). J2-3T3 were irradiated at a dosage of 60 Gy using a Caesium source. For 
routine passaging approximately 1.4x106 feeders were seeded in a T75 flask in 10 ml of 
FI medium and left to attach for 2 hours prior to plating NIKS cells. NIKS were 
cultured to a maximum of 80 % confluence and split approximately once a week 
between 1:5 and 1:30, depending on the growth rate of the cells. Generally, only cells 
below passage 15 were used for experimental purposes. To harvest, NIKS were washed 
with 7 ml of PBS and then incubated with 2 ml of trypsin-versene for 2 minutes at 
37 °C, in order to remove the feeder layer. After tapping the flask several times to 
completely lift off the feeders, trypsin was aspirated. Keratinocytes were incubated in 
2 ml of fresh trypsin-versene at 37 °C for about 15 minutes. When all cells had detached 
from the flask, 8 ml of FI medium was added, cells were resuspended into a single cell 
suspension and transferred to a flask of γ-irradiated feeders for further culturing. Cells 
were provided with fresh FI or FC medium every second day. For long-term storage, a 
flask of low passage cells was harvested, spun down at 1500 rpm for 5 minutes. 
Approximately 2-3x106 cells were resuspended in 1 ml of NIKS freezing medium, 
transferred to a cryovial and frozen down at -80 °C or in liquid nitrogen. 
 
2.2.4 Counting of NIKS, NIKS HPV16 clones and other NIKS-derived cell 
populations 
For all experiments involving NIKS, cells were counted using a Z1 Coulter® particle 
counter (Beckman Coulter; UK). After cell harvest, as described above, 0.5 ml of the 
cell suspension was resuspended in 9.5 ml of isoton III diluent (Beckman Coulter; 
8546733) in a coulter counter cuvette (VWR International Ltd.; 720-0812). The coulter 
counter program used was optimized specifically for NIKS (Erin Isaacson; NIMR, 
London, UK), which are between 11 and 20 µm in size. To account for cells that are 
slightly larger, the counter parameters were set to count all cells above 11 µm. 
 
2.2.5 Transfection of NIKS and NIKS HPV16-positive cells 
For transfections, NIKS and varieties thereof, were harvested and plated on 60 mm 
6-well plates at a density of 5x105 cells per well on a layer of 1x105 feeders and left to 
grow overnight in FC medium. Transfections were carried out using the Effectene® 
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Transfection Reagent Kit (Qiagen; 301425) following the manufacturer’s instructions. 
Cells were transfected with up to a total of 1 µg of circular or linearized DNA, which 
was purified from bacterial cultures. Six hours after transfection cells were given fresh 
FC medium. 
 
2.2.6 Treatment with DAPT 
N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), or DAPT 
(Thermo Fisher; D5942), is a gamma secretase inhibitor. DAPT was made up in either 
DMSO or ethanol and stored at -20 °C in 2 mM aliquots. To use the inhibitor NIKS and 
NIKS varieties were seeded in a short growth assay format (as described in Section 2.4). 
From day 1 onwards cells were treated with 10 µM of DAPT or DMSO/ethanol as a 
control (either DMSO or ethanol was used depending on the experiment) that was 
replaced every 24 hours. Cells are normally only given fresh FC medium (with EGF) 
every second day of a growth assay (on days 2, 4, and 6). To enable the change of 
medium every day, to replace the DAPT and DMSO/ethanol, additional wells with 
completely untreated cells for each cell type were seeded. The medium given to these 
cells one day (2, 4, or 6) was used to feed the cells that were part of the growth assay on 
the next day (3 or 5). Since nothing but fresh DAPT or DMSO/ethanol was added to 
this “conditioned” FC medium prior to feeding cells, the growth factors and other 
supplements were presumably equally depleted in the medium in these wells as in the 
one of treated cells. This system ensured that the growth conditions throughout the 
experiment were consistent.  
 
2.2.7 Treatment with R04929097 
R04929097 (BioVision Inc.; 2011-1) is a gamma secretase inhibitor. R04929097 was 
made up in DMSO and stored at -20 °C in 8 mM aliquots. To use the inhibitor NIKS 
and NIKS varieties were seeded in a short growth assay format (as described in Section 
2.4) following the same set-up as for DAPT in Section 2.2.7. Cells were treated with 
8 nM of the drug or DMSO as a control. 
 
2.3 Growth assays of NIKS, NIKS HPV16 clones and other NIKS-derived cell 
populations 
To assess the proliferation patterns of NIKS, and varieties thereof, 1x105 keratinocytes 
were seeded on top of a layer of 1x105 γ-irradiated J2-3T3 fibroblasts per well of a 
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6-well plate. Duplicate wells were set-up for each cell type and time-point. The day of 
seeding was denoted as day 0. Cells were left to grow overnight in 2 ml of FI medium. 
On the following day (day 1) cells were counted to determine the seeding efficiency. 
For most experiments cells were grown for a total of 9 days and counted at days 1, 3, 5, 
7 and 9. On day 1 and every other day thereafter (days 3, 5, and 7) cells were fed with 
2 ml of FC medium. For harvesting, cells were washed with 2 ml of PBS and then 
incubated for 2 minutes with trypsin-versene at 37 °C to dislodge the feeders. After 
tapping the plate several times to completely lift off the fibroblasts, trypsin was 
aspirated. To remove the keratinocytes, 1 ml of fresh trypsin-versene was added to each 
well and cells were incubated at 37 °C for about 15 minutes. When all cells had 
detached from the bottom of the wells, 4 ml of FI medium was added, cells resuspended 
into a single cell suspension and 0.5 ml of the mix used for counting. The cell numbers 
at seeding were optimized in such a way that at day 3 the wells are sub-confluent 
(individual NIKS colonies are not contacting), at day 5 the wells are confluent 
(individuals colonies are contacting) and from day 7 onwards the wells are 
post-confluent (individual colonies have merged completely). Cells left over from 
counting at each time-point were pelleted and frozen at -80 °C for protein and/or 
transcript analysis. 
 
2.4 Short growth assays of NIKS, NIKS HPV16 clones and other NIKS-derived cell 
populations 
This growth assay format was developed to assess the proliferation patterns of NIKS, 
and varieties thereof, during a shorter time frame to allow for the treatment of cells with 
certain drugs. 6x105 keratinocytes were seeded on top of a layer of 1x105 feeders per 
well of a 6-well plate in FI medium. Duplicate wells were set-up for each cell type and 
time-point. The day of seeding was denoted as day 0. On the following day (day 1) cells 
were given fresh FI medium and counted as described in Section 2.3 to assess the 
seeding efficiency of cells. On days 2, 4 and 6 cells were counted and all remaining 
cells fed with 2 ml of FC medium. The cell numbers at seeding were optimized in such 
a way that at day 2 the wells were confluent (equivalent to day 5 of a full-length 
time-course) and at days 4 and 6 the wells were post-confluent (equivalent of days 7 and 
9 of a regular growth-assay). Cells left over from counting at each time-point were 
pelleted and frozen at -80 °C for protein and/or transcript analysis. 
 
Chapter	  2:	  Materials	  and	  Methods	  
	   69	  
2.5 siRNA treatment 
All siRNA sequences that were custom designed are listed in Table 2.3. Additionally, 
the regions of the E6 and E7 ORFs that they target are shown in Figure 2.1. The 
siRNAs were ordered from Thermo Scientific (UK) as a dried pellet and had 3' dTdT 
overhangs. siRNAs were made up to a concentration of 20 µM using 5X siRNA buffer 
(Thermo Scientific; B-002000-UB-100) and stored in 100 µl aliquots (to avoid repeat 
freeze-thawing) at -20 °C. siNT (non-target) and siGAPDH were commercially 
available from Thermo Scientific.  
 
Table 2.3: List of siRNAs and sequences  







(Jiang and Milner, 2002, 
Allison et al., 2009) 
siE7-1 
(E7 only) 
AGGAGGAUGAAAUAGAUGG (Jiang and Milner, 2002, 
Allison et al., 2009) 
siE7-2 
(E7 only) 
CAGAGCCCAUUACAAUAUU (Allison et al., 2009) 
siE6/E7-1 
(both E6 and E7) 
GACCGGUCGAUGUAUGUC 
 
(Gu et al., 2009) 
siE6/E7-2 
(both E6 and E7) 
GCAACAGUUACUGCGACGU 
 
(Putral et al., 2005, Gu et 
al., 2008) 
siE6/E7-3 
(both E6 and E7) 
GAGCUGCAAACAACUAUA (Ben Khalifa et al., 2011) 
siE6/E7-4 
(both E6 and E7) 
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HPV16 E6 ORF 
	  ATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACAGGAGCGACCCAGAAAGTTACCACAGTTATGCA	  	   	  	  E6/E7-3       E6/E7-2 CAGAGCTGCAAACAACTATACATGATATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGT	  	  	  	  	  	  	  	  	  	  SD	   	  	  	  	  	  	  	  	  	  	  	  	  E6-1 GAGGTATATGACTTTGCTTTTCGGGATTTATGTATAGTATATAGAGATGGGAATCCATATGCTGTATGTG	  	  ATAAATGTTTAAAGTTTTATTCTAAAATTAGTGAGTATAGACATTATTGTTATAGTGTGTATGGAACAA	  	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  SA CATTAGAACAGCAATACAACAAACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACT	  	  GTGTCCTGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCATAATATAAGGGGTCGGTGGACC	  
        E6/E7-1   SA GGTCGATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAA	  	  	  
 
 
HPV16 E7 ORF  
 ATGCATGGAGATACACCTACATTGCATGAATATATGTTAGATTTGCAACCAGAGACAACTGATCTCTACT	  	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  E6/E7-4	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  E7-1 GTTATGAGCAATTAAATGACAGCTCAGAGGAGGAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACC	  	   	  	  	  	  	  	  	  	  	  	  E7-2 GGACAGAGCCCATTACAATATTGTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGGTTGTGCGTACAA	  	  AGCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATCT	  	  GTTCTCAGAAACCATAA	  	  	  
Figure 2.1 Sequences of the HPV16 E6 and E7 ORFs showing the regions targeted 
by the E6, E7 and E6/E7 siRNAs 
The DNA sequence of the E6 ORF (region 83-559) and E7 ORF (region 562 to 858) of 
HPV16 are shown. The regions targeted by E6-1, E7-1, E7-2, E7/E7-1, E6/E7-2, E6/E7-
3 and E6/E7-4 siRNAs are shown in colored highlights. Additionally, the splice donor 
(SD) and slice acceptor (SA) sites of E6 are indicated in red and blue writing, 
respectively. Please note that the sequences targeted by E6/E7-1, -2 and -3 are located 
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2.5.1 siRNA transfection 
 
2.5.1.1 SiHa For SiHa, 2x105 cells were seeded into each well of a 6-well plate and left 
to grow overnight in medium without FBS and pen/strep. Cells were transfected with 
20 nM of each siRNA with Lipofectamine® RNAiMAX (Life Technologies; 13778), 
following the manufacturer’s instructions and given fresh DMEM complete 6 hours 
later. Cells were harvested 48 and/or 72 hours post-transfection to determine the 
efficiency of the knock-down either by assessing protein and/or mRNA levels. 
 
2.5.1.2 NIKS and NIKS HPV16-positive cells 
For NIKS, 3x105 cells were seeded on top of 1x106 feeders per well and left to grow 
overnight in medium without FBS and pen/strep. Cells were transfected with 100 nM of 
each siRNA with Lipofectamine® RNAiMAX according to the manufacturer’s 
instructions and given fresh FC medium 6 hours later. Cells were harvested 48 and/or 
72 hours post-transfection to determine the efficiency of the knock-down either by 
assessing protein and/or mRNA levels. 
 
2.5.2 Electroporation 
NIKS and NIKS HPV16 clonal cell lines were harvested, washed twice with PBS, 
counted and divided into aliquots of 1.5x106 cells in individual microcentrifuge tubes. 
Cells were electroporated with 100 nM of siRNA using the 4D Nucleofector® X Unit 
from Lonza (UK) and the Amaxa™ SE Cell Line 4D-Nucleofector™ X Kit L (Lonza; 
V4XC-1024), according to the manufacturer’s instructions. The specific program used 
for NIKS cells was previously optimized by Cinzia Borgogna and Emilio Pagliarulo 
(both NIMR, London, UK). Subsequently cells were seeded into 6-well plates on top of 
1x105 feeder cells in FC medium and given fresh FC medium the next day. The cells 
were cultured in a short growth assay format, as described above, to assess proliferation 
patterns of cells, with the day post-electroporation equating to day 1. Due to the short 
term effects of siRNA, cells were counted at days 1, 2, 3 and 4 only which equates to 
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2.6 Infection of NIKS and NIKS HPV16-positive cells 
 
2.6.1 Retroviral expression system 
A retroviral expression system using Phoenix cells was used to make NIKS cell 
populations stably expressing wild type or mutant E6, E7 or E6/E7.  
 
2.6.1.1 Culture of Phoenix cells 
Phoenix cells are a 293T-based cell line which is capable of producing the gag-pol and 
envelope proteins of amphotropic viruses. The cells were kindly provided by Dr Garry 
Nolan (Stanford University, Stanford, USA). The cells were cultured in the same way as 
J2-3T3 cells (see Section 2.2.3.1). On the day prior to transfection, cells were seeded in 
10 cm plates (NUNC; 150350) at a density of 6.5x106 cells per plates in 10 ml of 
DMEM complete. 
 
2.6.1.2 Transfection of Phoenix cells and harvest of retroviruses 
Cells were transfected using polyethyleneimine (PEI). The medium in each plate was 
replaced with 5 ml of high glucose DMEM without supplemented FBS and pen/strep 
(plain DMEM). Two mixes were prepared (volumes indicated are for one plate): 
A) 655 µl of plain DMEM and 45 µl PEI (1mg/ml) and B) 15 µg plasmid DNA (LXSN 
vectors) made up to 700 µl with plain DMEM. Mixtures A and B were combined, 
vortexed and incubated at room temperature for about 20 minutes. At the very end of 
the incubation period media was aspirated off the plates. The A + B mixture was diluted 
with 3.6 ml of plain DMEM and the full volume was added to the cells in each plate. 
After 6 hours the cells were given 10 ml of fresh DMEM complete medium. The 
medium was replaced again on the following day with a further 10 ml of DMEM 
complete. Two days post-transfection the medium in each plate, which contained the 
retroviruses, was collected and spun down at 240 x g for 4 minutes. The supernatant 
was collected and 1ml aliquots were used to either directly infect NIKS or HPV16 
clones or stored at -80 °C. 
 
2.6.1.3 Retroviral infection of NIKS and NIKS HPV16-positive cells 
On the day prior to transfection 5x105 NIKS were plated per well of 6-well plates along 
with 1x105 feeder cells and allowed to recover in FC medium overnight. On the 
following day, 1ml of the virus medium was mixed with 3ml of plain F12-Ham’s along 
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with all the supplements (except FBS and EGF) at the required concentrations for 
making FC medium (volumes indicated are for 1 well). Additionally, polybrene (Santa 
Cruz; sc-134220) was added to the mix for a final concentration of 10 µg/ml. The 
medium in the wells was aspirated and replaced with the virus mixture and then the 
cells were incubated at 37 °C for 6 hours. Subsequently, the medium was aspirated and 
replaced with fresh FC. On the next day, NIKS cells were passed to T75 flasks on top of 
1.4x106 antibiotic-resistant feeders. Cells were left to recover in FC medium overnight 
and then treated with geneticin (Life Technologies; 10131) at a concentration of 
300 µg/ml. Cells were selected for approximately 4-5 days with the medium (and 
geneticin) being replaced every second day. 
 
2.6.2 Ready-made shE6 lentiviral particles  
Two different approaches were used to obtain shE6 lentiviruses. 
 
2.6.2.1 Commercially available ready-made particles 
Commercially available shE6 lentiviral particles (Santa Cruz; sc-156008-V) along with 
shcopGFP (Santa Cruz; sc-108084) and shScrambled (Santa Cruz; sc-108080) control 
lentiviral particles were ordered. The shE6 sequence is based on the previously 
published UGUGUACUGCAAGCAACAGTT siE6 sequence (Niu et al., 2006) 
targeting both E6 and E7. For all three sets, 200 µl of viral stock was supplied 
containing a total of 1x106 infectious units of virus. On the day prior to transfection, 
1.4x105 NIKS were plated per well of a 24-well plate (Thermo Scientific; 142475) 
along with 2x104 feeder cells and allowed to recover in 1 ml of FC medium overnight. 
On the following day, the medium in the wells was replaced with 1 ml FC medium 
without supplemented FBS or pen/strep with added polybrene at a final concentration of 
10 µg/ml. Cells were infected at multiplicities of infection (MOIs) of 1, 2 and 3 using 
32, 64 and 96 µl, respectively, of the virus solution for the all 3 types. Cells were 
incubated at 37 °C for 6 hours before replacing the medium with 1 ml of fresh FC. On 
the next day, cells were passed to T75 flasks on top of 1.4x106 antibiotic-resistant 
feeders. Cells were left to recover in FC medium overnight and then treated with 
puromycin (Santa Cruz; sc-108071) at a concentration of 1 µg/ml. Cells were selected 
for approximately 10 days with the medium (and puromycin) being replaced every 
second day. At day 7 or 8 of the selection process cells were passed to new T75 flasks 
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(on top of 1.4x106 antibiotic-resistant feeders). Without this step, uninfected cells in the 
control plate seem to be able to recover from the puromycin treatment. 
 
2.6.2.2 Custom-designed ready-made particles 
shE6 and shE6/E7 lentiviral particles were designed based on published siRNA 
sequences and supplied by Sigma-Aldrich Mission®. Both sequences were previously 
tested in the siRNA format (siE6 and siE6/E7-1, respectively), as outlined in Section 
2.5. The sequences of the shRNAs are listed in Table 2.4. The lentiviral vector used is 
pLKO.1_puro and the loop sequence is TCAAGAG. 
 
Table 2.4: Custom-designed shE6 and shE6/E7 sequences 
Name and target 
(Target specificity) 
Sequence of sense strand Reference(s) 
shE6 
(E6 only) 
GAGGTATATGACTTTGCTT (Jiang and Milner, 2002, 
Allison et al., 2009) 
shE6/E7 
(both E6 and E7) 
GACCGGTCGATGTATGTC (Gu et al., 2009) 
 
 
In addition to the sequences targeting E6 or E6/E7, shNT (non-target) control lentiviral 
particles were used (Sigma-Aldrich; SHC002V). For infecting and subsequently 
selecting cells the same protocol as described in Section 2.6.2.1 was used, the one 
difference being that all cells were infected at an MOI of 4. 
 
2.6.3 shRNA lentiviruses targeting cellular mRNA 
The RNAi Consortium (TRC) lentiviral shRNA pLKO.1 vectors targeting APH-1α and 
PS-1, which both comprise part of the gamma secretase complex, Notch1 and GFP (as a 
control) were ordered from Thermo Scientific (UK). To produce virus in 293TT cells, 
p8.91 and pczVSV-G were co-transfected alongside the shRNA plasmids. p8.91 is a 
gag-pol vector while pczVSV-G is an envelope plasmid. More details regarding all 
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2.6.3.1 Culture of 293TT cells 
293TT cells are human embryonic kidney cells derived from the HEK 293 adenovirus-
transformed cell line (Graham et al., 1977). 293TT cells were generated by introducing 
SV40 DNA to express a small t antigen and a second SV40 expression cassette with 
large T antigen into HEK 293 cells (Buck et al., 2005). The cells were cultured in the 
same way as J2-3T3 cells (see Section 2.2.3.1) and used for the production of 
lentiviruses. On the day prior to transfection, cells were seeded in 10 cm plates at a 
density of 4x106 cells per plate in 10 ml of DMEM complete. 
 
2.6.3.2 Transfection of 293TT cells and harvest of lentiviruses 
Cells were transfected using polyethyleneimine (PEI). The medium in each plate was 
replaced with 5 ml of high glucose plain DMEM. For one plate of cells, 650 µl of plain 
DMEM was mixed with a total of 7.5 µg of DNA. The mixture was vortexed and spun 
down briefly before adding 45 µl PEI (1mg/ml) and vortexing again. The mixture was 
incubated at room temperature for 10 minutes and then added drop by drop to the 
medium in the plate. After 6 hours the cells were given 10 ml of fresh DMEM complete 
medium. The medium was replaced again on the following day with a further 10 ml of 
DMEM complete. Two days post-transfection the medium in each plate, which 
contained the lentiviruses, was collected and spun down at 240 x g for 4 minutes. The 
supernatant was collected and 1 ml aliquots were used to either directly infect NIKS 
HPV16 clonal cell lines or stored at -80 °C. 
 
As described above 293TT cells were transfected with a total of 7.5 µg of DNA. 2.5 µg 
of each of the two packaging vectors, p8.91 and pczVSV-G, was used. Since not just 
one but a whole set of shRNA vectors was acquired for APH-1α, PS-1 and Notch1, a 
varying amount of DNA from each individual vector was used, depending on the total 
number available per target. To knock-down Notch1, 0.5 µg of each of the five vectors 
was used. To target the gamma secretase complex, 0.4 µg of each vector was used (five 
specific for PS-1 and 2 specific for APH-1α), giving a total of 2.8 µg.  
 
2.6.3.3 Lentiviral infection of NIKS and NIKS HPV16-positive cells 
Cells were infected using the same method described for retroviral infection in Section 
2.6.1.3. 
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2.7 Organotypic Raft Cultures of NIKS and NIKS HPV16-positive cells 
 
2.7.1 Media and reagents for raft cultures  
The various media used throughout the rafting process are F12 medium, keratinocyte 
plating medium and cornification medium 1. Media components and supplements 
required are listed in Table 2.2. 
 
2.7.2 Preparation of dermal equivalents  
Dermal equivalents were made by resuspending 20 ml of collagen (approximately 
3.5 mg/ml) (BD Biosciences; 354236) on ice with 2.5 ml 10X F12 medium (Gibco; 
21765-029), 460 µl 1M NaOH, 250 µl 100X pen/strep and 2.5 ml filtered FBS. 1 ml of 
this premix was plated into individual 24 mm transwell inserts (Costar; 3450) that had 
previously been placed in deep 6-well plates (BD Biosciences; 355467). The plate was 
left in the hood for 5 minutes at room temperature to allow the collagen mixture to gel. 
600 µl of a 10x106 cells/ml suspension of EF-IF cells were added to the remaining 
collagen premix and 2.6 ml of this mixture was layered into each transwell insert.  The 
plate placed in the incubator to allow the dermal equivalents to solidify at 37 °C. After 
30 minutes 19 ml of EF-1F medium was added to each deep well. The plates were left 
in the incubator for 3-5 days to allow the dermal equivalents to take on their appropriate 
shape.  
 
2.7.3 Seeding and differentiation of keratinocytes  
NIKS or HPV16 clonal cell lines were harvested, counted and resuspended in FI 
medium at a concentration of 3.75x106 cells/ml. The medium in each deep well was 
aspirated carefully, using a sterile P20 or P200 pipette tip to cover the end of the glass 
Pasteur to gently remove excess medium from the top of the dermal equivalent itself. 
200 µl of keratinocyte cell suspensions was seeded drop-wise into the center of each 
dermal equivalent. The plates were placed in the incubator at 37 °C for 2 hours to allow 
cells to attach. Then 19 ml of keratinocyte plating medium was slowly added to each 
deep well. Two days later the medium was replaced with a further 19 ml. On the fourth 
day post-seeding all medium was removed, including excess medium within the insert 
surrounding the raft, and three sterile cotton pads (2.5 cm x 2.5 cm) (Schleicher & 
Schuell Bioscience Inc.; 740-E) were placed in the bottom of each deep well to lift 
transwell inserts. The raft cultures were fed from underneath by gently adding 12 ml of 
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cornification medium to the deep well, taking great care to keep the raft itself dry. On 
day 2 post-lifting and every other day thereafter until the point of harvest the medium in 
the deep well was replaced with 9 ml of fresh medium. Raft cultures were left to 
differentiate for a varying number of days post-lifting, ranging from 8 to 12. 
 
2.7.4 Harvesting and fixation of raft cultures  
Prior to harvest the fixation solution was prepared. To do this 2 g of Bacto Agar (BD 
Biosciences; 214010) was added to 90 ml of sterile dH2O and boiled in the microwave 
on a low-medium setting for approximately 3 minutes until homogeneous. The solution 
was left to cool and stored at 4 °C. On the day of harvest the 2 % Bacto Agar solution 
was reheated and 10 ml of 10 % formalin added in the fume hood for a final 
concentration of 1 % formalin. The fixation solution was then kept in a 50 °C water 
bath during the harvesting process. To fix each raft, 2-3 ml of the fixation solution was 
applied to a glass plate in a circular motion, to create a round layer roughly double the 
size of each raft culture, and left to solidify in the cell culture hood for 1-2 minutes. The 
medium was removed from each deep well and the transwell insert was lifted out using 
clean forceps. The raft culture (including any remaining dermal equivalent) was pealed 
of the membrane of the insert using forceps and placed on the solidified layer of fixation 
solution. To fix the raft, 2-3 ml of fixation solution was slowly applied on top and left to 
solidify for 1-2 minutes. Each glass plate was wrapped in cling film and placed at 4 °C 
overnight. On the following day, excess solidified fixation solution around the 
perimeter of the raft culture was removed with a sterile blade (Swann Morton Ltd.; 
0502). The circular raft (now sandwiched between two layers of fixation solution) was 
cut into two halves with sterile scissors and placed side by side in a tissue-tek cassette 
(Simport; M510-10). The cassettes were kept in a 4 % formalin/PBS solution at 4 °C 
overnight. On the next day, the cassettes were transferred to 70 % ethanol and kept at 
4 °C until the time of sectioning. 
 
2.7.5 Sectioning of raft cultures 
Rafts were paraffin embedded in wax and sectioned by an NIMR histologist. They were 
sectioned transversely onto Superfrost plus slides (Thermo Scientific; 8037/1) at a 
thickness of 10 µm.  
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2.8 Immunocytology and Immunohistochemistry 
 
2.8.1 Immunohistochemistry of raft culture sections  
Prior to beginning the immunostaining process the sections were placed at 42 °C 
overnight to soften the wax. 
 
2.8.1.1 De-paraffinization and epitope exposure of raft sections 
In order to immunostain raft cultures, the paraffin embedded sections underwent a 
dewaxing and rehydration process followed by epitope exposure. To dewax sections, 
slides were submerged in xylene, first in one container for 10 minutes and then in a 
second container with fresh xylene for 5 minutes. The sections were rehydrated using 
ethanol; first a quick rinse was done in 100 % ethanol to remove excess xylene, then 
twice for 2.5 minutes each in 100 % ethanol followed by 2 minutes each in 80 %, 50 % 
and 30 % ethanols and finally in PBS for 5 minutes. To unmask target antigens, the next 
step was a microwave-based epitope exposure. Slides were transferred into a plastic 
beaker with 500 ml of 0.01 M citric acid (Sigma Aldrich; 251275) buffer at pH 6 
(prepared fresh during the dewaxing and rehydration steps). The container was covered 
with paper towels with several small punched-out holes. The sections were left to 
equilibrate in the buffer for 10 minutes prior to two rounds of boiling. Slides were 
boiled for 7 minutes at a high setting (90 % power), allowed to stand for 2 minutes at 
room temperature, followed by 5 more minutes of boiling at a high setting (90 % 
power). The sections were allowed to cool for at least 15 minutes at room temperature 
prior to blocking and application of antibodies.  
 
2.8.1.2 Applying primary and secondary antibodies to raft sections 
Directly following the epitope exposure step, the sections were equilibrated in PBS for 
5 minutes. Then slides were gently dried and the area immediately surrounding the 
sections marked with a hydrophobic pen. The slides were transferred to a humidity 
chamber and blocked in 3 % BSA (PAA; K41-001) for at least 30 minutes at room 
temperature. After blocking, the primary MCM7 antibody (Neomarkers; MS-862-P1) 
was made up in 1 % BSA at a 1:100 dilution, applied to the sections (100 µl each) and 
left overnight at room temperature. If E4 staining was also required the antibody 
(prepared in house, B11 clone) was added at a dilution of 1:100 alongside MCM7.  The 
following day the slides were washed in 0.1 % PBS/Tween (Sigma-Aldrich; P1379) 
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three times for 5 minutes each at room temperature. The biotinylated anti-mouse 
secondary antibody (Vector Labs; BA9200) for MCM7 was made up in 1 % BSA at a 
1:100 dilution, applied to each section (100 µl each) and incubated at room temperature 
for 30 minutes. Then slides were washed in 0.1 % PBS/Tween 3 times for 20 minutes 
each. 
 
2.8.1.3 Primary antibody signal amplification  
The first step in the signal amplification process for MCM7 involved the avidin-biotin-
peroxidase complex (ABC) method following the washes after the secondary antibody 
incubation. The complexes were made up using the Vectastain ABC Elite kit (Vector 
Laboratories; PK-7200) at a dilution of 1:400 in 50 mM Tris HCl pH 7.6. The 
complexes were applied to sections (100 µl each) and allowed to incubate for 30 
minutes at room temperature. Thereafter the slides were washed in 0.1 % PBS/Tween 
three times for 5 minutes each. To complete the amplification process, the TSA™ 
Cyanine 3 Tyramide Reagent Pack (Perkin Elmer; SAT704A001EA) was used. 
Fluorochrome (diluted at 1:50) labeled Tyramide (rhodamine) was applied to sections 
(100 µl each) for 8 minutes at room temperature. Then slides were washed in 0.1 % 
PBS/Tween three times for 15 minutes each. DAPI (Sigma-Aldrich; D9542) was 
applied to each section (100 µl each) as a nuclear counterstain at a dilution of 1:800 for 
up to 1 hour at room temperature. Subsequently, the sections were washed in 0.1 % 
PBS/Tween three times for 15 minutes each. 
 
2.8.1.4 Mounting raft culture slides for microscopy 
Slides were rinsed once in dH2O and dried. Then 10-20 µl of citifluor reagent (Citifluor 
Ltd; AF1) was dropped on each section and a coverslip (Menzel-Gläser; BB024060A1) 
was laid on top. Great care was taken to ensure no air bubbles were trapped underneath 
the coverslip. Slides were kept in a folder at 4 °C. 
 
2.8.2 Immunoctyology of NIKS, NIKS HPV16 clones and other NIKS-derived cell 
populations 
To harvest monolayer keratinocytes for immunocytology, square coverslips (VWR 
International Ltd.; 631-0127) were sterilized using 70 % ethanol and placed in 6-well 
plates. Irradiated fibroblasts and keratinocytes were seeded on top as described in 
Section 2.3. 
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2.8.2.1 Fixation of coverslips 
Depending on the antibodies to be used for immunostaining, cells on coverslips were 
fixed with either methanol or paraformaldehyde. To do this, growth medium was 
aspirated from the wells and cells washed once in PBS. Subsequently, coverslips in 
each well were submerged in 2 ml of ice-cold 100 % methanol for 10 minutes or 2 ml of 
4 % paraformaldehyde/PBS at room temperature for 5 minutes. After the incubation 
period, cells were washed twice with PBS and stored in 0.01 % sodium azide in PBS at 
4 °C.  
 
2.8.2.2 Immunocytology and mounting monolayer coverslips 
The PBS/azide solution in each well with the coverslips was aspirated. The cells were 
blocked in 5 % normal goat serum (NGS) (Cell Signaling Technology; 5425) in PBS for 
1 hour at room temperature. After blocking, the phospho-histone 3 antibody (Cell 
Signaling Technology; 9733) was made up in 5 % NGS in PBS at a 1:200 dilution, 
applied to the coverslips and left for 1 hour at room temperature. Thereafter, 5 quick 
rinses of the coverslips (within the wells) were done using PBS. Next, Alexa Fluor® 
488 Goat Anti-Rabbit IgG (Life Technologies; A11008) was applied as a secondary 
antibody in 5 % NGS in PBS at a 1:75 dilution and left for 1 hour at room temperature. 
DAPI was added as a nuclear counterstain alongside the secondary antibody at a 1:1000 
dilution. Subsequently, the coverslips (within the wells) were rinsed 5 times using PBS. 
Coverslips were rinsed once in dH2O, lifted out of the wells carefully and dried gently. 
Then 10-20 µl of citifluor reagent was dropped onto a Superfrost plus slide and the 
coverslip inverted on top, taking great care to ensure no air bubbles were trapped 
underneath. Slides were kept in a folder at 4 °C. 
 
2.8.3 Microscopy and imaging software 
All fluorescently stained cells were viewed on a Zeiss A1 microscope equipped with 
fluorescent filters. Fluorescent images were captured using a Zeiss AxioCam MRm 
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2.9 DNA techniques 
 
2.9.1 DNA constructs used 
Table 2.5: List of vectors used in this study 





Retroviral vectors used 
for the stable expression 
of HPV16 E6 and E7 
proteins 
Kindly provided by Denise 
Galloway (Fred Hutchinson 
Cancer Research Center, 
Seattle, USA) 
(Halbert et al., 1991)  
 LXSN_E6SAT and 
LXSN_E6ΔPDZ 
Retroviral vectors used 
for the stable expression 
of HPV16 E6SAT and 
E6ΔPDZ 
Made by site-directed 
mutagenesis by Lietta 
Nicolaides (NIMR, London, 
UK) 
pMV11 and  
pMV11_E6 
Used for overexpressing E6 Kindly provided by John 




Used for overexpressing E6 Life Technologies; V790-20 
(Elston, 1996) 
pBABE_puro Used for overexpressing E6 Kindly provided by Qian 
Wang (NIMR, London, UK) 
(Addgene; 1764) 
pczVSV-G Envelope plasmid for 
producing viral particles 
Kindly provided by Kate 
Bishop (NIMR, London, 
UK) (Bock et al., 2000) 
p8.91 Plasmid for producing viral 
particles, includes Gag and 
Pol 
Kindly provided by Kate 
Bishop (NIMR, London, 





Used for the production of 
control lentiviruses to 
knock-down GFP 
TRC Lentiviral shRNA 
(Thermo Scientific; UK) 
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pLKO.1_shNotch1 Used for the production of 
lentiviruses to knock-down 
Notch1 
TRC Lentiviral shRNA 




TRCN0000003361 and  
TRCN0000003362 
pLKO.1_shPS1 Used for the production of 
lentiviruses to knock-down 
gamma secretase 
TRC Lentiviral shRNA 






pLKO.1_shAPH1α Used for the production of 
lentiviruses to knock-down 
gamma secretase 
TRC Lentiviral shRNA 





2.9.2 Transformation of E.coli with DNA 
Plasmid DNA was mixed with 50 µl of competent XL10-Gold® Ultracompetent cells 
(Stratagene; 200314) and incubated on ice for 30 minutes. The mix was heat-pulsed in a 
water bath at 42 °C for 30 seconds and then cooled on ice for 2 minutes. Subsequently, 
800 µl of SOC medium (Life Technologies; 15544-034) was added and cells were 
incubated at 37 °C for 45 minutes at constant shaking (220 rpm). Cells were plated on 
LB agar plates containing either ampicillin (Sigma Aldrich; A5454) at 100 µg/ml (for 
VSV-G, p8.91, pMV11, pMV11_E6, pcDNA3.1, pcDNA3.1_E6SD, pBABE_puro, 
LXSN, LXSN_E6, LXSN_E6SAT, LXSN_E6ΔPDZ, LXSN_E6/E7) or carbenicillin at 
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2.9.3 Plasmid purification 
To extract plasmid DNA from bacteria, three commercial kits were used depending on 
the amount and purity of plasmid required. The QIAprep® Spin Miniprep Kit (Qiagen; 
27106) was used from small-scale preps, from 2-5 ml overnight bacterial cultures. The 
QIAGEN® Plasmid Midi Kit (QIAGEN; 12143) and the QIAGEN® Plasmid Maxi Kit 
(QIAGEN; 12162) were used for larger-scale preps, from 100 ml up to 500 ml cultures, 
respectively. The purification was done according to the manufacturer’s instructions. 
 
2.9.4 Quantification of plasmid DNA  
Plasmid DNA was quantified using a Nanodrop ND-1000 Spectrophotometer. 
 
2.9.5 Restriction enzyme plasmid digestion  
To allow for the transfection of cells with linearized DNA (as outlined in Section 2.2.5), 
pMV11, pcDNA3.1 and pBABE_puro vectors were digested using restriction enzymes. 
BglII (New England Biolabs; R0144) is a single cutter for pcDNA3.1 while BamH1 
(New England Biolabs; R0136) cuts both pMV11 and pBABE_puro in just one place. A 
total of 20 µg of plasmid DNA was used in the reaction for each of the vectors and 
digested with 20 units of the appropriate enzyme. For both restriction enzymes, an 
additional tube was prepared where dH2O was used instead of the enzyme. This was 
used to ensure that both enzymes were working correctly. 
 
2.9.6 Agarose gel electrophoresis 
To assess the presence and quality of plasmid DNA or for subsequent gel extraction, 
DNA was separated on a 1 % (w/v) agarose (company) gel in TAE containing 0.5 µg/ml 
Ethidium Bromide (Bio-rad; 161-0433) at 120 V for up to 45 minutes. 
 
2.9.7 Gel extraction 
To do gel extractions, the relevant bands were visualized in the agarose gel using 
Ultraviolet light and excised using a sterile blade. The QIAquick Gel Extraction Kit 
(QIAGEN; 28704) was used according to the manufacturer’s instructions.  
 
2.10 Quantitative PCR (qPCR) 
Quantitative real-time (RT) polymerase chain reaction (PCR) was carried out using 
cDNA as a template. Forward and reverse primers were used to assess the levels of 
Chapter	  2:	  Materials	  and	  Methods	  
	   84	  
HPV16 E6, HES1 and p21 transcripts in NIKS and HPV16 clonal cell lines. β-actin, 
GAPDH or ELF1 primers were used as endogenous controls.  
 
2.10.1 Extraction of total RNA  
For extraction of RNA, cells were harvested, washed with PBS and then placed on ice. 
Total RNA extraction was carried out using the RNeasy® Mini Kit (Qiagen; 74104) and 
QIAshredder™ kit (QIAGEN; 79654) according to the manufacturer’s protocol. RNA 
was stored at -80 °C. If RNA extraction was not carried out immediately after harvest of 
cells, pellets were resuspended in RNAprotect® Cell Reagent (QIAGEN; 76526) 
following the manufacturer’s instructions and stored at -80 °C indefinitely. 
 
2.10.2 DNase digestion and reverse transcription  
Prior to making cDNA, genomic DNA was removed from 2 µg of total RNA using the 
DNA-free™ kit (Ambion; AM1906) according to the manufacturer’s protocol. The 
reverse transcription was done using the SuperScript™ III First-Strand Synthesis Kit 
(Life Technologies; 18080-051). A volume of 16 µl (approximately 0.5 µg) of clean 
RNA was added to a tube along with 2 µl oligo(dT)20 primers and 2 µl dNTPs. The 
mixture was incubated at 65 °C for 5 minutes and then placed on ice for at least 1 
minute. Subsequently 4 µl of 10X RT Buffer, 8 µl of MgCl2, 4 µl of DTT, 2 µl RNase 
OUT™ and 2 µl SuperScript™ III reverse transcriptase was added to each tube before 
incubating at 50 °C for 1 hour. To stop the reaction, tubes were placed at 85 °C for 5 
minutes. Thereafter, cDNA was stored at -80 °C or used for qPCR. For each RNA 
sample an additional tube was prepared where 2 µl of nuclease-free H2O (Life 
Technologies; AM9935) was used instead of the enzyme. This was used to control for 
the absence of genomic DNA. cDNA was generally diluted 50-100-fold with 
nuclease-free H2O prior to doing qPCR. 
 
2.10.3 qPCR primer design and primer sequences 
E6, β-actin and GAPDH primers were designed using Primer Select software and 
ordered from Eurogentec (UK). HES1, p21 and ELF1 primers are commercially 
available through Origene (USA) (HK209713, HK201880, HK202783, respectively) 
along with appropriate template standards for making standard curves. A list of the 
primers and their sequences is shown in Table 2.6. 
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Table 2.6: Primers used for qPCR 
E6 primers* Forward: TGTTTCAGGACCCACAGGAGC 
Reverse: CGCAGTAACTGTTGCTTGCAG 
β-actin primers Forward: TGGGCATGGGTCAGAAGGAT 
Reverse: CGGCCAGAGGCGTACAGGGA 
GAPDH primers Forward: CCTCCCGCTTCGCTCTCT 
Reverse: CTGGCGACGCAAAAGAAGA 
HES1 primers Forward: GGAAATGACAGTGAAGCACCTCC 
Reverse: GAAGCGGGTCACCTCGTTCATG 
p21 primers Forward: AGGTGGACCTGGAGACTCTCAG 
Reverse: TCCTCTTGGAGAAGATCAGCCG 
ELF1 primers Forward: CTAAAGCAGTGTCCAGGTTGTGG 
Reverse: CGCTGACCTTCCACTTTTGCCA 
*The forward and reverse E6 primers amplify a 114bp fragment within the first exon of 
the HPV16 E6 ORF. Hence, all species of E6 (including the full length protein, E6*I 
and E6*II) are detected. 
 
2.10.4 qPCR reagent cocktails 
Power SYBR® Green PCR Master Mix (Applied Biosystems; 4367659) was used to 
amplify and detect cDNA in 96-well PCR plates (Thermo Scientific; TUL-962-011N) 
using an ABI 7500 Real-Time PCR System. A fresh master mix of reagents was 
prepared for each primer set (see Table 2.7 below) immediately prior to loading the 
plate. The final volume in each well was 25 µl. 
 
Table 2.7: qPCR master mix 
Custom-designed primers Origene primers 
) Reagent µl per reaction 
(per well) 
Reagent µl per reaction 
(per well) 
Forward (F) primer 1.75  Primers (F + R) 1 
Reverse (R) Primer 1.75    
Sybr Green 12.5 Sybr Green 12.5 
dH20 6 dH20 8.5 
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2.10.5 qPCR plating scheme and cycle parameters 
Samples were run in triplicate wells (for each primer set). To set up the reaction, 22 µl 
of the master mix was pipetted into each well, using a Multipette® Xstream from 
Eppendorf for added accuracy, followed by 3 µl of cDNA pipetted separately. Table 
2.8a outlines the qPCR cycle parameters. They include a dissociation curve at the end of 
the amplification steps. This was included because SYBR Green can bind to unspecific 
double stranded DNA, such as primer-dimers, which can interfere with results. The 
dissociation curve shows whether a single or multiple PCR products have been 
amplified. Table 2.8b outlines the parameters for the dissociation program. 
 
Table 2.8a: PCR cycle parameters 
Step Number of cycles Time per cycle Temperature 
1 1 2 minutes 50 °C 
2 1 15 minutes 95 °C 
3 40 15 seconds 95 °C 
4 1 1 minute 60 °C 
Table 2.8b: Dissociation parameters 
Step Number of cycles Time per cycle Temperature 
1 1 15 seconds 95 °C 
2 1 20 seconds 60 °C 
3 1 95 seconds 95 °C 
 
 
2.10.6 Standard curves for primers 
A standard curve was generated for each primer pair used in order to establish its 
efficiency and sensitivity. To make the standard curve, a DNA plasmid containing the 
sequence that is amplified by the primers was chosen as a template. For the three pairs 
of Origene primers (p21, HES1 and ELF1) the template standard was ordered along 
with primers. Six serial 10-fold dilutions of the template were prepared which 
corresponded to a known number of copies of the template, from 1 to 1x106, and served 
as a template for the qPCR reaction. To generate the standard equation, the logarithms 
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of the values of the known copy numbers in each dilution (either 1, 10, 100, 1000, 
10000 or 1000000) were plotted on a graph along the x-axis against the Ct (cycle 
threshold) value given by the qPCR machine for each dilution along the y-axis, and an 
equation was obtained in the form of y = mx + c. The slope (m) refers to the efficiency 
of the primer pairs, where a slope of -3.33 shows a perfect linear relationship between 
DNA copy number and Ct value and corresponds to an increase of 3.33 Cts for every 
10-fold dilution of sample. The y-value in this equation is the Ct value that the qPCR 
measures, which refers to the number of cycles needed to amplify one copy of DNA. 
 
Table 2.9: Standard curves for primers used for qPCR 
E6 primers y = -3.328x + 38.26 
β-actin primers y = 3-.308x + 35.757 
GAPDH primers y = -3.416x + 39.632 
HES1 primers y = -3.333 + 42.076 
p21 primers y = -3.338x + 34.526 
ELF1 primers y = -3.306x + 40.524 
 
 
2.10.7 Calculations for copy number determination 
The standard curves for the primer sets were used to calculate the copy numbers of the 
transcripts of interest in each sample. Each triplicate set of Ct values per sample and 
primer set was averaged. To account for pipetting error the software calculated the 
standard deviation for each set, with those above 0.5 indicating excessive variation. If 
so, the whole qPCR reaction was repeated for that sample. Acceptable Ct averages were 
used to calculate copy number. To do so, the standard curve equation was solved for x. 
The number of copies is the inverse log of x ie. 10x. Once transcript numbers had been 
established for all primer pairs, the values for E6, p21 and HES1 were divided by the 
values of either GAPDH, β-actin or ELF1 to normalize the results. The final number 
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2.11 Protein Analysis 
 
2.11.1 Cell lysis for western blot analysis 
Cells were harvested, washed and then lysed, or frozen at -80 °C and lysed at a later 
point after being allowed to thaw to room temperature. Prior to lysis, 1-2 µl of 
Benzonase® Nuclease (Sigma-Aldrich; E1014) in 4-8 µl of PBS was added to each tube 
and the pellet was resuspended. Then 100-500 µl (depending on pellet size) of either 
lysis buffer was added. Both the 1 % NP-40 and 6 % SDS RIPA buffers were used with 
1X Complete Protease Inhibitor Cocktail (EDTA-free) solution (Roche; 04 693 159 
001).  
 
2.11.1.1 1 % NP-40 buffer 
The 1 % NP-40 buffer was used to assess the soluble protein fraction of cells and is 
based on a previously published protein extraction buffer (Nakahara et al., 2005). It 
consists of 50 mM Tris pH 7.4, 150 ml NaCl, 1 mM EDTA and 1 % NP-40. After 
adding the buffer to cells and resuspending the pellet, the lysate was placed on ice for 
30 minutes. Subsequently, the samples were spun down at 14000 rpm using a Heraeus 
Fresco 17 centrifuge (Thermo Electron Corporation) for 15 minutes at 4 °C and the 
supernatant collected and stored at -80 °C. 
 
2.11.1.2 6 % SDS RIPA buffer 
The 6 % SDS RIPA buffer was used to prepare whole cell extracts. It is made up of 
150 mM NaCl, 1 % Triton X, 0.5 % Sodium deoxycholate, 6 % sodium dodecyl sulfate 
(SDS), 50 mM Tris pH 8 and 0.005 mM EDTA pH 8. After adding the buffer to the 
cells and resuspending the pellet, the lysate was boiled at 95 °C for 10 minutes and then 
spun down at 17000 rpm using a Heraeus Fresco 17 centrifuge (Thermo Electron 
Corporation) for 5 minutes. Thereafter, the supernatant was transferred to a new boil-
proof microcentrifuge tube (Corning; MCT-150-C) and stored at -80 °C. 
 
2.11.2 Protein quantification  
Protein quantification was carried out using the DC Protein Assay Kit (Bio-Rad; 500-
0111) according to manufacturer’s instructions. BSA standards, prepared in 0.5 mg/ml 
increments ranging from 0 to up to 10 mg/ml, were used to make a standard curve. 
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2.11.3 SDS PAGE 
 
2.11.3.1 Preparation of gels and gel electrophoresis 
Appleton Woods OmniPAGE Mini gel electrophoresis equipment was used for gels 
prepared in-house. Different percentage gels were prepared depending on the size of the 
proteins to be analyzed. Table 2.10 shows the compositions of the stack and 6, 10 or 
15 % Tris-glycine polyacrylamide resolving gels. The resolving gel was prepared first 
(8 ml per gel) and allowed to set for approximately 30 minutes. The stacking gel was 
then made and poured over the resolving gel (2 ml per gel). The combs, generally with 
10 wells, were put in place and the gel was left to polymerize for 30 minutes.  
 
Table 2.10: Composition of 6, 10 and 15 % Tris-glycine SDS-polyacrylamide 
resolving gels and 5 % stacking gel 
Resolving gel (for 10 ml) 
Reagent 6 % 10 % 15 % 
dH20 5.3 ml 4 ml 2.3 ml 
30 % acrylamide mix 2 ml 3.3 ml 5 ml 
1.5 M Tris (pH 8.8) 2.5 ml 2.5 ml 2.5 ml 
10 % SDS 0.1 ml 0.1 ml 0.1 ml 
10 % ammonium persulphate 0.1 ml 0.1 ml 0.1 ml 
TEMED 8 µl 4 µl 4 µl 
Stacking gel (2 ml) 
dH20 1.4 ml 
 30 % acrylamide mix 0.33 ml 
1 M Tris (pH 6.8) 0.25 ml 
10 % SDS 20 µl 
10 % ammonium persulphate 20 µl 
TEMED 2 µl 
 
For many experiments XCell SureLock® Mini-Cell electrophoresis equipment from 
Life Technologies was used for running ready-made NuPAGE 4-12 % Bis-Tris mini 
gels (Life Technologies; NP0335B0X), according to the manufacturer’s instructions.  
Between 10 and 30 µg of protein (depending on the protein to be assessed) was loaded 
into each well. 1 L of SDS electrophoresis buffer (see Table 2.1) was used in each 
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Appleton Woods tank containing up to 2 gels. Gels were run at 80 V for about 30 
minutes and then 150 V for 60-90 minutes.  
 
2.11.3.2 Membrane transfer for western blot 
All 15 % gels and some of the ready-made NuPAGE gels (if the protein to be assessed 
was small) were transferred onto 0.2 µm Immuno-Blot PVDF membranes (Bio-Rad; 
162-0176). All other gels were transferred onto 0.45 µm PVDF membranes (Millipore; 
IPVH00010). Before use, membranes were submerged in methanol, rinsed in dH2O and 
then left to soak in transfer buffer for 10-15 minutes. All transfers were done using 
500 ml of transfer buffer per Bio-Rad Mini Trans-Blot® Cell tank (containing up to 2 
gels) at 4 °C for 90 minutes at 150 V or overnight at 50 V, depending on the antibody to 
be used.  
 
2.11.3.3 Blocking, antibody incubations and washing 
Following transfer, the membranes were blocked in 5 % milk (Oxoid; LP0031) in 0.1 % 
TBS/Tween for 1 hour at room temperature or overnight at 4 °C. Subsequently, the 
membranes were incubated with primary antibody for 1-2 hours at room temperature or 
overnight at 4 °C. Generally, the membranes were cut into several smaller strips before 
applying antibody to allow incubation with several different antibodies at once. The 
antibodies were diluted in 5 ml of 5 % milk in 0.1 % TBS/Tween. Table 2.11a lists all 
the primary antibodies used for protein analysis and their respective dilutions. 
Following the incubation with the primary antibody, all membrane pieces were washed 
in 0.1 % TBS/Tween at room temperature for 1-2 hours with a change in wash buffer 
every 10-15 minutes. The membranes were then incubated with secondary antibody, 
listed in Table 2.11b, in 5 ml of 5 % milk in 0.1 % TBS/ Tween for 1 hour at room 
temperature. This was followed by a second round of washing with 0.1 % TBS/Tween 
at room temperature, lasting up to 4 hours with a change in wash buffer every 20-30 
minutes. Table 2.12 lists further E6 antibodies that were tested in an attempt to reduce 
the level of background in the western blots. 
 
2.11.3.4 Signal detection 
All proteins were detected using 3 different kits, partly depending on the level of 
sensitivity needed. The Amersham™ ECL western Blotting Detection kit (GE 
Healthcare; RPN2106) was used for highly abundant proteins while the Amersham™ 
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ECL Advance kit (GE Healthcare; RPN2135) was used to detect low level proteins. 
Halfway through the project the Amersham kits went out of production and the 
Immobilon western Chemiluminescent HRP Kit (Millipore; WBKLS0500) was used 
instead. 
 
Table 2.11a: Primary antibodies used for western blotting 
Antibody name Dilution (incubation time) Company; catalogue # 




1:500 each (overnight at 
4 °C) 
Santa Cruz; sc-65711 and 
sc-51951 
p53 (DO-1) 1:1000 (overnight at 4 °C) Santa Cruz; sc-126 
NICD (VAL1744) 1:1000 (overnight at 4 °C) Cell Signaling Technology; 
2421 
p21 (EA10) 1:100 (overnight at 4 °C) Abcam; ab16767 
Rb 1:2000 (overnight at 4 °C) BD Pharmingen; 554136 
Cyclin A (6E6) 1:500 (overnight at 4 °C) Leica Biosystems; 
CYCLINA 
GAPDH 1:5000 (1-2 hours at room 
temperature) 
Millipore; MAB374 
HSP70 (W-27) 1:2500 (1-2 hours at room 
temperature) 
Santa Cruz; sc-24 
Table 2.11b: Secondary antibodies used for western blotting 
Antibody name Dilution (incubation time) Company; catalogue # 
Anti-mouse IgG-HRP 
(from sheep) 
1:10000 (1-2 hours at room 
temperature) 
GE Healthcare; NA931V 
Anti-rabbit IgG-HRP 
(from donkey) 
1:10000 (1-2 hours at room 
temperature) 
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Table 2.12: Additional E6 primary antibodies tested 
Antibody name Company; catalogue # 
E6 (1E-6F4) Euromedex; 1E-6F4 
HPV16 E6 / HPV18 E6 (C1P5) Santa Cruz; sc-460 
E6 (N-17) Santa Cruz; sc-1584 
E6 Arbor Vita Corporation; AVC#1007 
HPV16 E6 / HPV18 E6 (C1P5) Abcam; ab70 
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Chapter 3: Establishing the Role of E6 and E7 in Controlling the 
Proliferation of Cells Containing Episomal HPV16 Genomes 
 
3.1 Introduction 
Previous work from my laboratory suggested that NIKS cells transfected with HPV16 
genomes can immediately present with rafting phenotypes that resemble LSILs or 
HSILs (Isaacson Wechsler et al., 2012). The cell lines also gave rise to corresponding 
proliferation patterns in monolayer cell culture with the HSIL-like cell lines reaching 
higher cell densities. These data further showed that the growth phenotypes may be 
caused, at least in part, by higher levels of the soluble protein fractions of both the viral 
E6 and E7 proteins.  
 
This novel cell line model has given me the opportunity to further characterize 
neoplastic progression caused by HPV infection and to investigate the underlying 
mechanism that causes an LSIL to advance to an HSIL. The fact that the cell lines have 
distinct growth characteristics even in monolayer has allowed me to work 
predominantly with this cell culture system; an environment that is much easier to 
manipulate than raft cultures and in vivo models. Hence, this chapter has aimed to 
address the role of E6 and E7 in giving rise to the LSIL- and HSIL- like growth 
phenotypes of these cells. 
 
When it comes to HPV-induced neoplastic progression, both E6 and E7 proteins are 
considered to be the main players (von Knebel Doeberitz et al., 1988, von Knebel 
Doeberitz et al., 1994). While the precise order and expression levels of all viral gene 
products is disrupted in high-grade neoplasias, only E6 and E7 (and to some extent E5 
(DiMaio and Mattoon, 2001, Barbaresi et al., 2010)) have transforming, tumor-
promoting capabilities when expressed at aberrant levels, due to, amongst other things, 
their well characterized effects on p53 (Werness et al., 1990) and Rb (Dyson et al., 
1989), respectively. Generally a low-grade lesion is associated with much lower levels 
of both proteins than a high-grade lesion, with high levels making cells much more 
vulnerable to the accumulation of genetic changes that can lead to cancer. It has been 
suggested that high-grade neoplasia is correlated with integration of the viral genome 
into host chromosomes (Klaes et al., 1999) and that both E6 and E7 are expressed more 
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stably once integrated (Jeon and Lambert, 1995), due to increased stability of transcripts 
and cis-regulatory effects on regulation of transcription of integrants (von Knebel 
Doeberitz et al., 1991). Nevertheless, other data have shown that 89 % of all cervical 
lesions, 71 % of HSILs and 49 % of HPV-related carcinomas present exclusively with 
viral episomes (Hafner et al., 2008), with E6 and E7 only being expressed from these 
extrachromosomal genomes. This means that the aberrant expression of these proteins, 
that is associated with high-grade neoplasias, can occur from intact viral episomes. 
 
Several groups have assessed the effects of E6 and E7 expression on neoplastic 
progression in transgenic mouse models (Arbeit et al., 1996, Brake and Lambert, 2005, 
Buitrago-Perez et al., 2012). However, these studies have not looked at endogenous E6 
and E7 expression in the context of the full viral genome.  
 
To explore the underlying mechanism, presumably involving E6 and E7, that gives rise 
to the LSIL- and HSIL-like proliferation patterns, most of my experiments were carried 
out in monolayer cultures. Although I have observed the growth phenotypes for several 
different clonal HPV16 cell lines, from two independent transfection and selection 
events (Isaacson Wechsler et al., 2012), for simplicities sake I used only two cell lines 
(one LSIL- and one HSIL-like) for the majority of my experiments. The two clones that 
were chosen, 1K and 2K, have, in the past, been shown to have the most different 
growth patterns out of all cell lines tested. 
 
The growth assay experiment was first optimized and carried out by Erin Isaacson 
Wechsler (NIMR). Proliferation of cells was quantified by counting them at specifically 
timed increments. The number of cells seeded and the time-points analyzed during the 
growth assays were such that the cells were sub-confluent at day 3, confluent at 
approximately day 5 and post-confluent from day 7 onwards. The term “confluent” 
means that the culture dish is completely covered in cells and looks full, with most 
NIKS colonies having merged with each other, so that all cells are surrounded by other 
cells. The divergence of the cell lines, to give rise to the two growth phenotypes, was 
very much dependent on the point of confluence, with the exact seeding efficiency of 
cells, which varied slightly from one experiment to another, dictating at which point 
exactly cells reached confluence. Generally, the cell lines began to diverge from day 3 
onwards half of the time, when cells seeded well, and only from day 5 onwards for the 
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other half, when cells did not seed with as high of an efficiency and looked slightly sick 
for the first day or two. While the faster growing HSIL-like cells continued proliferating 
even once confluence had been reached, the slower LSIL-like cells tended to plateau off 
and not grow very much between days 5 and 7. Hence, the two growth phenotypes 
could easily be distinguished by day 7. 
 
The dependence of the growth phenotypes on the confluence of cells makes this 
monolayer model very relevant in terms of studying the virus in the context of its 
normal environment. Since HPV infects the epithelium, the virus is generally not in a 
sub-confluent setting, as all cells within the epithelium are packed together tightly and 
surrounded by other cells, the exception to this being a wound. As a result, we consider 
a confluent monolayer to represent a reasonable model of the basal layer in raft culture 
and also real stratified epithelium because the cells are probably of a fairly equally 
density. Hence, the growth potential of cells and the levels of viral proteins observed at 
confluence should be similar to that of basal cells. Therefore the effects of the virus and 
the differences between the LSIL- and HSIL-like clonal cell lines observed during the 
growth assays, may reflect the real pathways and mechanisms that the virus is 
deregulating during neoplasia.  
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3.2 Results 
 
3.2.1 The two phenotypes, that NIKS clonal cell lines containing HPV16 episomes 
show, are consistently reproducible in monolayer culture 
Previous work in the laboratory has shown that in monolayer growth assays, 
HPV16-transfected, episomal NIKS clonal cell lines spontaneously present with two 
growth phenotypes (Isaacson Wechsler et al., 2012). One type of clone grows more 
quickly than the other type, from the point of confluence. The main focus of this project 
was to determine how this growth difference arises, and in what way and to what extent 
the two types of clones differ. However, before embarking on this, it was important to 
ensure that the growth phenotypes could be consistently reproduced. Therefore I 
repeated the growth assays following the same protocol as had previously been used. 
 
Two clonal HPV16 cell lines, 1K and 2K, were cultured in a 9-day growth assay. Cells 
were counted at days 1, 3, 5, 7 and 9 post-seeding to assess the differential proliferation 
patterns (Fig. 3.1A). A bar chart showing fold-increase relative to the previous time-
point is shown in Figure 3.1B. The growth rate of 1K and 2K is very similar between 
day 1 and day 3, when cells are sub-confluent. For NIKS, it is much lower at this point. 
This may be due to these cells taking longer to adhere to the bottom of the well post-
seeding which causes a delay in their growth. Between days 3 and 5 and days 5 and 7, 
when cells first reach confluence and then continue proliferating into post-confluence, 
respectively, the distinct slow and fast growth phenotypes start to emerge. The rate of 
proliferation of LSIL-like 2K cells is lower than that of both NIKS and the HSIL-like 
1K clone. It seems that NIKS have the capacity to grow quickly at this point because the 
wells are less full than those of both 1K and 2K, due to the later onset of growth. From 
day 7 to 9, 1K and 2K grow at a very comparable pace while NIKS have slowed down. 
However, since the number of cells for 1K was already much higher at day 7 than for 
2K, this results in the overall difference in cell number at day 9 to be even more 
pronounced than at day 7. Overall, between days 1 and 9, NIKS have increased their 
cell numbers 22-fold, while 1K and 2K have done so 39- and 24-fold, respectively. This 
means that 1K have grown to a density that is 2.2-fold higher than that of NIKS while 
2K have reached a 1.4-fold higher cell density. 
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The data in Figure 3.1 are an average of 19 individual experiments that were 
accumulated throughout the course of this project. Unpaired t-tests were used to 
compare 1K and 2K cell numbers at each time-point. There is no significant difference 
at day 1 and 3 with p values of 0.94 and 0.84, respectively. At days 5, 7 and 9 the 
overall cell numbers are significantly different with p values of 0.02 at day 5 and less 
than 0.00001 at both days 7 and 9. 
 
The growth curve illustrates that the proliferation phenotypes of my cells are not 
identical to what was previously described (Isaacson Wechsler et al., 2012). One 
difference is that my HPV16 clones have the capacity to grow to a much higher cell 
density than before. Furthermore, the growth of my slow growing LSIL-like clone does 
not stop after reaching confluence at day 5. Instead, cells continue growing well into 
post-confluence. Therefore it seems that the overall divergence of the LSIL- and HSIL-
like cells is less than before. Nevertheless, the most important feature of the growth 
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Figure 3.1: The two phenotypes, that NIKS clonal cell lines containing HPV16 episomes 
show, are consistently reproducible in monolayer culture 
NIKS, 1K and 2K cell lines were counted in duplicate at days 1, 3, 5, 7 and 9 post-seeding and 
compared in terms of their growth phenotypes. The cells become confluent at approximately 
day 5. The 1K clone (red) consistently grows to a higher cell density than the 2K clone (green). 
A) The mean number of cells per 6-well plate well was plotted against the time in days. The 
error bars represent +/- the standard error of 19 individual experiments. Unpaired t-tests were 
used to compare 1K and 2K cell numbers at each time-point. The p values are 0.94, 0.84 and 
0.02 at days 1, 3 and 5, respectively, and less than 0.00001 at both days 7 and 9. 
B) Fold-increase relative to the previous time-point was calculated and plotted in a bar chart. 
The error bars represent +/- the standard error of 19 individual experiments. 
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3.2.2 The difference in cell densities between NIKS and HPV16-containing clonal 
cells can be observed by microscopy 
The majority of experiments in this project were carried out in monolayer culture, 
where cell density plays an important role in determining the growth phenotype of the 
cells. To visualize what the cells look like in the wells at the different time points, 
NIKS, 1K and 2K were cultured in a growth assay format and photographs of the cells 
were taken using brightfield microscopy at days 1, 3, 5, 7 and 9 post-seeding. 
 
The images (Fig. 3.2) confirm that at days 1 and 3 the 6-well plate wells are sub-
confluent with individual cell colonies visible, more so at day 1 than at day 3. There are 
plenty of feeder cells that fill up the empty space between colonies. At day 5, for the 
HPV16 clones, the colonies have merged to give rise to one confluent monolayer, with 
feeder cells having been pushed out of the way and very few remaining. NIKS are 
lagging behind with some individual colonies still distinguishable. At days 7 and 9, all 
the wells are packed tightly with cells. Both the LSIL- and HSIL-like cells have become 
much smaller in size to accommodate increasing numbers. NIKS too have decreased in 
size but much less so than the clones. For NIKS, at day 7 some colonies are still 
discernible, however, most have merged. For the clones, next to no feeders remain 
adhered to the bottom of the well while for NIKS, even at day 9, the post-confluent 
monolayer seems to be interspersed with them. 
 
Overall, the images of the cells are helpful in visualizing the various degrees of 
confluency; the differences between a sub-confluent, confluent and post-confluent well 
can be readily observed for each cell line. NIKS grow considerably slower than the 
clones and therefore take longer to reach confluence.  
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Figure 3.2: The difference in cell densities between NIKS and HPV16-containing 
clonal cells can be observed by microscopy 
NIKS, 1K and 2K were cultured in duplicate wells in a growth assay format. 
Photographs were taken using brightfield microscopy at days 1, 3, 5, 7 and 9 
post-seeding to visualize cells. 
Sub-confluence 
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3.2.3 The LSIL- and HSIL-like growth phenotypes are not dependent on the 
specific stock of cells that is used for the different cell lines  
As described in Section 3.2.1, my growth assays have shown me that the two 
proliferation phenotypes are reproducibly obtained. However, there are some 
differences between the growth patterns observed in Figure 3.1 and those previously 
found (Isaacson Wechsler et al., 2012). The current experiments show that the average 
number of cells per well are higher for all cell lines compared to the original data, and 
also that the LSIL-like 2K cell line, does not stop growing after reaching confluence.  
 
To determine whether the differences between the current and previous experiments 
resulted from having to use higher passage cells, I did a proliferation assay using the 
HSIL and LSIL-like 1K and 2K cells from my current cell stock, and HSIL- and LSIL-
like 1K and 4Q cell lines from the old stock (Fig. 3.3). As no early passage stocks of the 
2K cell line were available, we used the 4Q cell line which had a very similar growth 
pattern to the original 2K cell line. As expected, the LSIL- and HSIL-like growth 
phenotypes emerge from the point of confluence at day 5 for cells from both the old and 
current cell stocks. Although the LSIL-like 4Q cells from the old stock grew slightly 
faster between days 3 and 7 than the 2K cell line, by day 9, both 2K and 4Q clones have 
reached the same cell number. 
  
The proliferation assay suggests that the current and old stocks of cells have very 
similar growth patterns and grow to comparable densities. While the growth assay 
(Fig. 3.3) does show that 4Q cells from the old cell stock plateau between day 7 and 9, 
this is not the case between day 5 and 7. The original experiments were only taken out 
to day 7, and hence, I was expecting the 4Q cell line to plateau from day 5 onwards, as 
previously shown. Therefore the slight difference in growth patterns between the 2K 
cells from the current cell stock and 4Q cells from the old stock seems negligible. These 
data suggest that the current cell stock is suitable for all subsequent experiments and 
that any results obtained in past experiments should be replicable with these cells. 
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Figure 3.3: The LSIL- and HSIL-like growth phenotypes are not dependent on the 
specific stock of cells that is used for the different cell lines 
Four clonal HPV16 cell lines were grown up in a 9-day growth assay. One LSIL- (2K 
and 4Q, respectively) and one HSIL-like clones (both are 1K) were taken from both the 
current and old stocks of cells. Cells were counted in duplicate at days 1, 3, 5, 7 and 9 
post-seeding to assess the differential growth patterns. The clones that are colored red 
consistently grow to a high cell density whereas the cell lines marked in green reach a 
lower cell number. The average number of cells per 6-well plate well was plotted 
against the time in days. The error bars represent +/- the standard deviation of the 
duplicate wells. 
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3.2.4 The LSIL- and HSIL-like growth phenotypes are independent of the presence 
of feeder cells 
Having shown that the decreased divergence in LSIL- and HSIL-like growth 
phenotypes is not a result of using higher cell passage numbers, I considered other 
factors that might be affecting proliferation. I speculated that decreasing the number of 
feeder cells could affect the growth of NIKS cells and the difference between 
phenotypes.  
 
In an attempt to recreate the more extensive growth differential, I monitored the 
proliferation of HSIL- and LSIL-like 1K and 2K cells in the absence of feeder cells 
(Fig. 3.4). The results were plotted on a graph, with the 1K and 2K average cell counts 
presented in Figure 3.1 used as a reference for how these cells grow in normal culture 
conditions. The absence of feeder cells appears to decrease the proliferation rate of the 
cells, but does not seem to have a big effect on the LSIL- and HSIL-like growth 
phenotypes. The cell lines start to diverge in terms of their growth rate from day 3 
onwards and by day 9 1K has grown to more than 1.5-fold the cell number of 2K.  
 
These results seem to indicate that, although the overall rate of proliferation is affected 
by a lack of feeder cells, the LSIL- and HSIL-like growth phenotypes are not dependent 
on their presence. I hypothesize that the amount of growth factors supplied by the 
γ-irradiated feeders is so small compared to those supplemented in the media, that any 
dependence of the proliferation phenotype on growth factors may be masked in this 
experiment.  
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Figure 3.4: The LSIL- and HSIL-like growth phenotypes are independent of the 
presence of feeder cells 
The growth of 1K and 2K cells was monitored for 9 days, according to standard 
protocol, but without the layer of γ-irradiated feeder cells. Cells were counted in 
duplicate at days 1, 3, 5, 7 and 9 post-seeding. In a standard growth assay, the clone that 
is colored orange consistently grows to a high cell density whereas the cell line marked 
in blue reaches a lower cell number. The average number of cells per 6-well plate well 
was plotted against the time in days. The error bars represent +/- the standard deviation 
of the duplicate wells. The cell counts for 1K and 2K, marked in dotted red and green 
lines, respectively, represent the growth patterns that are normally observed in the 
presence of feeder cells. These data have been presented previously in Figure 3.1.  
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3.2.5 The LSIL- and HSIL-like growth phenotypes arise even if significantly more 
LSIL-like cells are seeded at the beginning of the growth assay 
To further confirm the phenotype, I wanted to ensure that the growth differentials did 
not result from the LSIL-like cells seeding less well than the HSIL cells in the growth 
assay. This was important, as I had noticed that the HSIL-like cells tended to survive the 
seeding procedure better than the LSIL-like cells.  
To test whether differential seeding efficiency was causing the growth differences, I 
monitored 1K and 2K cells in a 9-day growth assay in which 50 % more 2K cells were 
seeded (Fig. 3.5). Cells were counted at days 1, 3, 5, 7 and 9 post-seeding to assess the 
proliferation patterns. The cell count at day 1 shows 37 % more 2K than 1K cells 
(140,000 and 103,000 cells, respectively) while the final cell count for 1K is more than 
50 % higher than for 2K (3,320,000 and 2,220,000, respectively). This is consistent 
with previous growth assays, in which equivalent cell numbers were used for seeding, 
and shows that the two distinct growth phenotypes still emerge. 
This experiment confirms that the HSIL-like phenotype is not a result of the greater 
seeding ability of the 1K cells. 
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Figure 3.5: The LSIL- and HSIL-like growth phenotypes arise even if significantly 
more LSIL-like cells are seeded at the beginning of the growth assay 
The growth of 1K and 2K cells was monitored for 9 days. The initial seeding densities 
were 150,000 1K and 100,000 2K cells and this resulted in 140,000 and 103,000 cells 
adhering, respectively; approximately 37 % more 2K than 1K cells. Cells were counted 
in duplicate at days 1, 3, 5, 7 and 9 post-seeding to characterize their proliferation 
patterns. In a standard growth assay, the clone that is colored red consistently grows to a 
high cell density whereas the cell line marked in green reaches a lower cell number. The 
mean number of cells per 6-well plate well was plotted against the time in days. The 
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3.2.6 The HSIL-like growth phenotype does not arise from outgrowth within the 
population during the growth assay 
It is known that cells containing HPV genomes can change their growth phenotype over 
time (Gray et al., 2010), for example in sub-optimal culturing conditions. Therefore, I 
routinely passaged my cells 1-2 times a week and did not let them grow to confluence. 
For this reason, I thought that it was important to determine whether the HSIL-like 
phenotype arises as a result of outgrowth of a fast-growing sub-population of the 1K 
cells.  
The 1K and 2K clonal cell lines were cultured in a growth assay using the normal 
protocol, and counted every other day from day 1 to 21 post-seeding (Fig. 3.6A). The 
normal LSIL- and HSIL-like growth phenotypes are apparent between days 5, 7 and 9, 
as expected. From day 9 onwards, the cell numbers for both the LSIL- and HSIL-like 
clones continue increasing, albeit at a slower rate, up until day 17. It is only at this point 
that both cell lines cease growing. When looking at the cells down the microscope, I 
find that they look fairly healthy and normal up until day 17 and then look unhealthy at 
days 19 and 21. The number of cells floating in the media increases quite dramatically 
for these last two time-points. This led me to believe that both the 1K and 2K cell lines 
are still mitotically active at this time but that the number of cells dying is enough to 
offset the cell growth and give the false impression that overall the cells are not 
proliferating.  
I have established so far, that both the LSIL- and HSIL like growth phenotypes are 
stable during an extended growth assay. To test whether the phenotypes result from 
outgrowth within the lines, I took cells from days 5 and 17 of the extended growth assay 
and reseeded them at low density in a standard growth assay (Fig. 3.6B and C). I 
hypothesized that if the lines were changing due to outgrowth, cells derived from day 5, 
when the cells first become confluent, and day 17, when the cells last look healthy, may 
show different growth characteristics.  
Cells harvested at day 5 of the extended growth assay, give rise to normal LSIL- and 
HSIL-like growth phenotypes during the second growth assay (Fig. 3.6B). The 1K and 
2K cell lines diverge in terms of their growth patterns from day 3 onwards and by day 9 
the 1K clone has an almost 2-fold higher cell number than 2K. Similarly, Fig. 3.6C 
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shows that cells harvested at day 17 of the extended growth assay, also give rise to the 
normal LSIL- and HSIL-like growth phenotypes. The two cell lines only start to diverge 
from day 5 onwards but once again by day 9 the total cell number of 1K is considerably 
higher than for 2K.  
When further assessing the actual cell numbers in the growth assays seeded with day 5 
and day 17 cells, it becomes apparent that, overall, the rates of proliferation of the cell 
lines have not increased. At day 9 both batches of 2K cells have grown to a total of 
2.5x106 cells whereas 1K cells have grown to 4.5 and 4 x106 cells in the day 5 and 17 
proliferations assays, respectively.  
In conclusion, the results of the extended growth experiments suggest that no significant 
outgrowth occurs within the 21-day period measured. The LSIL- and HSIL-like 
proliferation patterns are reproducibly maintained even if cells are allowed to grow a 
long way past the point of post-confluence. Therefore outgrowth cannot be responsible 












Chapter	  3:	  The	  Role	  of	  E6	  and	  E7	  in	  Controlling	  the	  LSIL-­‐	  and	  HSIL-­‐like	  Growth	  Patterns	  








Chapter	  3:	  The	  Role	  of	  E6	  and	  E7	  in	  Controlling	  the	  LSIL-­‐	  and	  HSIL-­‐like	  Growth	  Patterns	  




Figure 3.6: The HSIL-like growth phenotype does not arise from outgrowth within 
the population during the growth assay 
A) 1K and 2K were grown up in a growth assay. Cells were counted in duplicate every 
other day from day 1 to 21 post-seeding to assess differential growth patterns. 1K and 
2K cells harvested at day 5 (B), or day 17 (C), post-seeding from A) were reseeded in a 
new growth assay (identical to the first in terms of the set-up). Cells were counted in 
duplicate at days 1, 3, 5, 7, and 9 to reassess their growth patterns. Graphs show the 
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3.2.7 HSIL-like cells are more mitotically active than LSIL-like cells when 
compared at both confluence and post-confluence 
As mentioned before, the faster growing 1K cells are associated with an HSIL-like 
rafting phenotype whereas the slower 2K cells resemble a LSIL lesion in raft culture 
(Isaacson Wechsler et al., 2012). 1K epithelia have a larger number of cells in S phase 
than 2K, as determined by the amount of MCM staining. Therefore I hypothesized that 
the monolayer 1K HSIL-like phenotype similarly arises from an increased number of 
cycling cells, compared to the 2K LSIL-like cells.  
 
To test this, I cultured parental NIKS, LSIL-like 2K and HSIL-like 1K cells on top of 
cover slips in a normal growth assay, and counted cells and harvested coverslips at days 
1, 5, 9, 13, 17 and 21 post-seeding. From my previous experiments I know that my 
HPV16 clones reach confluence at day 5 and are post-confluent from day 7 onwards. 
However, the actual cell numbers that I measure at each time-point can be very different 
between cell lines, especially for NIKS which grow much slower. For this specific 
experiment it was important to compare cells at the same density (as determined by the 
exact cell count), as this is a major determinant of whether cells continue proliferating, 
and are therefore mitotically active. I found that at confluence at day 5, there are about 
2x106 cells per well for the HSIL-like 1K cells. In contrast, although the cells do not 
look very different microscopically, 2K only reach this cell number at day 9 and NIKS 
only reach this cell number at day 13. At day 9, I measure about 3x106 cells for 1K, 
whilst NIKS and 2K only reach this cell number at days 21 and 13, respectively.  
 
Having determined at which time-points to compare the lines, the cells were 
immunostained with antibodies to the mitotic marker anti-phospho-histone 3 (H3P) and 
also DAPI to detect their DNA, and analyzed by fluorescence microscopy (Fig. 3.7A 
and B). I used H3P as it is a highly specific cell cycle marker and only detects cells in 
prophase and metaphase (Gurley et al., 1978). It is clear that 1K cells are much more 
mitotically active than both NIKS and 2K, with a larger number of cells being positive 
for H3P at both cell densities. 
 
I also observed when looking at the DAPI staining, especially at the later time-point, 
that 1K cells are all on the same plane, and becoming increasingly small, thereby 
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making space for new cells. This is consistent with my observations in Section 3.2.2. In 
contrast, for NIKS and 2K many of the nuclei are overlapping. This suggests that cells 
have starting growing on top of each other to accommodate the cell surplus. Hence, it 
seems that 1K is overcoming contact inhibition in a different way than NIKS and also 
2K. I speculate that this difference may be allowing 1K cells to grow quicker than 2K 
(and NIKS) from the point of confluence.  
 
This experiment has confirmed that the HSIL-like 1K cell line is more mitotically active 
than LSIL-like 2K cells when confluent, and this could account for their different 
growth phenotypes. 
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Figure 3.7: HSIL-like cells are more mitotically active than LSIL-like cells when 
compared at both confluence and post-confluence 
NIKS, 1K and 2K cells were cultured on coverslips in an extended growth assay. Cells 
were counted in duplicate every other day from day 1 to 21 post-seeding. The lines were 
compared at two different cell densities (2x106and 3x106cells per well) in terms of their 
expression levels of the mitotic marker H3P (green). Additionally, cells were stained 
with DAPI (blue) to detect their nuclei.  
A) At confluence at day 5, there are approximately 2x106 cells per well for the HSIL-
like 1K cells. NIKS and 2K reach this cell number at days 13 and 9, respectively.  
B) At post-confluence at day 9, there are about 3x106 cells for 1K. NIKS and 2K reach 
this cell number at days 21 and 13, respectively. 
!
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3.2.8 E6 transcript levels are similar for both LSIL- and HSIL-like cell lines at 
confluence 
Having established in the previous sections that the phenotypic differences between 1K 
and 2K are inherent to these lines, and do not arise as a consequence of the growth 
assay procedure, I then wanted to characterize the reason for this. Preliminary data in 
the laboratory (Isaacson Wechsler et al., 2012) suggested that increased levels of E6 and 
E7 correlate with the HSIL-like growth phenotype from confluence. Therefore I wanted 
to assess whether differences in E6 transcript levels correlate with the phenotypes.  
 
Since the growth phenotypes arise from the point of confluence at day 5 I decided to 
analyze this time-point in terms of E6 transcript levels. To do this I cultured two LSIL-
like (4K and 4Q) and one HSIL-like (6K) clones to confluence (the equivalent of day 5 
in a growth assay) in individual T75 flasks, according to standard laboratory protocol. 
During harvest the cells from each flask were split into three pellets, all of which were 
treated as individual samples. Subsequently I did RNA extraction and performed RT-
qPCR to analyze E6 mRNA. Figure 3.8 shows that E6 transcript levels are not different 
between the two LSIL- and the HSIL-like clones at confluence. The bar chart indicates 
in fact that the levels are higher for the LSIL-like cell lines. As this experiment was 
repeated twice I performed two-tailed unpaired t-tests to assess these differences and 
found that they are not statistically significant with p values of 0.55 and 0.47 for 4K vs. 
6K and 4Q vs. 6K, respectively. 
 
My data show that E6 transcript levels are not significantly different between the LSIL- 
and HSIL-like clones at confluence when the differences in the proliferation patterns of 
these cells arise. This means that differential transcription of E6 (and presumably also 
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Figure 3.8: E6 transcript levels are similar for both LSIL- and HSIL-like cell lines 
at confluence 
Two LSIL-like (4K and 4Q, in green) and one HSIL-like (6K, in red) clones were 
cultured to confluence in T75 flasks. During harvest each flask was split into three 
pellets, all of which were treated as individual samples. The levels of E6 mRNA for 
each clone were assessed by RNA extraction and RT-qPCR and normalized to the levels 
of actin. The experiment was repeated twice and the data compiled. Differences in E6 
mRNA levels between the LSIL- and HSIL-like clones were assessed using two-tailed 
unpaired t-tests (p=0.55 for 4K vs. 6K and p=0.47 for 4Q vs. 6K). The error bars in the 
represent the standard error of the two repeats. 
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3.2.9 Assessment of a range of anti-E6 antibodies 
Leading on from the qPCR work in the previous section, I wanted to assess E6 and E7 
protein levels in both the LSIL- and HSIL-like clones. Although the laboratory has been 
using the same Euromedex HPV16 E6 antibody for some time, the newer batches do 
not work as well as the depleted original ones. When I run western blots there are very 
high levels of background and when I expose the membranes for a sufficient time to 
detect the E6 bands, the negative NIKS control is often positive. This non-specific band 
in the NIKS lane seems to be caused by the secondary antibody (data not shown). 
However, several different secondary antibodies tested give the same effect.  
 
As a result of this I have tried to re-optimize western blotting conditions using different 
blocking buffers and different E6 antibodies. The gels for both new blocking buffers 
(Fig. 3.9A) look cleaner overall. However, lane A in both gels, in which I loaded lysate 
from a parental NIKS cell line, which I confirmed contains no HPV DNA, presents with 
a band that is as clear as the band in lane B from cells which actually express E6. 
Hence, these data indicate that using BSA to block gels enhances the problem of the 
negative control being positive.  
 
I then tested several new E6 antibodies, one each from Abcam, Arbor Vita Corporation, 
Euromedex and two from Santa Cruz. For each I tested four different blocking buffers 
(5 % milk, 5 % BSA, 5 % milk and 2 % BSA, 5 % BSA and 2 % milk) and various 
concentrations of the antibody (ranging from 1:500 to 1:2000). The blots (Fig. 3.9B) 
show the best result for each of the antibodies. As can be seen, there are no bands in any 
of them that correspond to the known 15-16 kDa size of E6. Based on the results here I 
have decided to use p53 as an inverse marker of E6 levels for all further westerns. 
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Figure 3.9: Assessment of a range of anti-E6 antibodies 
Whole cell extracts from confluent wild type and E6-expressing NIKS cells were 
western blotted using the original Euromedex E6 antibody and different blocking 
buffers (A), and a range of different anti-E6 antibodies (Abcam: ab70; Arbor Vita 
Corporation: AVC#1007; Euromedex: 1E-6F4; Santa Cruz I: sc-460 and Santa Cruz II: 
sc-1584) (B). E6 runs at approximately 15-16 kDa. 
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3.2.10 From the point of confluence, E6 activity appears higher for HSIL-like cells 
than LSIL-like cells  
Having shown that differences in E6 transcript levels do not correlate with the LSIL- 
and HSIL-like growth patterns, I decided to determine whether the phenotypes correlate 
with protein levels of E6 and E7.  
 
To assess protein levels, I cultured LSIL-like 2K and HSIL-like 1K clones in a growth 
assay and harvested cells at days 3, 5, 7 and 9 post-seeding. Cell pellets were prepared 
in duplicate throughout the proliferation assay and were stored at -80 °C. After the 
10-day period all samples were lysed using a buffer containing 1 % NP-40. The levels 
of E6 and E7 were determined by western blot (Fig. 3.10A and B). In the blots, “a” and 
“b” samples from the four time-points were run on one gel for each clone separately to 
assess the overall trend in protein levels. For 1K, the levels of p53 is low at sub-
confluence at day 3 and then consistently high from the point of confluence at day 5 
onwards. This indicates that the levels of E6 are high at the beginning of the growth 
assay and then decrease with confluence. In contrast, the 2K blot shows that the levels 
of E6 are high at day 3, much lower at day 5 and then higher again at day 9. The levels 
of E7 are higher at post-confluence at both days 7 and 9 than at sub-confluence and 
confluence at days 3 and 5, respectively. This can be observed for both clones.  
 
To enable a direct comparison of protein levels between the clones, the same samples 
were rerun in a different order (Fig. 3.10C and D). This time all the “a” samples from 
both clones were run on one gel and all the “b” samples on another. The p53 westerns 
show that E6 levels are significantly higher for 1K than for 2K, from the point of 
confluence at day 5 onwards. Unfortunately, the “a” and “b” replicates that were run on 
different gels are not always internally consistent. Regardless of this, the levels of E6 
remain consistently higher for 1K than for 2K at days 5, 7 and 9. Again, I have found 
that the levels of E7 are the same for both clones at all time-points.  
 
From the western blotting data there is a strong indication that the levels of E6 are 
higher in the HSIL-like clones as compared to the LSIL-like clone from the point of 
confluence at day 5 onwards. This suggests that it may be differences in the levels of 
E6, and not E7 that are giving rise to the two growth phenotypes. 
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Figure 3.10: From the point of confluence, E6 activity appears higher for HSIL-
like cells than LSIL-like cells 
1K and 2K clones were cultured in a growth assay format and harvested on days 3, 5, 7 
and 9 post-seeding. The levels of 1 % NP-40-soluble p53, used as an inverse marker of 
E6, and E7 were determined by western blot. Whole cell extracts from confluent wild 
type and E6-expressing NIKS cells were used as controls. 
A) + B) Changes in the levels of p53 and E7 during the time-course for clones 1K and 
2K, respectively. 
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3.2.11 LXSN_E6 and LXSN_E6/E7 cells grow significantly faster than LXSN_E7 
and control cells 
As it appears that higher levels of E6 in the HSIL-like clone correlate with the fast 
growth phenotype, I wanted to test if E6 alone has the capacity to drive proliferation in 
such a way that would lead to the HSIL-like pattern of cell growth.  
 
To do this LXSN retroviruses containing HPV16 E6, E7 or both E6 and E7 (Halbert et 
al., 1991) were used to infect NIKS cells. After infection, cells were selected using 
geneticin to make stable cell populations. Pellets of confluent cells were lysed using a 
RIPA buffer containing 6 % SDS, and these whole cell extracts were used in western 
blots (Fig. 3.11A). Each population expresses the expected proteins.  
 
Subsequently the growth of LXSN, LXSN_E6, LXSN_E7 and LXSN_E6/E7 cells was 
assessed in a 9-day growth assay (Fig. 3.11B). Cells expressing E6 or both E6 and E7 
grow considerably faster than both E7-only expressing and control cells. E7 alone does 
not stimulate these cells to proliferate faster than control cells. Overall between days 1 
and 9 LXSN, E6-, E7- and E6/E7-expressing cells have increased their cell numbers  
18-, 25-, 17-, and 23-fold, respectively. This means that E6- and E6/E7 expressing cells 
have grown to a density that is 1.8- and 1.7-fold fold higher, respectively, than that of 
LXSN controls cells while the difference in density at day 9 between E7-expressing and 
LXSN cells is negligible. The data in Figure 3.11 are an average of 8 individual 
experiments. Unpaired t-tests were used to compare the numbers of LXSN- and E6-
expressing cells at each time-point. There is no significant difference at day 1 with a p 
value of 0.4. At days 3, 5, 7 and 9 the overall cell numbers are significantly different 
with p values of less than 0.01. 
 
The experiment shows that E6 alone can push cells to proliferate. Hence, the higher 
levels of E6 in the HSIL-like clone from the point of confluence, may be the cause of 
the faster growth phenotype of this cell line. 
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Figure 3.11: LXSN_E6 and LXSN_E6/E7 cells grow significantly faster than 
LXSN_E7 and control cells 
LXSN retroviruses were used to make stable NIKS cell populations expressing only E6, 
E7 or both E6 and E7.  
A) Cells were cultured to confluence, and lysed using a RIPA buffer containing 6 % 
SDS. Whole cell extracts were used to confirm by western blot that the cell lines 
express only E6, E7 or both proteins.  
B) The growth patterns of LXSN-, E6-, E7- and E6/E7-expressing cells were compared 
in a 9-day growth assay. Cells from duplicate wells were counted at days 1, 3, 5, 7 and 9 
post-seeding. The graph shows the mean number of cells per 6-well plate well. The 
error bars represent +/- the standard error of 8 individual experiments. Unpaired t-tests 
were used to compare LXSN and LXSN_E6 cell numbers at each time-point. At day 1 
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3.2.12 Both E6 and E7 can stimulate cell proliferation in a growth 
factor-diminished monolayer environment 
The growth data with E7-expressing cells in the previous section are surprising. Current 
literature suggests that E7, not E6, drives cell proliferation by degrading Rb (Dyson et 
al., 1989), causing release of E2F and hence transcription of many components required 
for G1/ S phase transition, including cyclin A and E (Zerfass et al., 1995). I came to the 
conclusion, that, in hindsight, one might expect the result obtained in the previous 
section. In monolayer culture, cells are provided with growth factors, from the media 
and also the feeder cells. Epidermal growth factor (EGF) is the main growth factor 
present when I culture cells. EGF family members activate a signaling cascade via the 
ErbB1 receptor (also known as epidermal growth factor receptor (EGFR)) that involves 
the ERK1/2 pathway of the Mitogen-activate protein kinase (MAPK) system (reviewed 
in (Shirakata, 2010)). This leads to, among other things, cyclin D activation (Dhillon et 
al., 2007). Cyclin D interacts with both cyclin-dependent kinase (CDK) 4 and CDK6 to 
bring about phosphorylation of Rb and release of E2F (reviewed in (Sherr, 1994)). E2F 
induces the expression of S phase promoting genes, such as cyclin A and CDK2 
(Soucek et al., 1997), which promote further Rb phosphorylation and thereby enable 
cell cycle progression (reviewed in (Woo and Poon, 2003)). The function of E7 is to 
drive cells into cycle by degrading Rb (Dyson et al., 1989, Munger et al., 1989) and 
thereby releasing E2F (Boyer et al., 1996). However, since the growth factors in my 
medium are essentially targeting the same point in the cell cycle, the release of E2F 
from Rb, E7 cannot induce additional proliferation and thus its function is redundant. 
Based on this, I hypothesized that E7 may have a positive effect on the growth potential 
of cells in growth factor-diminished culture conditions. 
 
To test this theory I assessed the growth of LXSN, LXSN_E6, LXSN_E7 and 
LXSN_E6/E7 cells in a 9-day growth assay, both in the presence and absence of growth 
factors (Fig. 3.12A and B, respectively). To remove growth factors I made media 
without supplemented FBS and EGF.  
 
As expected, in the normal culture environment only E6-expressing cells drive 
proliferation. E7 alone cannot stimulate cells to grow significantly faster than control 
cells. In contrast, in a growth factor diminished environment, E7 is able to promote 
proliferation. E6- and E7-only expressing cells can drive cell proliferation to a very 
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similar extent while cells expressing both E6 and E7 present with even more cell 
growth. 
 
Cell pellets prepared in duplicate at confluence at day 5 for both proliferation assays 
were lysed using a buffer containing 6 % SDS. Whole cell extracts were used to assess 
the levels of cyclin A and Rb by western blot (Fig. 3.12C). As expected the levels of Rb 
are lowest for E7-only expressing cells, irrespective of the presence of growth factors, 
with the higher levels in E6/E7-expressing cells presumably being caused by the 
generally lower levels of E7 (see Fig. 3.11A). While cyclin A levels are generally very 
low for cells expressing E7 in both proliferation time-courses, the levels are slightly 
higher than for LXSN control cells in the presence of growth factors. Since this is not 
associated with faster growth than LXSN cells, I speculate that there may be a threshold 
of cyclin A levels necessary for promoting fast growth (like that observed in cells 
expressing E6) that is not being met here. According to my model, I would expect E7 to 
bring about cyclin A activation in the absence of growth factors. However, this does not 
seem to be the case here. This may indicate that a different mechanism is driving 
E7-dependent cell growth. Rb and cyclin A levels are high for fast growing 
E6-expressing cells in both culture environments. This is in accordance with published 
data (Malanchi et al., 2002, Malanchi et al., 2004). For this reason I propose that E6 is 
targeting something other than the release of E2F from Rb to promote proliferation.  
 
The data in Figure 3.12 seem to confirm my model in that the lack of enhanced growth 
of E7-expressing cells is a result of the normal cell culture environment. The 
proliferation assay without growth factors may indicate that E6 and E7 are affecting 
growth by two distinct mechanisms, as the presence of both proteins leads to a higher 
overall cell number than the presence of just one. However, the exact pathways through 
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Figure 3.12: Both E6 and E7 can stimulate cell proliferation in a growth factor-
diminished monolayer environment 
The growth of LXSN, LXSN_E6, LXSN_E7 and LXSN_E6/E7 cells in the 
presence (A) and absence (B) of growth factors was assessed in a 9-day growth assay. 
Cells from duplicate wells were counted at days 1, 3, 5, 7 and 9 post-seeding. The error 
bars represent +/- the standard deviation of the duplicate wells and the graph is 
representative of multiple similar experiments. 
C) Cell pellets prepared in duplicate at confluence at day 5 were lysed using a RIPA 
buffer containing 6 % SDS to prepare whole cell extracts. The levels of cyclin A and Rb 
were determined by western blot. 
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3.2.13 In organotypic raft cultures, more E6-expressing cells are in S phase in the 
basal and also suprabasal layers than in control cells 
The 1K and 2K clonal cells not only give rise to two distinct proliferation patterns in 
monolayer growth assays, but also show distinct HSIL- and LSIL-like rafting 
phenotypes, respectively(Isaacson Wechsler et al., 2012). As the levels of E6 are higher 
for the HSIL-like clone from confluence onwards and E6 on its own may be driving 
these cells to grow faster than their LSIL-like counterparts, I speculated that I would 
also see differences between LXSN and LXSN_E6 rafts in terms of their MCM staining 
patterns. 
To test this, LXSN and E6-expressing cells were grown in raft cultures that were left to 
differentiate for 12 days post-lifting. The normal protocol failed to produce good 
results. By re-attempting the rafts several times and tweaking the protocol I eventually 
found that supplementing the media with EGF, both prior to and post-lifting, produces 
good rafts with a properly stratified, differentiating epithelium.  
In Figure 3.13A, cross sections of rafts were stained with MCM7 (red), to identify the S 
phase compartment, and DAPI (blue) was applied as a nuclear counterstain. The MCM7 
expression patterns are quite different for the LXSN and E6-expressing cells. In the 
LXSN rafts, MCM7 positive cells, which are considered to be in S phase, are limited to 
mainly the basal layer. In contrast, for the E6 rafts the number of MCM7 positive cells 
is generally higher. Additionally, there are lots of cells that are in S phase in the 
suprabasal layers, up to five or even six cell layers above the basal cells. 
Using the stained raft sections, I carried out some quantitative analysis (Fig. 3.13B) 
where I counted mitotically active cells in the basal layer. Approximately 13 % of 
E6-expressing cells are MCM7 positive whereas less than 7 % of LXSN controls cells 
express the S phase marker. 
The rafting experiment indicates, that E6-expressing cells give rise to a more high-grade 
rafting phenotype than LXSN cells. This result further supports my on-going theory that 
differences in E6 levels (not E7) seem to be the underlying cause of not only the slow 
and fast monolayer growth patterns, but also the LSIL-and HSIL-like rafting 
phenotypes that have previously been described (Isaacson Wechsler et al., 2012). 
Chapter	  3:	  The	  Role	  of	  E6	  and	  E7	  in	  Controlling	  the	  LSIL-­‐	  and	  HSIL-­‐like	  Growth	  Patterns	  

























Figure 3.13: In organotypic raft cultures, more E6-expressing cells are in S phase 
in the basal and also suprabasal layers than in control cells 
LXSN and LXSN_E6 cells were rafted in duplicate according to standard laboratory 
protocol. Media was supplemented with EGF both prior to and post-lifting. On day 12 
post-lifting rafts were harvested and subsequently sectioned.  
A) Raft sections were stained with MCM7 (red), to identify the S phase compartment, 
and DAPI (blue) as a nuclear counterstain. The broken white line indicates the basal 
layer of rafts.  
B) MCM7-positive cells were counted in the basal layer and the mean numbers plotted 
in a bar chart. The error bars represent +/- the standard deviation of the mean. 
!
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3.3 Discussion 
The work in this chapter is based on past findings in the laboratory that showed that 
HPV16-positive NIKS clonal cell lines spontaneously present with two growth 
phenotypes. One type of clone proliferates more quickly in monolayer culture from the 
point of confluence onwards. This fast growth pattern has previously been associated 
with an HSIL-like rafting phenotype whereas the slower cells consistently resemble 
LSILs (Isaacson Wechsler et al., 2012).  
 
Using just one LSIL- and one HSIL-like clonal line I have found that the two distinct 
growth phenotypes are very reproducible and seem to correlate with higher E6 protein 
levels in the HSIL-like clone from confluence. My results also indicate that in the 
monolayer cell culture environment, which mimics the basal cell layer of a stratified 
epithelium, E6 on its own allows cells to proliferate rapidly while cells expressing only 
E7 do not have a growth advantage over control cells. When I assessed the growth of 
cells in a growth factor-diminished environment I found that in this situation, which 
mimics the upper layers of the epithelium, both E6 and E7 can drive cell proliferation. 
Additionally, the rafting experiment has shown me that E6 may delay differentiation 
and extend the period in which cells are actively cycling when allowed to stratify. All 
together, the data suggest that high levels of E6 in the HSIL-like clones do not merely 
correlate but may be directly involved in giving rise to both the rafting and the 
monolayer growth phenotypes. 
 
At present I cannot explain why the LSIL- and HSIL-like cell lines are inherently 
different. I speculate that variations in episomal copy number or epigenetic differences 
in the viral genomes such as DNA methylation or histone acetylation may be involved. 
 
The finding that E7 cannot stimulate cell proliferation in the normal culture 
environment is surprising. I hypothesized that the growth promoting function of E7 is 
rendered redundant by the presence of growth factors, as they target the same point in 
the cell cycle as E7 (the G1/S phase transition), and thereby do not allow the viral 
protein to induce additional proliferation. While removing growth factors does enable 
E7 to drive cell growth, this does not occur via the proposed pathway. Hence, the exact 
mechanism by which E7 promotes cells growth in my NIKS model needs to be further 
investigated. However, the theory that the pathways targeted by E7 and growth factors 
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seem to overlap, at least to some extent, is still applicable as otherwise the cells would 
not present with two distinct patterns of proliferation when cultured in the presence and 
absence of growth factors. 
 
In NIKS, it seems that E6 can stimulate cells to grow faster by driving them into cycle 
and also by pushing them through the cell cycle more quickly. The data suggest that E6 
and E7 are targeting distinct pathways to bring about their specific effects. This may 
explain why E6 can promote enhanced proliferation independent of the presence of 
growth factors. In a stratified epithelium, only the basal and the adjacent suprabasal 
layers are considered to be a growth factor-rich environment while in the upper layers 
the concentration of growth factors is low. Therefore I consider the two different culture 
conditions (high and low concentrations of growth factors) in the growth assays in 
Section 3.12 to mimic these environments. Based on the results, I hypothesize that in a 
stratified epithelium, E6 can induce rapid cell growth, and thus promote neoplasia in all 
cell layers, while the function of E7, to drive cells into cycle, may be limited to the 
upper layers where growth factors are sparse. 
 
While E7 is the viral protein that is traditionally associated with induction of cell 
growth, there are several studies that have found that E6 can have a growth promoting 
effect. It was shown in 1994 that in human embryonic fibroblasts (HEF) the presence of 
only HPV16 E6 allows cells to proliferate to a two-fold higher density within six days 
than control cells (Ishiwatari et al., 1994). Hence, in HEF cells, E6 alone is sufficient to 
stimulate proliferation. Another study in the same year found that HPV16 E6 can 
stimulate mouse fibroblasts to grow slightly faster than control cells in a high-serum 
environment (Inoue et al., 1994) and that the positive effect of E6 on proliferation is 
enhanced in a low-serum environment. A few years later the same group showed that 
this function of E6 is independent of its ability to degrade p53, in both high- and low-
serum conditions (Inoue et al., 1998). The authors of yet a further publication have 
established that E6 can bring about hyperproliferation of cells and also epidermal 
hyperdysplasia in transgenic mice and that this is associated with a delay in the normal 
cell differentiation program (Song et al., 1999). Furthermore this effect is independent 
of p53 (Nguyen et al., 2003). 
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A separate study has implicated E6 in the G1/S transition through activation of cyclin A 
and E (Malanchi et al., 2002). The authors suggest that E6 can alleviate the growth 
inhibitory effects of both p16 and p27 and that this is independent of p53 degradation. 
My results in Section 3.2.12 seem to confirm these findings, in that I too observe E6-
dependent cyclin A activation. However, I have not yet investigated this further in my 
cell model.  
 
When the authors continued this line of work (Malanchi et al., 2004) they found that in 
fibroblasts, E6 is able to promote proliferation by inducing the activation of 
CDK4/CDK6 complexes, which are involved in hyperphosphorylating Rb, by an 
unknown mechanism. Their E6-expressing cells present with high levels of 
phosphorylated Rb. A different group working with transgenic mouse models (Shai et 
al., 2007) further established that E6 can deregulate the p16/Rb pathway in mouse 
epithelium. E6 can inactivate Rb to induce E2F and its downstream targets, which leads 
to cell cycle progression. The mechanism by which E6 achieves this is different to that 
of E7. While the presence of E7 correlates with high levels p16 and low levels of Rb, 
there are low levels of p16 and high levels of hyperphosphorylated Rb in cells 
expressing E6. The authors proposed that E6 may deregulate Rb by inactivating p53, 
thereby hindering the expression of the CDK inhibitor p21. This causes higher CDK 
activity resulting in increased hyperphosphorylated Rb, E2F release and expression of 
E2F-responsive genes such as MCM7 and cyclin E. They also suggested another 
mechanism that is independent of p53. Hence, it seems that E6, much like E7, can 
deregulate the restriction point in G1 phase and promote cell cycle progression to 
induce proliferation. 
 
All together these studies, that have analyzed the potentially growth promoting 
functions of E6, make it seem likely that the enhanced E6-dependent proliferation that I 
have observed in my cells is real and not just specific to NIKS cells or a result of the 
way they are cultured. Therefore it seems worthwhile to assess these pathways in my 
cells to determine, which of them, if any, and to what extent, are involved in giving rise 
to the LSIL- and HSIL-like growth phenotypes.  
 
The work in this chapter has given me some important insight into the specific 
characteristics of the LSIL- and HSIL-like clonal cell lines. However, my progress has 
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been impeded considerably by reproducibility issues. Isaacson Wechsler et al. showed 
in 2012 that the 1K and 2K cell lines give rise to HSIL- and LSIL-like rafting 
phenotypes, respectively. Although I refer to these cell lines as LSIL- and HSIL-like in 
this chapter and also throughout the rest of this report, I (and other laboratory members) 
have not been able to reproduce these rafting phenotypes since my work with the cells 
began. I have carried out rafts to attempt to reproduce the phenotypes on three separate 
occasions, following the same protocol described in the study by Isaacson Wechsler and 
colleagues, and none of them have succeeded. I have consistently found that both 1K 
and 2K resemble LSIL epithelia, with abundant E4 expression detectable in the upper, 
differentiating layers. As the rafting protocol I used has not changed since the original 
study, I propose that changes in the various individual components of the FI medium 
used for culturing NIKS, and also for making the Keratinocyte plating and Cornification 
media for rafting, may be having an effect. Originally, my laboratory routinely mixed 
F12-Hams and high glucose DMEM media to obtain the required 3:1 ratio, respectively, 
for F Medium. However, throughout this study I have been using pre-mixed medium. 
Moreover, the laboratory supplier of fetal bovine serum (FBS) has also changed. As 
FBS is a natural product, there is variation between each batch and hence the FBS used 
presently may be quite different to that used at the time of the original study. 
Additionally, other laboratory members have shown that the duration of storage of 
collagen, used for making the dermal equivalent support structure for rafting, can have 
an impact on how well the cells differentiate into a stratified epithelium. This is often 
not something that can be controlled easily as, for cost reasons, collagen is generally 
bought in large batches. These three factors combined may be having a significant 
impact on the growth of the clonal cell lines. Hence, it seems reasonable to assume that 
they may be contributing, at least in part, to the reproducibility issues.  
 
Another important issue to address is the obvious limitations of my model system. As 
discussed in Section 1.10 of the main Introduction, two big challenges of HPV research 
include host specificity of the virus and dependency of the viral life cycle on the 
stratified, differentiating epithelium. This has an impact on the models that can be used 
to study the virus and makes real in vivo work difficult.  While raft cultures have proven 
very useful since they were first developed, it is still difficult to truly mimic real life 
epithelial conditions, for instance in terms of calcium and growth factor concentrations. 
Additionally, for the raft cultures produced in my laboratory, immortalized human 
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fibroblasts are used. Immortalization of these cells is necessary to allow them to grow to 
sufficiently high numbers, however, immortalized cells are not normally found in real 
epithelium. 
 
There are also limitations of using specifically NIKS cells for our work. For one, as 
mentioned in Section 1.18 outlining the aims of my work, I am using foreskin cells to 
characterize cervical disease. Hence, I am using cutaneous skin cells to model mucosal 
conditions, which in itself poses a problem, not least because mucosal epithelia are not 
associated with a cornified layer while cutaneous epithelia are. Furthermore one 
problem of NIKS is that they are spontaneously immortalized cells (Allen-Hoffmann et 
al., 2000). While the fact that they are immortalized allows them to grow well in 
culture, it also means that there are inherent genetic differences (they are “near diploid”) 
between normal foreskin and NIKS cells. One other limitation of my cell culture model 
is that I use immortalized J2-3T3 mouse fibroblasts as feeder cells for my work with 
NIKS. These immortalized cells grow very quickly and hence make experiments much 
easier than using human fibroblasts. However, as described above, the fact that they are 
immortalized means that real life conditions are not being mimicked. Additionally, the 
fact the they are mouse cells means that the signals they provide and growth factors they 
express may be different to those from human cells. 
 
The work in this chapter has laid the foundations for the rest of the project. I have found 
that the precise levels of E6 seem to dictate how quickly cells containing viral episomes 
can proliferate. The data suggest that HSIL-like cells grow faster than LSIL-like cells 
from the point of confluence and that this correlates with higher E6 levels in the HSIL-
like cells. Hence, logic dictates, that if I reduce the levels of E6 in the HSIL-like cells I 
should see a slower growth phenotype, while increasing E6 in the LSIL-like cells 
should lead to faster proliferation. For this reason the next chapter will focus primarily 
on the manipulation of E6 levels in the cells to determine whether this has these 
corresponding growth effects. 
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Chapter 4: Manipulating the levels of E6 and/or E7 in LSIL- and 




The data presented in the previous chapter have shown that the two growth patterns that 
arise in clonal NIKS cell lines stably expressing HPV16 episomes correlate with E6 
protein levels from the point of confluence. I have also shown that E6, when 
overexpressed, on its own can drive proliferation of keratinocytes in my monolayer 
cultures. 
 
In this chapter I wanted to further address the exact role of E6 in promoting growth. 
I used RNA interference (RNAi) to knock-down E6 and/or E7 in HSIL-like 1K cells. 
Based on my working hypothesis, that high levels of E6 are pivotal in bringing about 
enhanced proliferation, I expected to find that the cells would grow much slower than 
before. Depending on the extent levels knock-down, I hoped to show that they would 
present with a more LSIL-like growth phenotype. As a complementary method, I used a 
plasmid vector to increase the levels of E6 in the LSIL-like 2K clone. 
 
Fire and Mello first described RNA interference (RNAi) in Caenorhabditis elegans 
(Fire et al., 1998) and presented a novel method by which endogenous mRNA could be 
degraded by the introduction of complementary double stranded RNA into cells. The 
use of RNAi to silence genes was later also found to be effective in mammals (Elbashir 
et al., 2001) and most other animals, plants, fungi and metazoans (Hammond et al., 
2001). The RNAi pathway is used for regulating endogenous genes during plant and 
metazoan development (Hannon, 2002) and is thought to have come about in eukaryotes 
as a form of cell-based immunity against viruses and other microbes (Paddison and 
Hannon, 2002). Originally, small interfering RNAs (siRNAs) were developed for 
research and therapeutic purposes, followed later by short hairpin RNAs (shRNAs), 
which can be used for a stable knock-down of target genes. 
 
The discovery of RNAi brought with it immense therapeutic potential, as cells could 
now be easily treated with siRNAs to bring about inhibition of disease-specific genes 
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(Phalon et al., 2010). To this end several siRNA molecules are now in clinical trials 
(reviewed in (Burnett et al., 2011)). However, the introduction of siRNA into cells 
brings with it some major side effects, for instance on non-target gene transcription 
patterns and also activation of the innate immune response (Robbins et al., 2009). To 
solve the issue of lack of precise sequence specificity, online tools have been developed 
that not only facilitate the design of efficient siRNA sequences but also make 
predictions about off-target effects (Boese et al., 2005), though these efforts are still 
ongoing. Additionally, to avoid an immune response a better form of delivery of the 
siRNA into target cells is being developed. Currently the most common form of siRNA 
uptake is the use of positively charged lipids that complex with negatively charged 
RNA and are subsequently endocytosed by cells. Other delivery methods that have 
shown some success include targeted nanoparticles (Davis et al., 2010) and inhalation 
(Moschos et al., 2011). 
 
In the treatment of cervical cancer the HPV E6 and E7 oncoproteins make ideal targets 
for RNAi as they promote cell proliferation and prevent apoptosis. Hence, if their 
silencing does not bring about cell death it should at the very least induce growth arrest.  
Additionally, by targeting viral proteins, only diseased cells will be affected, as healthy 
cells surrounding the site of infection do not contain any viral mRNAs. The problem of 
siRNA delivery could be resolved very soon, when it comes to RNAi targeting HPV, as 
topical delivery to the cervix may be possible through PEGylated Lipoplex-entrapped 
Alginate Scaffold (PLAS) (Singhania et al., 2012). 
 
The exact effects of the knock-down of E6 and E7, although shown to be effective, 
differ from study to study. Some groups have shown that their knock-down in SiHa and 
HeLa cells is associated with growth inhibition and a decrease in cell viability (Putral et 
al., 2005, Sima et al., 2008, Qi et al., 2010, Zhou et al., 2012). In contrast, other groups 
have found that, in these same cell lines, E6 and E7 knock-down is not associated with 
apoptosis but instead that cells have reduced invasive ability and growth potential 
(Yoshinouchi et al., 2003, Bai et al., 2006).  
 
Since E6 and E7 are transcribed together and only spliced prior to translation, most 
si- or shRNAs target both genes. Nevertheless, depending on the exact sequence used, 
some groups have managed to achieve a knock-down of just one of the oncogenes. 
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Several studies have made use of these si- and shRNAs, targeting either E6 or E7 on its 
own, and again their results are not in agreement. The authors of one publication show 
quite convincingly that use of siE6 leads to the induction of apoptosis (Butz et al., 
2003). In contrast, Jiang and Milner showed in 2002 that siRNA targeting E7 leads to 
apoptosis while treatment with siE6 only results in slower cell growth. In contrast, 
another group found that use of shE6 results in a minor retardation on growth while 
shE7 results in a more pronounced decrease in cell proliferation without any associated 
apoptosis (Bousarghin et al., 2009).  
 
One common theme in all of these studies, is that they have found that either E6 or E7 
or both seem to be involved in promoting proliferation, as their knock-down leads to the 
loss of cellular growth potential. The point where they seem to conflict most is whether 
cell viability is affected. Additionally, there is disagreement as to the extent to which 
the individual oncogenes drive cell proliferation. The lack of agreement means that the 
effect of E6 and E7 knock-down in these cells needs to be further characterized. 
 
I hypothesized that in HPV-positive NIKS cells growing in monolayer culture, knock-
down of E6 alone would be able to reduce proliferation. Based on the literature it was 
difficult to predict the exact effects that a knock-down would have in the HPV16-
expressing cell lines. Most previous studies have used SiHa, HeLa or CaSki, which are 
cervical carcinoma cells with integrated viral genomes, while only a small amount of 
RNAi work has been done in episomal keratinocyte cell lines. The levels of viral and 
cellular proteins and, consequently, some of the downstream pathways that are affected 
to promote growth, are very different in my cells. Hence, I speculated that the results of 
RNAi in NIKS would differ substantially from those observed in cervical carcinoma 
cells. 
 
Importantly, the dependence of the LSIL- and HSIL-like growth phenotypes on the 
confluence of cells makes my monolayer model very relevant in terms of studying the 
virus in the context of its normal environment. As described earlier, I consider a 
confluent monolayer to represent a reasonable model of the basal layer in real stratified 
epithelium because the cells are probably equally dense. Based on this, I propose that 
any effects observed as a consequence of E6/E7 knock-down in my cells, should be 
similar to the effects that would be observed in the basal cells of a lesion.  
Chapter	  4:	  Manipulating	  the	  Levels	  of	  E6	  and/or	  E7	  in	  LSIL-­‐	  and	  HSIL-­‐like	  Cells	  	  
	   137	  
4.2 Results 
 
4.2.1 Knock-down of E6 and /or E7 using siRNA in SiHa was not achieved in the 
monolayer cell culture environment  
My data in Chapter 3 have conclusively shown that E6 on its own has the capacity to 
increase cell growth and that higher levels of E6 seem to correlate with enhanced 
proliferation. I wanted to assess whether knocking down the levels of E6 using siRNA 
would lead to a corresponding decrease in growth in the HSIL-like clonal 1K cell line. 
As NIKS cells are not easily transfectable I decided to test various E6 and/or E7 siRNA 
sequences in SiHa cells first. Although I primarily wanted to target E6, as mentioned 
earlier, the majority of siRNAs will knock-down both oncogenes. The sequences tested 
here were synthesized as duplexes by Dharmacon and have all been published 
previously and shown to successfully reduce E6 and/or E7 levels. 
 
The siE6 and both siE7 sequences were previously shown to be specific for their 
respective mRNAs, and a 70 % reduction in E6 levels and 50-60 % reduction in E7 
levels has been described in CaSki and SiHa cells (Jiang and Milner, 2002, Allison et 
al., 2009, Jiang and Milner, 2005). The siE6/E7-1, -2, -3 and -4 sequences do not 
differentiate between E6 and E7. The siE6/E7-1 sequence was originally published as 
an shRNA (Gu et al., 2009) and I ordered the corresponding siRNA for my 
experiments. The siE6/E7-2 oligo has been shown to reduce mRNA levels by up to 
81 % in CaSki cells (Putral et al., 2005, Gu et al., 2008). The siE6/E7-3 sequence was 
shown to reduce E6 and E7 mRNA levels by about 60 % in CaSki cells (Ben Khalifa et 
al., 2011), and siE6/E7-4 was shown to work well in SiHa cells (Accardi et al., 2011). 
 
One day after seeding, SiHa were transfected with various siRNAs targeting E6 and/or 
E7, siGAPDH and one siNon-target (siNT) control sequence. Quadruplicate cell pellets 
were harvested 48 hours later. Whole cell extracts were prepared for two pellets per 
transfection condition, using a buffer containing 6 % SDS, and the levels of E6, E7 and 
GAPDH were assessed by western blot (Fig. 4.1A and B). The remaining two pellets 
were used for RNA extraction and subsequent RT-qPCR to quantify the levels of E6 
mRNA (Fig. 4.1C and D). 
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Treating SiHa cells with siGAPDH (Fig. 4.1A) shows that the transfection procedure 
itself is working. The levels of GAPDH in the siGAPDH-treated cells are low compared 
to both untreated control and siNT-treated cells. As expected, siNT does not 
significantly reduce the levels of E6 or E7 (Fig. 4.1B). However, neither do the siE6, 
siE7 or siE6/E7 sequences, irrespective of whether they target just one or both mRNAs. 
The protein levels of E6 and E7 remain as high as in the untreated control, for all cells 
transfected with siRNA.  
 
In addition to its effects on protein levels, transfection of SiHa with siGAPDH also 
reduces the amount of GAPDH transcript (Fig. 4.1C). This is a further confirmation that 
the experiment itself is working and that GAPDH mRNA is being degraded in the 
presence of its siRNA counterpart. The siE6 and siE6/E7-1 oligos, the effects of which 
were shown to be negligible by western blot (see Figure 4. 1A and B), also do not seem 
to induce a measurable decrease in E6 mRNA levels (Fig. 4D). The effects of three 
further siE6/E7 sequences (siE6/E7-2, -3 and -4) were also assessed by qPCR. While 
treatment with siE6/E7-4 does not result in any decrease in E6 transcript levels, both 
siE6/E7-2 and -3 do. However, after several repeats of this experiment, the effects were 
still not significant, and no corresponding change in protein was observed. This 
suggests that any effect is marginal, and may be insufficient to significantly affect 
protein level. 
 
These experiments show that SiHa cells can be transfected with siRNA, and that the 
correct pathways that reduce mRNA levels, and subsequently protein levels, are 
activated. However, siRNAs targeting E6 and E7 do not deplete corresponding RNAs. 
Only two siE6/E7 sequences seem to reduce, to some extent, the levels of E6 transcript 
levels in cells. While this is promising, the effect is not significant enough to warrant 
further siRNA experiments. As cells with high levels of E6 grow faster than cells with 
low levels, using these two siRNAs to reduce E6 in cells may still not result in an 
overall slower growth of cells. The faster, lesser transfected or completely untransfected 
cells with high levels of E6 would outgrow the slower, well-transfected ones with low 
E6. Hence, to measure a corresponding reduction in E6-dependent proliferation of cells, 
I need to knock-down the levels of E6 with a much higher efficiency.   
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Figure 4.1: Knock-down of E6 and /or E7 using siRNA in SiHa was not achieved in 
the monolayer cell culture environment 
SiHa cells were transfected with various siRNA sequences and harvested 48 hours later. 
UT (untreated), siNT- (non-target) and siGAPDH-transfected cells were used as 
controls. One E6 specific (siE6), two E7 specific (siE7-1 and -2) and four siE6/E7 
(siE6/E7-1, -2, -3 and -4) sequences were tested.  
A + B) Whole cell extracts were prepared and western blotted for GAPDH, E6 and E7. 
HSP70 was used as a loading control.  
C + D) The levels of GAPDH and E6 mRNA were assessed by RT-qPCR and 
normalized to the levels of actin. The error bars in the bar charts represent the standard 
deviation of qPCR triplicates. 
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4.2.2 Commercially available shE6 lentiviral particles do not knock-down the 
levels of E6 in my cells 
It is not clear why the knock-down of E6 and E7 was unsuccessful. It may be that the 
siRNAs were insufficiently transfected or that they were not stable in my cells. 
Therefore, I decided to use shE6 and shE6/E7 to reattempt a knock-down of E6 and/or 
E7, as unlike siRNA, the effects of shRNA are not transient. I hoped that using shRNA, 
would allow me to create stable cell lines with permanently low levels of E6. I decided 
to use the clonal HPV16-expressing NIKS cell lines for the shRNA work as, to truly test 
my hypothesis, I needed the cell line model. Hence, it seemed simpler to attempt a 
knock-down in the HSIL-like 1K cell line. Based on my previous data, I speculated that 
this would result in a more LSIL-like growth phenotype. 
 
In this experiment, I used commercially available E6 lentiviral particles (Santa Cruz, 
USA) that were developed using published siRNA sequences targeting E6 (Niu et al., 
2006). The sequence targets both E6 and E7 mRNAs and therefore I expected a 
decrease in both E6 and E7 levels. The HSIL-like 1K clone was infected with the 
lentiviral particles on the day post-seeding. In addition to shE6, two sets of control 
shRNA lentiviral particles were used; shScrambled, is the same as a non-target control, 
and shGFP, should essentially also function as a non-target control as my cells do not 
express GFP. I tested three different multiplicities of infection (MOIs), however, due to 
the small volume of lentiviral supernatant supplied by the company, these were limited 
to MOIs of 1, 2 and 3. After selection, 1K shRNA populations were grown to the point 
of confluence at which point cells were harvested and lysed using a buffer containing 
6 % SDS. The whole cell extracts were used to assess the levels of E6 and E7 by 
western blot. I found that untreated 1K and cells infected with either of the shRNA 
controls have high E6 and E7 levels (Fig. 4.2). However, cells infected with shE6 
lentiviral particles have equally high levels, irrespective of the amount of viral particles 
(as measured by MOI) used during the infection.  
 
These results indicate, that although the infection itself was successful, as cells were 
selected with puromycin, this shE6 sequence does not work in the cells. Hence, I will 
pursue my work with shRNA and use other sequences to hopefully achieve a 
knock-down of E6 levels. 
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Figure 4.2: Commercially available shE6 lentiviral particles do not knock-down 
the levels of E6 in my cells 
1K cells were infected with shRNA lentiviral particles targeting E6 and E7. Cell 
populations stably expressing shE6, shScrambled or shGFP were grown to confluence. 
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4.2.3 Cells infected with custom-made shE6 lentiviral particles present with a 
modest decrease in E6 transcript levels 
In the previous section, I found that the shE6 sequence that was tested, was ineffective 
at reducing the levels of both E6 and E7. Hence I ordered custom-made shE6 and 
shE6/E7 lentiviral particles (Mission®, Sigma-Aldrich, USA) using other sequences that 
were previously published and found to work. As I wanted to achieve a knock-down of 
just E6 levels, I ordered one shE6, that was based on the siE6 sequence tested in Section 
4.2.1 (Jiang and Milner, 2002, Jiang and Milner, 2005, Allison et al., 2009). Previously, 
this siE6 was shown to reduce E6 levels by about 70 % without affecting E7. I also 
ordered a shE6/E7 based on the siE6/E7-1 sequence tested in Section 4.2.1. This 
sequence was originally published as an shRNA (Gu et al., 2009) that seemed to work 
really well. Therefore, I was optimistic that lentiviral particles based on this would 
result in a reduction of E6 and also E7 levels. 
 
To test the efficacy of the two shRNAs, the HSIL-like 1K clone was infected with the 
lentiviral particles, including an shNT control, on the day after seeding. After antibiotic 
selection, the new 1K shRNA populations were left to grow to the point of confluence. 
Cell pellets were used to do RNA extraction and subsequently RT-qPCR was carried 
out to assess the levels of E6 mRNA. The qPCR results (Fig. 4.3) show that E6 
transcript levels are high in both untreated 1K and 1K infected with shNT lentiviral 
particles. While cells stably expressing shE6/E7 do not show a decrease in E6 level, 
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Figure 4.3: Cells infected with custom-made shE6 lentiviral particles present with 
a modest decrease in E6 transcript levels 
1K cells were infected with shRNA lentiviral particles targeting E6 or both E6 and E7. 
Cell populations stably expressing shE6, shE6/E7 or shNT were grown to confluence. 
The levels of E6 mRNA were assessed by RT-qPCR and normalized to actin. The error 
bars in the graph represent the standard deviation of qPCR triplicates. The data here are 
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4.2.4 Cells infected with custom-made shE6 lentiviral particles do not grow slower 
than control cells 
In this section I assessed the specific growth patterns of ushE6-expressing 1K. I found 
that the level of E6 transcript in these cells is slightly decreased as compared to 1K 
shNT control cells and hoped to show that even a very modest reduction in E6 levels 
could bring about a corresponding decrease in cell growth. As described earlier, my 
concerns was that within a heterogeneous population of transfected cells, such as in my 
siRNA experiments in Section 4.2.1, cells with higher levels of E6, which had been 
transfected with a low efficiency or not at all, would outgrow cells that had taken up the 
siE6 well and expressed low levels of E6. However, as these 1K shE6 cells had been 
selected with puromycin, I expected to have a more homogeneous population of cells. 
Hence, I speculated that shE6-expressing 1K would grow slower than 1K shNT cells. 
 
Untreated 1K, 1K shNT and 1K shE6 cells were cultured in a 9-day growth assay along 
with untreated 2K and 2K shNT cells. 2K shNT cells were prepared following the same 
protocol as the corresponding 1K cells (see Section 4.2.3) using the same lentiviral 
particles. The two 2K infected cell populations were used for comparisons with the 1K 
populations. Cells were counted at days 1, 3, 5, 7 and 9 post-seeding to assess the 
growth patterns (Fig. 4.4). The graph shows that the 1K and 2K clonal cell lines give 
rise to their normal HSIL- and LSIL-like growth phenotypes, respectively. As expected, 
2K shNT cells present with a similar growth phenotype as wild type 2K cells and can 
grow to same overall cell density within the time-course. However, 1K shE6-expressing 
cells grow slightly faster than their uninfected counterparts. The same effect can be 
observed for 1K shNT control cells. 
 
The assessment of the proliferation of these cell populations has shown me that a minor 
decrease in E6 mRNA is not enough to significantly reduce the growth of cells. It seems 
that the process of infecting cells with lentiviruses and subsequently selecting them has 
the capacity to make cells grow more quickly. Therefore any growth decrease brought 
about by the knock-down of E6, would have to negate this increase first before any 
“real” effect can be observed. 
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Figure 4.4: Cells infected with custom-made shE6 lentiviral particles do not grow 
slower than control cells 
NIKS, untreated 1K, 1K shNT, 1K shE6, untreated 2K and 2K shNT cells were counted 
in duplicate at days 1, 3, 5, 7 and 9 post-seeding and compared in terms of their growth 
phenotypes. The average number of cells per 6-well plate well was plotted against the 
time in days. The error bars represent +/- the standard deviation of the duplicate wells. 
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4.2.5 Infection of LSIL- and HSIL-like cells with LXSN_E6 retrovirus does not 
bring about higher E6 levels 
The experiments in this chapter so far have shown me that using RNAi to knock-down 
the levels of E6 and/or E7 in both SiHa and HSIL-like 1K cells does not work well. 
When I did see modest reductions in the level of E6 transcript, this did not lead to 
slower growth. Therefore I decided to attempt to change E6 levels by using the opposite 
approach; increase the levels of E6 in the slower growing 2K cells and investigate 
whether the LSIL-like pattern of proliferation could be transformed into an HSIL-like 
phenotype. 
 
Having worked with the LXSN vector system before (in Chapter 3), I used LXSN_E6 
retroviruses to infect both HSIL-like 1K and LSIL-like 2K cells. I decided to infect 1K 
in addition to 2K to assess whether this would result in even faster growth of these cells. 
Following antibiotic selection, 1K and 2K cells, now stably expressing LXSN_E6, were 
seeded in a growth assay. Cells were counted at days 1, 3, 5, 7 and 9 post-seeding to 
assess the differential patterns of proliferation (Fig. 4.5A). Cell pellets harvested at 
confluence at day 5 were lysed using a RIPA buffer containing 6 % SDS and used to 
assess the levels of E6 by western blot (Fig. 4.5B) 
 
The proliferation data show that both 1K and 2K expressing LXSN_E6 do not have any 
growth advantage whatsoever over wild type 1K and 2K cells, respectively. Untreated 
1K cells are actually growing slightly faster than 1K E6 cells. The western blotting data 
seem to correlate with this. Neither 1K E6 nor 2K E6 present with higher levels of E6 
than wild type 1K and 2K.  
 
The western blots do show that the levels of E6 for 1K are higher than for 2K. This is 
good as, on this rare occasion where the E6 antibody has worked, these results confirm 
what the p53 western blots in Chapter 3 suggest; that the levels of E6 are higher in 1K 
than 2K at confluence. 
 
It seems that over-expressing E6 using the LXSN vector system does not work. While I 
am unsure as to why this is, I do think that testing a different vector is worthwhile.  
Chapter	  4:	  Manipulating	  the	  Levels	  of	  E6	  and/or	  E7	  in	  LSIL-­‐	  and	  HSIL-­‐like	  Cells	  	  










Figure 4.5: Infection of LSIL- and HSIL-like cells with LXSN_E6 retrovirus does 
not bring about higher E6 levels 
LXSN_E6 retroviruses were used to infect 1K and 2K clonal cell lines.  
A) The growth patterns of NIKS, 1K, 1K E6, 2K and 2K E6 cells were compared in a 
9-day growth assay. Cells from duplicate wells were counted at days 1, 3, 5, 7 and 9 
post-seeding. The average number of cells per 6-well plate well was plotted against the 
time in days. The error bars represent +/- the standard deviation of the duplicate wells.  
B) Cells were cultured to confluence at day 5, and lysed using a RIPA buffer containing 
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4.2.6 Testing of two vectors to over-express E6 in LSIL-like cells 
Other laboratory members have previously used both pMV11 and pcDNA3.1 to express 
HPV16 E6 in cells and found that both of them work quite well. For this reason, I 
decided to repeat the experiment with these two vectors. (The pcDNA vector used here 
(pcDNA_E6SD) contains a splice defective form of E6. This means that only 
full-length E6 is expressed and none of the truncated E6* species).  
 
Further personal communication with my colleagues suggested that integration of 
vector DNA into host chromosomes, which is necessary for the production of stable cell 
populations, is more efficient if DNA is transfected in the linear format. Therefore I 
digested vectors with an appropriate restriction enzyme prior to use. 
 
LSIL-like 2K cells were transfected with pMV11_E6 (together with 
pBABE_puromycin) or pcDNA_E6SD plasmids on the day after seeding. The pBABE 
plasmid had to be used alongside pMV11_E6, as this vector itself does not contain an 
antibiotic resistance gene. Following antibiotic selection, cells were grown to 
confluence, harvested and then lysed using a RIPA buffer containing 6 % SDS. Whole 
cell extracts were used to assess the levels of p53, an inverse marker for E6, by western 
blot (Fig. 4.6). The results show that, as expected, compared to wild type NIKS cells, 
the levels of p53 are much lower in 2K cells. While 2K MV11_E6 cells present with 
considerably lower p53 levels, 2K pcDNA_E6SD cells do not show a further decrease. 
This indicates that only MV11_E6 seems to be increasing E6 levels successfully. 
I am unsure whether the pcDNA vector itself is less efficient at expressing E6, as 
compared to pMV11, or whether the fact that only full-length E6 is being expressed 
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Figure 4.6: Testing of two vectors to over-express E6 in LSIL-like cells 
LSIL-like 2K cells were transfected with linearized pcDNA_E6SD (splice-defective E6) 
or pMV11_E6. Stable cell populations were seeded in 6-well plates and cultured to 
confluence. Cells were lysed using a RIPA buffer containing 6 % SDS and whole cell 
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4.2.7 LSIL-like cells over-expressing E6 grow faster than HSIL-like cells 
LSIL-like 2K cells stably expressing MV11_E6 were shown in the previous section to 
present with higher levels of E6 as compared to wild type 2K cells. Here I continued the 
work with these cell populations and characterized their growth characteristics. 
 
Untreated 1K, 2K and 2K MV11_E6 cells were counted at days 1, 3, 5, 7 and 9 
post-seeding to assess their differential patterns of proliferation (Fig. 4.7A). Cell pellets 
harvested at each of the time-points were lysed using a RIPA buffer containing 6 % 
SDS. Whole cell extracts were used to assess the levels of p53, an inverse marker of E6, 
and also E7 by western blot (Fig. 4.7B). 
 
The growth curve shows that 1K and 2K cells present with the normal LSIL- and HSIL-
like phenotypes from the point of confluence at day 5 onwards. Surprisingly, 2K 
MV11_E6 cells not only grow faster than their wild type 2K counterparts but also than 
1K cells.  
 
The western blot data for p53 inversely correlate well with the ability of these cells to 
grow. Wild type 2K have much lower levels of p53 than NIKS at all time-points. 
Furthermore, as expected, they are higher than in 1K, suggesting that the levels of E6 
are higher in 1K than 2K. Importantly, at all time-points analyzed, except at day 9, the 
levels of p53 in 2K MV11_E6 are as low as for 1K. At day 7, they are much lower in 
2K MV11_E6 than in 2K. The levels of E7 are similar for 1K, 2K and 2K MV11_E6 
throughout the growth assay. These were measured to ensure that the levels of p53 are 
not merely being altered by differences in E7. The results indicate that the variation in 
p53 levels observed is due to E6. 
 
The data together seem to suggest that high levels of E6 in 2K MV11_E6 allow these 
cells to grow faster than untreated 2K. This further supports my theory that E6 on its 
own can enhance cell growth, suggesting that higher levels in HSIL-like cells cause 
these cells to proliferate more rapidly than LSIL-like cells. 
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Figure 4.7: LSIL-like cells over-expressing E6 grow faster than HSIL-like cells 
A) The growth patterns of NIKS, 1K, 2K and 2K MV11_E6 were compared in a 9-day 
growth assay. Cells from duplicate wells were counted at days 1, 3, 5, 7 and 9 post-
seeding. The average number of cells per 6-well plate well was plotted against the time 
in days. The error bars represent +/- the standard deviation of the duplicate wells.  
B) Cells were harvested at day 3, 5, 7 and 9 and lysed using a RIPA buffer containing 
6 % SDS. Whole cell extracts were used to assess the levels of p53, an inverse marker 
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4.2.8 Assessment of new endogenous controls for normalization of qPCR  
Work in the previous two sections showed that 2K MV11_E6 cells express higher 
levels of E6 and that this leads to faster proliferation. As a direct consequence of the 
presence of more E6 in the infected 2K cells, this cell population could grow to a much 
higher cell density than not only its parental 2K counterpart, but also HSIL-like 1K 
cells. In Chapter 3 I showed that the differences in p53 protein levels, which I use to 
inversely measure E6, were not reflected in the E6 transcript levels of LSIL- and HSIL-
like clones. Hence, it seems that in wild type 1K and 2K the differences in protein levels 
are caused by post-transcriptional modifications. To assess this I aimed to determine 
whether increasing the levels of E6 using pMV11_E6 in 2K cells would correlate with 
higher E6 transcript levels. I hypothesized that since E6 in these cells is being expressed 
from a separate source and is not under the control of the HPV promoter, the transcript 
levels may as a result be higher.  
 
Having done a considerable amount of RNA work to this point in the project I found 
that the transcript levels of actin, the endogenous housekeeping control used for 
normalization during most of the qPCR experiments, and also GAPDH, vary 
significantly throughout a proliferation time-course. As shown in Figure 4.8A and B, 
respectively, the levels of actin and GAPDH mRNA fluctuate substantially between 
sub-confluence, confluence and post-confluence at days 3, 5 and 7.  
 
Therefore I decided to find a better control that would allow me to make more accurate 
conclusions about the transcript levels of E6. I used a TaqMan® Express Human 
Endogenous Control 96-well plate (Life Technologies; 4396840) with three sets of 32 
different housekeeping genes to assess the levels in one sub-confluent and one post-
confluent cDNA sample from HSIL-like 1K cells and one post-confluent NIKS cDNA 
sample. After performing the qPCR according to the manufacturer’s instructions, the 
data were analyzed and I determined which of the 32 controls had the least amount of 
variation (as measured by the standard deviation of the Ct values obtained) across the 
three samples that I had run. I found that RPL30, RPS17, ELF1 and E1F2B1 were the 
best housekeeping genes to consider for my experiments. The standard deviations for 
some of the other genes were up to 12-fold higher. I carried out qPCR with 2K day 3 
and 7 (sub-confluence and post-confluence) cDNA, 2K MV11_E6 day 3 and day 7 
cDNA and wild type NIKS day 7 cDNA and compared E1F2B1, ELF1, RPL30 and 
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RPS17 levels in terms of Ct value variation across these samples (Fig 4.9A-D, 
respectively). I tested each primer set with two dilutions (1:50 and 1:500) of each cDNA 
sample. As some genes are expressed at much higher levels than others, and it is 
important to keep linear amplification of each cDNA within the optimum range of 
qPCR (Ct values in the high 20s or low 30s), I wanted to establish which dilution was 
best for each primer pair. The copy numbers that I calculated based on the 1:500 
dilution Ct values were multiplied by 10 so that they could be plotted on the same graph 
as the copy numbers calculated for the 1:50 dilution results. 
 
The data show that the control with the least variability is ELF1 or E74-Like Factor 1 
(Ets Domain Transcription Factor), a transcription factor. Regardless of the presence of 
HPV and whether cells are sub-confluent or post-confluent, the levels of ELF1 do not 
fluctuate very much. Furthermore in terms of the optimum range of qPCR the 1:50 
dilution of cDNA is better than 1:500.  
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Figure 4.8: The transcript levels of the endogenous qPCR controls actin and 
GAPDH fluctuate substantially during a growth assay  
1K cells were cultured in a growth assay format and harvested at sub-confluence at 
day 3, confluence at day 5 and post-confluence at day 7 post-seeding. The levels of 
actin (A) and GAPDH (B) mRNA were assessed by RNA extraction and RT-qPCR. The 
error bars in the graph represent the standard deviation of qPCR triplicates. 
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A.       B. 
 
C.      D. 
 
Figure 4.9: Assessment of new endogenous controls for normalization of qPCR 
Sub- and post-confluent 2K and 2K MV11_E6 cDNAs from days 3 and 7 and post-
confluent NIKS cDNA from day 7 were used to do qPCR with E1F2B1 (A), ELF1 (B), 
RPL30 (C) and RPS17 (D) primer sets. Copy number variation across the cDNA 
samples is shown in the bar charts. Each primer set was tested with two dilutions 
(1:50 and 1:500) of each cDNA sample. The copy numbers calculated based on the 
1:500 dilution Ct values were multiplied by 10 so that the values could be plotted on the 
same graph as the 1:50 dilution results. 
 
Chapter	  4:	  Manipulating	  the	  Levels	  of	  E6	  and/or	  E7	  in	  LSIL-­‐	  and	  HSIL-­‐like	  Cells	  	  
	   157	  
4.2.9 LSIL-like cells over-expressing the E6 protein present with increased E6 
transcript levels  
In the previous section I addressed an ongoing issue with my qPCR and found that 
ELF1 is a much better endogenous control for use in my experiments than both actin 
and GAPDH. Having established this, I decided to measure whether the higher levels of 
E6 protein in 2K MV11_E6 cells correspond with elevated E6 transcript levels.  
 
To test this I cultured 1K, 2K and 2K MV11_E6 cells in a growth assay format, 
extracted RNA at sub-confluence at day 3 and post-confluence at day 7 post-seeding, 
and assessed the levels of E6 mRNA, relative to ELF1, using RT-qPCR (Fig. 4.10A 
and B, respectively). At day 3 the levels of E6 mRNA in 1K are slightly higher than for 
2K, with levels in 2K MV11_E6 being higher still. At day 7, E6 mRNA levels are 
slightly lower for 2K than for 1K, more so than at day 3. The levels in 2K MV11_E6 
appear to be similar to those measured in 1K. 
 
The levels of E6 transcript do not correlate exactly with E6 protein levels. I found in 
Figure 4.7B that the levels of E6, as inversely measured by p53, are similar for 1K and 
2K MV11_E6 at sub-confluence at day 3 and higher for the latter at post-confluence at 
day 7. The results here show the opposite trend for E6 mRNA. From this I conclude, 
that the higher protein levels of E6 in this cell population must be brought about by 
post-transcriptional regulation. However, the data confirm that the levels of E6 
transcript are higher in 2K MV11_E6 cells than for the 2K clone.  
 
Moreover, at both days 3 and 7 the levels of E6 mRNA in HSIL-like 1K cells are higher 
than in LSIL-like 2K cells. This is in contrast to what I found in Section 3.2.8 where the 
levels in the HSIL-like clone where not significantly different to the levels in the LSIL-
like clones. I believe that this difference in results, was brought about by using the new 
superior ELF1 endogenous control for my qPCR experiments. This means that the 
LSIL- and HSIL-growth phenotypes correlate with both the transcript and protein levels 
of E6.  
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Figure 4.10: LSIL-like cells over-expressing the E6 protein present with increased 
E6 transcript levels  
1K, 2K and 2K MV11_E6 cells were cultured in a growth assay format and harvested at 
sub-confluence at day 3 and post-confluence at day 7 post-seeding. The levels of E6 
mRNA for each clone were assessed by RNA extraction and RT-qPCR and normalized 
to the levels of ELF1 at day 3 (A) and day 7 (B).  The error bars in the graph represent 
the standard deviation of qPCR triplicates. 
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4.2.10 Generation of cell populations expressing E6 from plasmid vectors can lead 
to integration of the original viral episomes into the cellular genome 
Having established that high E6 levels seem to be involved in giving rise to fast 
monolayer proliferation, I hypothesized that 2K MV11_E6 cells would, as a result of 
their increased E6 levels, also give rise to a high-grade raft phenotype. 
 
To test this, 2K and 2K MV11_E6 cells were rafted using the procedure outlined in 
Chapter 2. Raft cultures were left to differentiate for 12 days post-lifting. Cross sections 
of rafts were stained with MCM7 (red), to identify the S phase compartment, E4 
(green), to detect late viral gene expression and DAPI (blue) was applied as a nuclear 
counterstain (Fig. 4.11A). The results of the experiment show that, as expected, wild 
type 2K cells give rise to a LSIL-like rafting phenotype. There is quite a large S phase 
compartment, with many cells in the upper half/upper third of the epithelium positive 
for MCM7. Furthermore, there is abundant E4 expression in the upper layers. For 2K 
MV11_E6 cells E4 expression cannot be detected. In terms of MCM7 expression, the 
2K MV11_E6 and wild type 2K rafts are very similar, with the S phase compartment 
comprising comparable portions of the epithelium. 
 
A phenotype like this, with absence of E4 yet no HSIL-like MCM7 expression pattern, 
suggests that the viral episomes may have integrated into the host genomes. To test this, 
I carried out Southern blot analysis of total genomic DNA extracted from confluent 
monolayer cultures for 2K, 2K MV11_E6 and 2K INT, which is a 2K population with 
fully integrated viral genomes. For 2K MV11_E6 both low and high-passage cell 
populations were used.  
 
DNA was digested with BamHI or HindIII and hybridized to a [32P] radioactively-
labeled full-length HPV16 genome probe. BamHI cuts the HPV16 genome only once 
and therefore digestion of episomes with this enzyme produces a single 8kb linear band. 
HindIII does not cut within the genome and, hence, the bands represent open circular 
and supercoiled DNA normally associated with episomes. To allow me to establish the 
episomal copy numbers of my cells, I also loaded varying amounts of linearized HPV16 
plasmid DNA of a known concentration. The Southern blot analysis (Fig. 4.11B) shows 
that 2K cells contain only episomal viral DNA, as there is just one 8kb band in the lane 
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where BamHI-treated cut DNA was loaded. In contrast, for 2K MV11_E6, at both low 
and high passage, and 2K INT cells there are bands of varying sizes within the lanes of 
cut DNA. This shows that the viral genome has integrated, with the different integration 
events in the cell populations giving rise to different sized fragments. Additionally, due 
to the integration, HindIII no longer does not cut the DNA. In the lanes that should 
represent uncut DNA for these three cell populations, there are now bands that are not 
associated with episomes. The arrows labeled “A” and “B” show the positions of faint 
bands in BamHI (cut) and HindIII (uncut) lanes, respectively, for 2K MV11_E6 at both 
low and high passages. 
 
The experiments here have shown that, although 2K MV11_E6 cells have higher levels 
of E6 than their wild type 2K counterparts, these cells now have integrated viral DNA. I 
am unsure what specifically has lead to the integration of episomes. It may have been 
the process of making the populations, for instance the antibiotic selection. 
Alternatively, it could be that the act of putting additional E6 into the cells, the 
expression of which is not under the control of the HPV promoter.  
 
Regardless of why the integration has occurred, these findings put an end to my work 
with the 2K MV11_E6 population. My earlier observation that higher E6 levels lead to 
faster growth still stands. However, comparing episomal and integrated lines is 
generally difficult as integration leads to many changes within the cells, with levels of 
both viral and cellular proteins being altered. Hence, using these populations to study 
the underlying mechanism that is giving rise to the LSIL- and HSIL-growth phenotypes 
may be very challenging. 
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Figure 4.11: Generation of cell populations expressing E6 from plasmid vectors 
can lead to integration of the original viral episomes into the cellular genome 
A) 2K and 2K MV11_E6 cells were rafted in duplicate according to standard laboratory 
protocol. On day 12 post-lifting rafts were harvested and subsequently sectioned. Raft 
sections were stained with MCM7 (red), to identify the S phase compartment, E4 
(green), to detect late viral gene expression, and DAPI (blue) as a nuclear counterstain. 
The broken white line indicates the basal layer of rafts. 
B) Southern blot analysis was carried out of total genomic DNA extracted from 
confluent monolayer cultures for 2K, 2K MV11_E6 (low and high passage) and 2K INT 
(a fully integrated sub-population of 2K). DNA was digested with BamHI or HindIII 
and hybridized to a [32P] radioactively-labeled full-length HPV16 genome probe. 
BamHI (C) cuts the HPV16 genome only once and produces a single 8kb linear band. 
HindIII (UC) does not cut within the genome; bands represent open circular and 
supercoiled DNA. Control DNA was loaded at varying concentrations to establish viral 
copy number of cells. The arrows labeled “A” and “B” show the positions of faint bands 
in BamHI and HindIII lanes, respectively, for 2K MV11_E6 at both low and high 
passage.  
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4.2.11 Optimization of conditions for treatment with siRNA in LSIL- and HSIL-
like clonal cell lines 
The work in this chapter so far has focused on manipulating the levels of E6 in 
LSIL-like 2K and HSIL-like 1K cells to show that this would result in a corresponding 
change in the specific growth phenotypes of these cell lines. In Section 4.1 I tested 
various siE6, siE7 and siE6/E7 sequences in SiHa cells, found that they did not work 
and decided not to test the siRNA in NIKS, as NIKS are much less transfectable than 
SiHa. In the meantime other laboratory members have tested a 4D Nucleofector® X 
Unit for electroporating cells and found that the transfection efficiency of NIKS using 
this approach is much higher than using standard laboratory protocol; up to 60 or 70 % 
instead of less than 1 %. Therefore, to achieve a better knock-down of E6 and/or E7, I 
decided to electroporate NIKS HPV-containing clones with siRNA. 
 
I began by testing the efficiency of siGAPDH. I electroporated 1x106 1K cells and 
seeded them into 6-well plates. I tested two different concentrations of siRNA, 66 and 
100 nM. At 48 hours post-transfection cell pellets were harvested and lysed using a 
RIPA buffer containing 6 % SDS. Whole cell extracts were used to assess the levels of 
GAPDH by western blot (Fig. 4.12A). I found that the siRNA treatment had worked 
very well. When 66 nM was used, I found a small decrease in GAPDH levels whereas a 
concentration of 100 nM of siRNA reduced the levels more substantially.  
 
One reason why use of siRNA in these cells is challenging is because the growth assays 
go on for longer than the effect of siRNA. Generally, most siRNA treatment analysis is 
done 48 or 72 hours post-transfection, with the upper limit being 4 days or 96 hours, 
before the effect deteriorates. However, my growth assays go on for 9 days. Since the 
preliminary results with the siGAPDH looked convincing, I decided to try to adapt my 
growth assay to a shorter time span. I hypothesized that if I seeded more cells at day 0, 
so that cells reach confluence earlier, and hence start to diverge into their respective 
growth phenotypes earlier, I could reduce the length of the growth assays. Generally, 
cells need 24 hours after seeding to adapt to the 6-well plate and start to grow normally. 
Hence, for optimum growth conditions and to allow cells to recover, cells should be 
approaching confluence about two days post-seeding. When I examined growth data for 
1K and 2K, I found that at confluence at day 5 there are approximately 1.5x106 cells in 
each well. Based on this I speculated that seeding 6x105 cells at day 0 would result in 
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approximately 1.5x106 cells per well on day 2 post-seeding, the equivalent of day 5 of a 
normal growth assay. 
 
To test this I seeded 1K and 2K at this higher cell density in a growth assay format. At 
day 1 I counted cells to check their seeding efficiency. At days 2, 4 and 6 I counted cells 
to assess their growth patterns (Fig 4.11B). These time-points should be the equivalent 
of days 5, 7 and 9, respectively, of the normal growth assay. A bar chart showing fold-
increase relative to the previous time-point is shown in Figure 4.11C. The data show 
that 1K and 2K start to diverge and give rise to their normal growth phenotypes from 
confluence at day 2 onwards. While the difference between the cell lines is much 
smaller than in a normal time-course, it is highly reproducible. The bar chart shows, that 
at each time-point 1K cell numbers have increased more than for 2K. NIKS take longer 
to recover from the seeding process and therefore only start to grow rapidly from day 2 
onwards. Hence, the increase in NIKS cell numbers is higher than for both clones prior 
to the last time-point although overall 2K, and especially 1K, can grow to a much higher 
cell density. Throughout the duration of the growth assay NIKS have increased their 
cell numbers 3-fold, while 1K and 2K have done so 6- and 4-fold, respectively. This 
means that 1K have grown to a density that is 2-fold higher than that of NIKS while 2K 
have reached a 1.5-fold higher cell density. The data in Figure 4.11B are an average of 8 
individual experiments. Unpaired t-tests were used to compare 1K and 2K cell numbers 
at each time-point. There is no significant difference at confluence at day 2 with a p 
value of 0.47. At post-confluence at days 4 and 6, the overall cell numbers are 
significantly different with p values of 0.031 and 0.0031, respectively. 
 
The shortened growth assay shows that the LSIL- and HSIL-like growth phenotypes 
arise as normal. Hence, I can use this format for siRNA experiments. This set-up should 
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Figure 4.12: Optimization of conditions for treatment with siRNA in LSIL- and HSIL-like 
clonal cell lines 
A) 1K cells were transfected with 66 or 100 nM of siGAPDH and harvested 48 hours later. 
Untreated NIKS cells were used as controls. Whole cell extracts were prepared and western 
blotted for GAPDH.  
B + C) NIKS, 1K and 2K were seeded at a high density (6x105) in 6-well plates and counted in 
duplicate at days 1, 2, 4 and 6 post-seeding. Day 2 corresponds to confluence at day 5 of a 
normal growth assay, while days 4 and 6 correspond to post-confluence at days 7 and 9. Cells 
were compared in terms of their growth phenotypes. Unpaired t-tests were used to compare 1K 
and 2K cell numbers at each time-point. The p values at day 2, 4 and 6 are 0.47, 0.031 and 
0.0031, respectively.  
B) The average number of cells per 6-well plate well was plotted against the time in days. The 
error bars represent +/- the standard error of 8 individual experiments.  
C) Fold-increase relative to the previous time-point was calculated and plotted in a bar chart. 
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4.2.12 The knock-down of E6 using siRNA by electroporation in HSIL-like cells 
results in slower proliferation 
The work in the previous section has shown that siGAPDH is successful at reducing the 
levels of GAPDH protein in 1K using electroporation. I also optimized the conditions 
for a short growth assay so that LSIL- and HSIL-like cells diverge into their respective 
growth phenotypes from day 2 onwards. Hence, the growth effects of any siRNAs 
should now be observable in this format. In this section I will use siE6/E7-3, the 
sequence that looked most promising in SiHa cells in Section 4.2.1, to reattempt the 
knock-down of E6 and E7.  
 
When I first tested the Nucleofector® I found that, although, the transfection efficiency 
is quite high, many cells, up to 60 or 70 %, die as a result of the electroporation process. 
Therefore I decided to increase the number of cells per individual electroporation from 
1 to 1.5x106 cells per cuvette. This way I hoped to end up with at least 6x105 adhering 
cells per well, with about 60-70 % successfully transfected. Hence, if any of the siRNA 
sequences work, I should be able to measure a reduction in E6 or E6 and E7 levels and 
see a corresponding growth effect.  
 
NIKS and 1K cells were electroporated with siNT (non-target) and 1K with siE6/E7-3. 
Cells were plated and subsequently counted on the day after to check their seeding 
efficiency. Cells were counted to assess their proliferation patterns at 48, 72 and 96 
hours after siRNA treatment, which corresponds to days 2 (confluence), 3 and 4 (both 
post-confluence) (Fig 4.12A). Cell pellets were prepared in duplicate throughout the 
growth assay and the day 3 pellets lysed using a RIPA buffer containing 6 % SDS. The 
levels of p53, used as an inverse marker of E6, were determined by western blot (Fig 
4.13B). 
 
The growth results in Figure 4.13A show that compared to 1K cells treated with siNT, 
siE6/E7-3 treated cells present with much slower cell growth at all stages of the short 
growth assay. Although 1K siNT cells seeded better, which means that I would expect 
them to outgrow 1K siE6/E7-3 cells, the latter no longer have the capacity to grow to a 
higher overall density than NIKS electroporated with siNT cells. 
 
Additionally, the western blot results in Figure 4.13B show that the levels of p53 are 
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much higher in 1K siE6/E7-3 than 1K siNT cells. This suggests that the levels of E6 are 
much lower in the former than the latter and that the growth effects observed are a 
direct consequence of these diminished E6 levels. 
 
The data in this section indicate that knock-down of E6, and presumably E7, using 
siRNA by means of electroporation leads to a dramatic reduction in the growth potential 
of 1K cells. All in all, I have further confirmed my working hypothesis that E6 on its 
own has the capacity to increase the proliferation of cells. 
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Figure 4.13: The knock-down of E6 using siRNA by electroporation in HSIL-like 
cells results in slower proliferation 
The growth of 1K cells electroporated with siE6/E7-3 or siNT (non-target) and NIKS 
treated with siNT was assessed in a short growth assay. Approximately 1.5x106 cells 
were electroporated per well with 100 nM of siRNA. Cells were counted at days 1, 2, 3 
and 4 post-electroporation.  
A) The average number of cells per 6-well plate well was plotted against the time in 
days. The error bars represent +/- the standard deviation of the duplicate wells. 
B) Cell pellets were prepared in duplicate at day 3 for 1K siE6/E7-3- and siNT-treated 
cells and lysed using a RIPA buffer containing 6 % SDS. The levels of p53, used as an 




1K siE6/E7-3 1K siNT 
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4.3 Discussion 
The work in this chapter aimed to determine whether altering the levels of E6 in the 
HPV positive cells lines, would convert the phenotype of the LSIL- to that of the 
HSIL-like cells. Initially, I found, using several previously published siE6, siE7 and 
siE6/E7 sequences, that the knock-down of E6 and/or E7 in SiHa did not work. 
Subsequently I attempted to reduce E6 and E7 levels using shRNA in HSIL-like 1K 
cells. Although two different retroviral delivery systems were tested, the experiment 
was unsuccessful. Hence, I decided to use a different approach and tried to increase the 
levels of E6 in LSIL-like 2K cells using a plasmid vector. This experiment was 
successful and I not only detected high levels of the E6 protein but also found that 2K 
cells now grew more rapidly than 1K cells. However, when I carried out raft cultures 
and Southern blot analysis I found that the transfection of cells with additional E6 had 
lead to the integration into the host chromosomes of the viral genomes. I then revisited 
my RNAi approach and this time electroporated HSIL-like 1K cells with a si6/E7 oligo. 
By using this method, the knock-down of E6 was successful. 1K cells expressing low 
levels of E6, as a result of the siRNA treatment, were only able to grow as quickly as 
NIKS control cells.  
 
Two separate plasmid infections, subsequent selections, rafting and Southern blot 
analysis have confirmed that 2K MV11_E6-expressing cells had fully integrated viral 
genomes. This finding, that cells expressing additional E6 cannot maintain their viral 
episomes, is interesting. Previous work in the laboratory has shown that when cells 
already expressing E6 (LXSN_E6) are transfected with the full HPV16 genome, the 
genome cannot persist. While some integration into host chromosomes occurs, most 
episomes are lost from the cells (Nicolaides, 2011). This was shown on multiple 
occasions. Therefore it was hypothesized that E6 has a role in preventing the “super-
infection” of cells, so that when one type of HPV is present in a cell, another type 
cannot infect the same cell and persist additionally. This hypothesis makes sense, as 
generally two different types of virus, although it has been reported (Egawa et al., 1993, 
McLaughlin-Drubin and Meyers, 2004), are not found within a single cell. 
Approximately 10 % of clinical lesions contain two or even multiple HPV types 
(Kalantari et al., 1997, Brown et al., 1999, Silins et al., 1999, Bachtiary et al., 2002) but 
this is likely associated with the regional separation of the various infections within the 
lesion (Christensen et al., 1997). While my experiments in this chapter were different to 
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the ones that gave rise to the “super-infection” theory, I still think that my findings 
complement the original ones. In the original study, integration occurred in cells with 
lots of E6. My data also show that integration was brought about in cells with high 
levels of E6. Hence, I propose that integration is E6 dose-dependent. Although, this 
concept is interesting I have not investigated this further. 
 
As discussed in the main introduction and at the end of Chapter 3, although E7 is 
classically associated with driving cell growth, there are numerous studies that have 
attributed this function to E6. E6 can interfere with the canonical Wnt pathway through 
the degradation of hDlg and hScrib via its PDZ motif (Ishidate et al., 2000, Nagasaka et 
al., 2006). E6 can also deregulate the Notch pathway, though there is disagreement in 
the field as to, how, and to what extent this occurs (Henken et al., 2012). Furthermore 
E6 can interfere with the regulation of the G1/S phase checkpoint and promote cell 
cycle progression and growth (Malanchi et al., 2002, Malanchi et al., 2004, Shai et al., 
2007). Hence, based on current literature, it seems likely that the E6-dependent growth 
effects I have consistently been observing are real. 
 
My results suggest that the next logical step is to determine the mechanism by which E6 
can bring about enhanced cell proliferation. The LSIL- and HSIL-like cell lines start to 
diverge in terms of their growth patterns from the point of confluence onwards. This 
also correlates with differences in the levels of E6. Hence, the HSIL-like cells may be 
able to more easily overcome the contact inhibition pathways that normally prevent cell 
growth when sufficient cell-to-cell contact has been established. Neither wild type 
NIKS nor LSIL-like cells contact inhibit completely upon reaching confluence, i.e. they 
do not cease growing. However, in Section 3.2.7 I observed that the mechanism through 
which the HSIL-like cell lines make room for additional cells is very different to NIKS 
and LSIL-like cells. While the former become increasingly smaller and stay within a 
single plane, the latter, though they also decrease in size, grow on top of each other and 
form cell piles. These observations suggest that contact inhibition pathways may be 
differentially regulated in the various cell lines. Based on my results so far I hypothesize 
that this may be brought about by E6. The contact inhibition pathways within cells are 
complex and there is a lot of overlap between them. One of the key ones in epithelial 
cells is the Notch signal transduction pathway and this will be analyzed in more detail in 
the next chapter. 
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The work in the previous two chapters has shown that HPV16 E6 alone can up-regulate 
cell proliferation, and that high levels of this protein correlate with the enhanced ability 
of the cells to grow to high density. The LSIL- and HSIL-like growth phenotypes 
emerge from the point of confluence onwards and this correlates with high E6 levels in 
the latter. This chapter aims to address how E6 leads to the increased cell numbers, in 
particular how it appears to overcome the NIKS contact inhibition pathways.  
 
In Chapter 3 I showed that the growth of E6-expressing cells is associated with cyclin A 
activation. These results are in agreement with published findings (Malanchi et al., 
2002, Malanchi et al., 2004). However, neither I nor the authors of those studies have 
determined the mechanism by which E6 is bringing about this effect. Furthermore, I 
want to characterize how E6 is specifically overcoming contact inhibition. Malanchi 
et al. were characterizing overall growth of fibroblasts, not growth in a high cell density 
environment. As outlined in Chapter 3 I believe that the confluent monolayer has a 
similar cell density as the basal layer of a raft culture or a real epithelium. This means 
that the pathways affected by viral proteins to drive proliferation past the point of 
confluence, should be reflective of their role in basal cells. Hence, unlike studies in 
fibroblasts, my cell line model can be used to characterize the signaling systems 
deregulated by the virus in its natural environment, which may make my findings more 
relevant to the HPV field on the whole. 
 
One of the most well characterized functions of high risk E6 is its ability to bind to and 
target p53 for proteasomal degradation (Werness et al., 1990, Scheffner et al., 1990) in 
an E6-AP-dependent manner (Huibregtse et al., 1991, Scheffner et al., 1993). There are 
numerous publications suggesting that degradation of p53 is essential to allow HPV-
infected cells to proliferate (Ishiwatari et al., 1994, Horner et al., 2004). Since p53 is a 
crucial regulator of the cell cycle and I observe differential cyclin A activation in my 
experiments, p53 inactivation by E6 in NIKS cells may be involved in allowing cells to 
proliferate. 
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The PDZ-binding motif of the high-risk E6 protein enables E6 to bind to PDZ proteins 
such as hDlg (Lee et al., 1997, Kiyono et al., 1997), and hScrib (Nakagawa and 
Huibregtse, 2000), and target them for degradation. It has been shown that the 
interaction of E6 with PDZ binding partners is required for its ability to induce 
epithelial hyperplasia (Nguyen et al., 2003). Additionally the PDZ motif of E6 may 
drive cell proliferation by increasing β-catenin activity in the canonical Wnt pathway. 
Both hDlg and hScrib, can bind to the adenomatous polyposis coli (APC) protein 
(Matsumine et al., 1996, Takizawa et al., 2006), which also contains a PDZ binding 
motif. APC forms part of the destruction complex of the canonical Wnt pathway that 
actively degrades β-catenin in the absence of Wnt ligands, to prevent activation of 
β-catenin transcriptional targets (Logan and Nusse, 2004). Binding of both hDlg and 
hScrib to APC has been shown to be involved in this cell cycle inhibitory function 
(Ishidate et al., 2000, Nagasaka et al., 2006). Hence, degradation of these PDZ proteins 
by E6 may lead to deregulated growth through Wnt signaling.  
 
Some of the PDZ proteins bound by E6 also have a role in maintaining adherens 
junctions. The main component of adherens junctions, found at certain cell-cell contact 
sites in the epithelium, is the cell adhesion receptor E-cadherin (Jeanes et al., 2008). 
These junctions allow adjacent cells to bind to each other and form connections and 
play essential roles in cell adhesion, recognition and motility, epithelial polarity, contact 
inhibition and differentiation. E-cadherin is linked to intracellular networks such as the 
actin cytoskeleton, via its direct association with β-catenin and the association of 
β-catenin with α-catenin. Both hDlg and hScrib are recruited to adherens junctions in an 
E-cadherin-dependent manner (Bilder et al., 2000, Firestein and Rongo, 2001, Navarro 
et al., 2005) and function to stabilize the linkage between E-cadherin and α-catenin (Qin 
et al., 2005). Furthermore, E6 has been shown to reduce surface E-cadherin and hence 
interfere with its function (Matthews et al., 2003). This means that in my cells, E6 may 
deregulate adherens junctions and promote proliferation in this way.  
 
As described in more detail in the main Introduction, the Notch pathway is one of the 
main players involved in regulating contact inhibition of cells. In the epithelium, Notch 
is implicated mainly in cell cycle withdrawal and keratinocyte differentiation (reviewed 
in (Watt et al., 2008, Dotto, 2008)), though some of its targets are involved in actively 
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promoting cell growth. Notch receptor activation generally requires cell-cell contact 
because its ligands (Delta-like1, -3, -4 and Jagged1, -2) are cell surface anchored 
molecules (Kolly et al., 2005). Upon activation Notch gets sequentially cleaved to give 
rise to Notch IntraCellular Domain (NICD), which translocates to the nucleus and 
associates with RBPJ (Recombining binding protein suppressor of hairless). In the 
absence of Notch, RBPJ is a repressor complex (Dou et al., 1994). However when 
NICD is bound, other proteins such as MAML1 (Mastermind-like protein 1) and p300 
(E1A binding protein p300) are recruited to the, now, activator complex and this 
enables transcriptional regulation of Notch targets including, amongst many others, 
HES1, p21 and AP-1 (Borggrefe and Liefke, 2012). The p21 protein (Cyclin-dependent 
kinase inhibitor 1) is activated by Notch and is involved in mediating its growth 
inhibitory and differentiation promoting effects (Abbas and Dutta, 2009). Several 
groups (Weijzen et al., 2003, Brimer et al., 2012, Henken et al., 2012, Tan et al., 2012, 
Meyers et al., 2013) have shown that E6 can interfere with the Notch pathway and 
thereby inhibit transcriptional activation of certain Notch targets. While the exact 
mechanism by which E6 affects Notch has yet to be determined, with much data 
contradicting each other, it seems that depending on the precise expression levels and 
cell environment (Henken et al., 2012), Notch, as deregulated by E6, can have growth 
promoting effects. Accordingly high expression of Notch1 has been shown to lead to 
growth arrest of cervical tumor-derived cells (Talora et al., 2002, Talora et al., 2005, 
Wang et al., 2007). 
 
Gamma secretase is a membrane complex involved in cleaving single-pass type I 
transmembrane proteins (reviewed in (Strooper and Annaert, 2001)). One of the main 
substrates of the complex is the Notch receptor. Upon binding an active ligand the 
receptor is cleaved twice, with the second cleavage giving rise to the NICD that can 
subsequently move to the nucleus and activate transcription of downstream Notch 
targets (reviewed in (Borggrefe and Liefke, 2012)). The gamma secretase complex 
consists of four essential proteins; presenilin (PS), presenilin enhancer-2 (PEN-2), 
nicastrin (Nct) and anterior pharynx-defective-1 (APH-1) (reviewed in (Kaether et al., 
2006)). In addition to a role in proteolytic activity, APH-1 promotes the assembly of all 
the components into the gamma secretase complex (Lee et al., 2004). Once it is fully 
formed the complex is activated through autocatalytic processing of PS-1, which is the 
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essential proteolytic component. The main role of both Nct and PEN-2 is to stabilize the 
whole assembled complex (Prokop et al., 2004, Zhang et al., 2005). 
 
Another substrate of the gamma secretase complex is amyloid precursor protein (APP). 
Its cleaved product, amyloid beta (Aβ) (Selkoe, 2001), is processed abnormally in 
people with Alzheimer’s disease and this is associated with amyloid plaques in their 
brain (Hardy and Allsop, 1991). Due to this condition being very widespread, several 
drugs and inhibitors against the gamma secretase complex have been developed to 
prevent the formation of amyloid plaques. Many of them do not distinguish between 
APP and other gamma secretase substrates, such as Notch, and therefore they can be 
used for studying signaling pathways that are not necessarily involved in Alzheimer’s 
disease.  
 
In this chapter I will address the roles of p53 degradation, the PDZ-binding motif and 
Notch signaling in promoting E6-dependent growth in a high cell-density environment.  
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5.2 Results 
 
5.2.1 E6∆PDZ- but not E6SAT-expressing cells grow slower than wild type E6-
expressing cells  
Having shown that E6 can induce cells to proliferate faster, I next wanted to determine 
what specific function(s) of E6 is involved in cell proliferation. The ability of high-risk 
E6 to degrade both p53 and several PDZ proteins has been characterized very well and 
shown to be important for the overall function of this protein. Thus I decided to first 
assess these two functions of E6 and determine whether they contribute to the enhanced 
cell proliferation observed in my cells. 
 
I made two E6 mutant cell lines using LXSN retroviruses (Halbert et al., 1991); 
LXSN_E6SAT (8S9A10T mutant) is unable to bind to and bring about the degradation 
of p53 while LXSN_E6∆PDZ (a truncated form of E6 with the ETQL PDZ-binding 
motif, located on the extreme C-terminus, cut off) cannot bind to and target PDZ 
proteins for degradation. The mutants were made by Lietta Nicolaides (NIMR) using 
site-directed mutagenesis in the wild type E6 retroviral LXSN vector. NIKS cells were 
infected and cells containing the retroviruses were selected with geneticin, in order to 
make stable cell populations. Pellets of confluent LXSN-, E6-, E7-, E6/E7-, E6SAT- 
and E6∆PDZ-expressing cells were lysed using a RIPA buffer containing 6 % SDS, and 
these whole cell extracts were used in western blot analysis (Fig. 5.1A). Each 
population expresses the expected proteins. Predictably, E6∆PDZ migrates slightly 
faster than wild type E6 due its truncated C-terminus. Moreover, it seems that the 
E6∆PDZ protein is less abundant in cells than wild type E6 or E6SAT proteins. This 
can be explained by a recent study showing that the stability of the E6 protein is 
dependent on its PDZ motif (Nicolaides et al., 2011). 
 
E6SAT- and E6∆PDZ-expressing cells were cultured alongside E6-, E7- and 
E6/E7-expressing cells in a 9-day growth assay. Cells were counted at days 1, 3, 5 and 9 
post-seeding to assess the differential growth phenotypes (Fig. 5.1B). As usual, I find 
that E6-expressing cells have the capacity to grow much quicker than E7-expressing 
and control cells, and that the cell population with both E6/E7 does not have a growth 
advantage over E6 only-expressing cells. While cells expressing E6SAT grow to the 
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same cell density as the wild type E6 population, E6∆PDZ-expressing cells grow 
slower. However, the E6∆PDZ population still grows much faster than cells expressing 
only E7 and control cells. Overall, this suggests that whereas the degradation of p53 by 
E6 does not affect growth, the PDZ binding motif may be involved in, but is not the 
sole contributor to E6-dependent enhanced proliferation. Due to the impaired stability 
of the E6∆PDZ protein and its resultant lower levels within the cell, it is difficult to say 
for certain that this is the case.  
 
These results suggest that there may be a further pathway(s) that E6 is regulating to 
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Figure 5.1: E6∆PDZ- but not E6SAT-expressing cells grow slower than wild type 
E6-expressing cells 
LXSN retroviruses were used to make stable NIKS cell populations expressing either an 
E6 8S9A10T mutant deficient for p53 degradation (E6SAT) or a truncated E6 mutant, 
with the ETQL PDZ-binding motif cut off, which is unable to bind and bring about 
degradation of PDZ proteins (E6∆PDZ).  
A) LXSN-, E6-, E7-, E6/E7-, E6SAT- and E6∆PDZ-expressing cells were cultured to 
confluence, and lysed using a RIPA buffer containing 6 % SDS. Whole cell extracts 
were used to detect E6 and E7 by western blot. 
B) The growth patterns of LXSN-, E6-, E7-, E6/E7-, E6SAT- and E6∆PDZ-expressing 
cells were compared in a growth assay. Cells from duplicate wells were counted at days 
1, 3, 5 and 9 post-seeding. The mean number of cells per 6-well plate well was plotted 
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5.2.2 The levels of NICD are lower in E6-expressing than control cells 
In epithelial cells, Notch signaling is involved in regulating cell proliferation and 
differentiation. Levels of active Notch (NICD) increase when cells reach confluence, 
thereby initiating cell cycle arrest and the onset of terminal differentiation (reviewed in 
(Watt et al., 2008, Dotto, 2008)). As the LSIL- and HSIL-like growth phenotypes 
displayed by my cells are very much dependent on confluence, I decided to assess 
whether the Notch pathway is involved in mediating E6-dependent growth. I opted to 
use the LXSN populations first as with these cells an effect that is caused by E6, as 
opposed to other viral proteins, can be easily distinguished. 
 
E6-expressing and LXSN control NIKS cells were cultured in a 9-day growth assay and 
counted at days 1, 3, 5, 7 and 9 to assess their differential proliferation patterns (Fig 
5.2A). Cell pellets harvested in duplicate at each of the time-points were lysed using a 
RIPA buffer containing 6 % SDS. Whole cell extracts were used to assess the levels of 
p53, an inverse marker of E6 levels, and NICD by western blot (Fig. 5.2B).  
 
As expected, the presence of E6 allows cells to proliferate to a much higher density than 
control cells, with the overall cell number at day 9 being almost 2-fold higher. 
 
The western blot analysis has shown that while p53 is abundant in control cells it is 
undetectable in cells expressing E6. The levels of NICD are low for both populations at 
sub-confluence at day 3, high for both at confluence at day 5. They stay elevated in 
control cells at post-confluence at days 7 and 9 while the E6 population has no 
detectable levels of NICD at these time-points. These results are highly reproducible 
between the two replicates of each cell population at each time-point analyzed. It seems 
reasonable that NICD is undetectable when cells are sub-confluent, as current literature 
suggests that Notch signaling, which triggers NICD expression, is dependent on 
confluence (Kolly et al., 2005). Therefore it also makes sense that NICD levels are high 
for both cell populations at confluence. However, only E6-expressing cells are then able 
to repress NICD levels allowing proliferation to a much higher cell density.  
 
Based on my work so far, I hypothesize that this differential regulation of Notch 
signaling may be involved in facilitating E6-mediated cell growth. 
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Figure 5.2: The levels of NICD are lower in E6-expressing than control cells 
LXSN- and E6-expressing cells were cultured in a 9-day growth assay and counted at 
days 1, 3, 5, 7 and 9 to assess their differential proliferation patterns.  
A) The average number of cells per 6-well plate well was plotted against the time in 
days. The error bars represent +/- the standard deviation of the duplicate wells. 
 B) Cell pellets harvested in duplicate at each of the time-points were lysed using a 
RIPA buffer containing 6 % SDS. Whole cell extracts were used to assess the levels of 
p53, used as an inverse marker of E6, and NICD by western blot. The pellets harvested 
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5.2.3 The levels of NICD are lower in HSIL-like cells than LSIL-like cells 
Having found that E6 can disrupt NICD levels of the Notch pathway, I wanted to test if 
this effect would also be observed in the NIKS HPV16-expressing clonal cells. Based 
on my data, I hypothesized that LSIL-like cells would have higher levels of NICD than 
the HSIL-like clone from confluence onwards. 
 
To this end, HSIL-like 1K and LSIL-like 2K cells were cultured in a growth assay 
format and counted at days 1, 3, 5, 7 and 9 to establish their patterns of proliferation 
(Fig 5.3A). Cell pellets harvested in duplicate at each of the time-points were lysed 
using a RIPA buffer containing 6 % SDS. Whole cell extracts were used to assess the 
levels of p53, an inverse marker of E6 levels, and NICD by western blot (Fig. 5.3B). 
 
As usual, the cell lines diverge in terms of their proliferation pattern from the point of 
confluence at day 5 onwards, with the HSIL-like cells growing to a much higher cell 
density than the LSIL-like cells. NIKS grow to a much lower cell number, presumably 
due to absence of E6. 
 
In accordance with this, the levels of p53 are consistently very high for NIKS, much 
lower for 2K and barely detectable for 1K. The levels of NICD are lowest in HSIL-like 
1K cells at all time-points assessed. I interpret this to mean that, much like in 
E6-expressing cells, Notch signaling is repressed in 1K, leading to reduced NICD levels 
and rapid cell proliferation. Hence, this effect may be involved in giving rise to the 
HSIL-like phenotype. The low levels of NICD in NIKS at days 7 and 9, are probably 
reflective of their slower growth and the resulting overall lower cell density at all time-
points as compared to the clonal HPV16-expressing cell lines. E7 levels are the same 
for 1K and 2K and are unchanging throughout the growth assay. This means that E7 is 
not involved in bringing about any aspect of the differential proliferation patterns 
observed.  
 
All together my results suggest that E6 can down-regulate NICD levels and that this 
correlates with growth. Generally, the higher the levels of E6, the more repression of 
NICD can be measured. 
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Figure 5.3: The levels of NICD are lower in HSIL-like cells than LSIL-like cells 
NIKS, 1K and 2K cell lines were cultured in a 9-day growth assay and counted at days 
1, 3, 5, 7 and 9 to assess their differential proliferation patterns.  
A) The mean number of cells per 6-well plate well was plotted against the time in days. 
The error bars represent +/- the standard deviation of the duplicate wells.  
B) Cell pellets harvested from duplicate wells at each of the time-points were lysed 
using a RIPA buffer containing 6 % SDS. Whole cell extracts were used to assess the 
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5.2.4 The p21 protein, a downstream effector of Notch signaling, is expressed at 
lower levels in HSIL-like cells than LSIL-like cells in an E6-dependent manner 
The p21 protein is a cyclin-dependent kinase inhibitor that is a key regulator of cell 
cycle progression in G1 phase. It acts by inhibiting CDK1 and CDK2 and also by 
abrogating the activity of PCNA (reviewed in (Abbas and Dutta, 2009)). Due to its 
cytostatic effects, p21 also promotes terminal differentiation of cells. Notch1 can 
stimulate p21 expression by binding of RBPJ directly to the p21 (CDKN1A gene) 
promoter (Rangarajan et al., 2001b). I hypothesized that low levels of NICD, mediated 
by the presence of E6 in my cells would result in diminished p21 levels, and hence that 
E6 could promote cell growth by indirectly inhibiting p21 via Notch. 
 
To determine whether E6-induced repression of Notch signaling has a corresponding 
effect on p21 levels, I assessed p21 levels in my cells by western blot. I used the whole 
cell extracts prepared in Section 5.2 for LXSN- and LXSN_E6 cells and in Section 5.3 
for NIKS, 1K and 2K clonal cell line (Fig 5.4A and B, respectively).  
 
For LXSN control cells, the levels of p21, although generally very low and hard to 
detect, are consistently higher throughout the time-course than for cells expressing E6.  
 
For parental NIKS, p21 levels are higher at sub-confluence at day 3 and confluence at 
day 5 but seem to be lower at post-confluence at days 7 and 9 than for both 1K and 2K 
cell lines. These different kinetics in protein expression are reflective of the slower rate 
of proliferation of NIKS and the resulting overall lower cell density at all time-points as 
compared to both clonal HPV16-expressing cell lines. More importantly, the levels of 
p21 are much lower for HSIL-like 1K cells than for LSIL-2K cells at days 3 and 5. At 
days 7 and 9 the levels are the same for both clones.  
 
My results confirm that p21 levels are diminished in the presence of E6. However, the 
kinetics of p21 levels during the time course do not fit with my hypothesis that this 
protein is regulated solely by Notch signaling. In Figure 5.2B I showed that the levels of 
NICD between E6-expressing and control cells are only different at days 7 and 9. Here I 
showed that p21 levels are different from day 3 onwards. For the clonal cell lines, I 
observed in Figure 5.3B that NICD levels are consistently lower for 1K than for 2K at 
all time-points, yet p21 levels assessed here are only different at days 3 and 5.  
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The data seem to suggest that low levels of p21, mediated by E6, are not necessary to 
allow cells to continue growing after reaching confluence. Nevertheless, p21 inhibition 
may be involved in promoting sub-confluent proliferation, as cells with lower levels of 
p21 grow faster than cells with higher levels at the beginning of the growth assay. 
Hence, I propose that differences in p21 levels may allow E6-expressing cells and 1K 
and 2K clonal lines to grow faster than their respective LXSN and NIKS control cells. 
However, the growth differences between 1K and 2K, which give rise to the LSIL- and 
HSIL-like phenotypes, are mediated by a different mechanism that may involve 
repression of Notch signaling.  
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A.      B. 
   
   
 
  













Figure 5.4: The p21 protein, a downstream effector of Notch signaling, is expressed 
at lower levels in HSIL-like cells than LSIL-like cells in an E6-dependent manner 
LXSN- and E6-expressing cells (A) and NIKS, 1K and 2K cell lines (B) were cultured 
in a 9-day growth assay. Cell pellets were harvested in duplicate at days 1, 3, 5, 7 and 9 
and lysed using a RIPA buffer containing 6 % SDS. Whole cell extracts were used to 
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5.2.5 The effects of E6 on p21 levels are Notch-independent and are not involved in 
cell growth at a high density  
In the previous section I showed that p21 may be involved in regulating proliferation of 
cells. I wanted to further analyze whether E6 disruption of Notch signaling affects p21. 
NICD forms a complex with, amongst other proteins, RBPJ and MAML1, and directly 
binds to the p21 (CDKN1A gene) promoter (Rangarajan et al., 2001b) to activate its 
transcription. 
 
To test this, I seeded 1K and 2K cells in growth assay format and harvested cells from 
duplicate wells at sub-confluence at day 3 and post-confluence at day 7. Pellets were 
used for RNA extraction and subsequent RT-qPCR to analyze the levels of p21 mRNA. 
Figure 5.5Ai and ii show the results of my analyses at day 3 and day 7, respectively. 
The data suggest that at both sub- and post-confluence the levels of p21 are not different 
between HSIL-like 1K and LSIL-like 2K cells. These results further suggest that p21 is 
not regulated by NICD-dependent direct transcriptional activation via E6.  
 
To further investigate whether E6 can, in fact, affect p21 independently of Notch I 
decided to use a gamma secretase inhibitor (GSI). Upon binding of a ligand from an 
adjacent cell, the Notch receptor protease cleavage site is exposed. This allows it to be 
cleaved by ADAM-proteases, which subsequently leads to an intracellular cleavage by 
the gamma secretase complex (reviewed in (Borggrefe and Liefke, 2012)). This second 
proteolytic cleavage event ultimately gives rise to the NICD. Treating cells with a GSI 
inhibits this cleavage and, hence, leads to reduced NICD levels. I hypothesized that in 
this situation, if p21 is a downstream effector of Notch signaling, I would find low p21 
levels, as NICD activity would be necessary to activate its expression. However, if p21 
was regulated by E6 independently of the Notch pathway, then I would expect to see 
that p21 is expressed normally, even in the absence of NICD.  
 
E6-expressing and LXSN control cells were seeded in 6-well plates in a growth assay 
format and grown to confluence at day 5. As induction of Notch signaling seems to 
occur primarily from the point of confluence, growing cells to this point is an important 
aspect of the experiment. Subsequently, cells were treated with 10 µM DAPT or an 
equivalent volume of DMSO for 24 hours, and then harvested. Cell pellets were lysed 
using a RIPA buffer containing 6 % SDS and subsequently the levels of NICD and p21 
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were assessed by western blot (Fig. 5.5B). As hypothesized, both NICD and p21 are 
high in LXSN cells treated with just DMSO. After treatment with DAPT the levels of 
NICD are diminished, yet p21 levels remain as high as in control cells. For E6-
expressing cells treated with DMSO the levels of both NICD and p21 are much lower 
generally than in LXSN cells. Treatment with DAPT results in even lower NICD levels. 
Yet, as with LXSN cells, the levels of p21 are not affected. The observation that after 
DAPT treatment NICD levels are diminished without a corresponding reduction in p21 
levels, further suggests that p21 is not predominantly regulated by E6 via Notch 
signaling in these cells. However, in both the LXSN population and clonal cell line 
model systems, p21 protein levels are lower for fast-growing cells with high levels of 
E6 (Fig. 5.4A and B). As p21 levels do correlate with enhanced proliferation, I 
speculated that E6 may be involved in post-translational regulation of p21. 
 
In Section 5.2.1 I showed that cells expressing the E6SAT mutant are deficient for p53 
degradation and that they can grow to a high density. The data in the previous section 
suggest that diminished p21, mediated by E6, seems to be involved in promoting cell 
growth in general. If low p21 levels are in fact a requirement for proliferation I would 
expect that E6SAT-expressing cells could bring about degradation of p21 in a p53-
independent manner. I wanted to determine whether high cyclin A levels (shown in 
Chapter 3 to correlate with E6-dependent proliferation) are involved in promoting 
proliferation in E6SAT-expressing cells. Based on my results and current literature, I 
hypothesized that these cells can degrade p21 as this is necessary to promote high levels 
of cyclin A and thus proliferation. 
 
To this end LXSN-, E6-, E6SAT- and E6∆PDZ-expressing cells were cultured to post-
confluence at day 7. Cell pellets were harvested and subsequently lysed using a RIPA 
buffer containing 6 %SDS. Whole cell extracts were used to assess the levels of 
cyclin A, p21 and p53, an inverse marker of E6, by western blot (Fig. 5.5C). The 
protein analysis shows that the levels of p53 are high in LXSN and E6SAT-expressing 
cells and much lower in cells with wild type E6 or E6∆PDZ. The levels of p21 are high 
in cells with E6SAT and undetectable in the other cell populations. Furthermore, cyclin 
A levels are undetectable in E6 SAT-expressing cells and abundant in all other cells. 
These results suggest that in the E6-expressing cells p21 regulation is brought about in a 
p53-dependent manner. However, degradation of p21 and high levels of cyclin A appear 
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not to be necessary for cells to grow rapidly post-confluence, as E6SAT cannot bring 
about either of them, but can still drive cells to grow to as high of a density as cells with 
wild type E6 (shown in Section 5.2.1). Additionally, the fact that even LXSN control 
cells have high levels of cyclin A but are still associated with slow proliferation shows 
that the growth of my cells in these conditions is not dependent on cyclin A activation.  
 
All in all, the experiments in this section have shown that p21 is not a direct effector of 
E6-dependent Notch signaling and that its repression is not essential in allowing growth 
post-confluence. This is in stark contrast to the Shai et al. study (discussed in Section 
3.3) where the authors proposed that E6 represses p21 by inactivating p53 to bring 
about growth. Additionally, to complement my findings at the end of Chapter 3 and 
those of Malanchi et al. in 2002 and 2004 in fibroblasts, I have extended my knowledge 
and have shown that high cyclin A levels are dependent on the down-regulation of p53. 
This is supported by published data showing that cyclin A is inhibited by p53 
(Yamamoto et al., 1994). Additionally, it seems that cyclin A is not involved in driving 
the growth of NIKS at a high cell density. As cyclins are known to be able to 
compensate for one another (Geng et al., 1999, Masamha and Benbrook, 2009), I 
propose that the low cyclin A levels measured here in E6SAT-expressing cells may 
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A i.       ii. 
 








Figure 5.5: The effects of E6 on p21 levels are Notch- independent and are not 
involved in cell growth at a high density 
A) 1K and 2K cells were cultured in a growth assay format and harvested in duplicate at 
sub-confluence at day 3 (i) and post-confluence at day 7 (ii). Subsequently RNA was 
extracted, RT-qPCR carried out and the levels of p21 mRNA assessed relative to ELF1.  
The error bars represent the standard deviation of duplicate wells. 
B) E6-expressing and LXSN control cells were seeded in 6-well plates in a growth 
assay format and grown to confluence at day 5. Cells were treated with 10 µM of the 
gamma secretase inhibitor DAPT or DMSO for 24 hours and then harvested. Cell 
pellets were lysed using a RIPA buffer containing 6 % SDS and subsequently the levels 
of NICD and p21 were assessed by western blot. 
C) LXSN-, E6-, E6SAT- and E6∆PDZ-expressing cells were cultured to post-
confluence at day 7. Cells pellets were harvested and subsequently lysed using a RIPA 
buffer containing 6 %SDS. Whole cell extracts were used to assess the levels of 
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5.2.6 Use of RNAi to knock-down Notch1 or gamma secretase is unsuccessful in 
LSIL- and HSIL-like cells 
Much of my work in this chapter to this point has focused on establishing that Notch 
signaling is disrupted by E6 and that this is necessary to allow cells to grow rapidly. 
Here I wanted to test whether reducing the expression levels of genes involved in Notch 
signaling would have a similar effect to knocking down E6/E7 using siRNA, as 
described in Section 4.2.12. In that section I found that a reduction in E6/E7 levels has a 
big negative effect on overall proliferation of NIKS. By only reducing the levels of 
members of the Notch pathway, I hypothesized that cells would only gain a growth 
advantage after reaching confluence, and thereby confirm that Notch signaling is 
specifically involved in allowing cells to grow in a high cell density environment. 
Hence, I speculated that by treating LSIL-like 2K cells with shRNA targeting the Notch 
pathway, these cells could grow to a density similar to that associated with 1K. 
 
I ordered commercially available TRC lentiviral shRNA vectors targeting either Notch1 
or both the APH-1α and PS-1 subunits of the gamma secretase complex. I also acquired 
an shGFP vector to use as a control during my experiment. I transfected 293TT cells 
with appropriate packaging and lentiviral vectors, and harvested viruses 48 hours later. 
The virus mix was used to directly infect 2K cells. After antibiotic selection, cells were 
seeded in 6-well plates for a 9-day growth assay and counted in duplicate at each time-
point to assess differential proliferation patterns (Fig 5.6A). As usual, the normal HSIL-
like 1K and LSIL-like 2K growth phenotypes become apparent from the point of 
confluence at day 5 onwards. Both 2K shγ-secretase- and 2K shNotch-expressing cells 
can grow faster than the wild type 2K clone. However, shGFP-treated cells can grow 
even faster, suggesting that this enhanced proliferation effect is a consequence of the 
infection and/or selection process and not the knock-down of Notch1 or gamma 
secretase. Additionally, both 2K shγ-secretase- and 2K shNotch-treated cells seem to 
have a growth advantage even at early time-points. As Notch pathway repression should 
result in fast growth only from the point of confluence onwards, this observation further 
suggests that the rapid proliferation is a side effect of my experiment and not a direct 
result of attenuating Notch signaling. All in all, my attempt to reduce the levels of 
Notch1 and gamma secretase in LSIL-like 2K cells has been unsuccessful. 
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Looking back over some of my old data I realized that I generally seem to observe this 
adverse effect on proliferation when using antibiotics to select cells after transfection or 
infection (Fig. 5.6Bi-iii). The shNT control cell populations used in the growth assay in 
Figure 5.6Bi were made in Section 4.4, when I tried to knock-down E6 levels using 
custom-made shE6 lentiviruses. The 1K and 2K cells with LXSN in Figure  5.6Bii were 
originally used as controls for the experiment in Section 4.5 where I tried to increase the 
levels of E6 in the clonal cell lines by infecting them with LXSN_E6 retroviruses. And 
the cells assessed in terms of their proliferation in Figure 5.6Biii where made as 
controls as part of the experiments in Sections 4.6 and 4.7 when I over-expressed E6 in 
2K cells using pMV11 and pcDNA3.1 vectors.  
 
The enhanced growth of these cells seems to result from the experimental procedure. To 
make the populations used in the various growth assays in Figure 5.6B, cells were both 
infected and transfected and selected with either puromycin or geneticin. Hence, I 
speculate that these fast-growing populations may be selected while treating cells with 
antibiotics. As I generally have to select cells for 7 to 10 days, due to the nature of 
NIKS cells, it seems reasonable that in this time fast cells, that are not adversely 
affected by the antibiotics, have a chance to outgrow slower cells that are struggling to 
survive. Based on my findings so far I propose that the cells that are outgrowing during 
the selection process have high E6 levels and that, as a result of this, the viral genomes 
may have integrated in host cell chromosomes. 
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Figure 5.6: Use of RNAi to knock-down Notch1 or gamma secretase is unsuccessful 
in LSIL- and HSIL-like cells 
A) NIKS, 1K, 2K and 2K shGFP-, 2K shNotch- and 2K shγ-secretase-expressing cells 
were counted in duplicate at days 1, 3, 5, 7 and 9 post-seeding and compared in terms of 
their growth phenotypes. The average number of cells per 6-well plate well was plotted 
against the time in days. The error bars represent +/- the standard deviation of the 
duplicate wells. 
B i-iii) Growth assays using control cells originally made in previous transfection or 
infection experiments, that involved an antibiotic selection step, were reanalyzed in 
terms of their rate of proliferation. The average number of cells per 6-well plate well 
was plotted against the time in days. The error bars represent +/- the standard deviation 
of the duplicate wells. 
i) 1K and 2K cells were infected with shRNA lentiviral particles. 1K, 1K shNT, 2K and 
2K shNT cells were counted in duplicate at days 1, 3, 5, 7 and 9 post-seeding.  
ii) LXSN_E6 retroviruses were used to infect 1K and 2K clonal cell lines. 1K, 1K 
LXSN, 2K and 2K LXSN cells were compared in a 9-day growth assay. Cells from 
duplicate wells were counted at days 1, 3, 5, 7 and 9 post-seeding. 
iii) 2K cells were transfected with linearized pcDNA3.1 or pMV11. 1K, 2K, 2K MV11 
and 2K pcDNA were counted in duplicate at days 1, 3, 5, 7 and 9 post-seeding. 
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5.2.7 Treating LSIL- and HSIL-like cells with DAPT results in a collapse of the 
differential growth phenotypes 
The use of shRNA to reduce Notch signaling in the cells has proven unsuccessful. 
However, I still felt that it was very important to establish if Notch is specifically 
involved in allowing cells to overcome contact inhibition. Therefore I decided to use a 
different approach to manipulate Notch signaling. DAPT, the GSI used in Section 5.2.5, 
inhibits the final cleavage of the Notch receptor that gives rise to NICD. I speculated 
that by treating cells with DAPT to block NICD formation, I would see a corresponding 
positive growth effect. 
 
When using DAPT I treat control cells with DMSO. NIKS suffer considerably when 
DMSO is present and therefore I decided to use my short growth assay format (for 
assessing the effect of DAPT on cell growth) so as to reduce the exposure time to the 
treatment. The short growth assay was fully optimized for NIKS, 1K and 2K in Section 
4.12. However, I also wanted to treat the LXSN populations with DAPT/DMSO during 
a time-course. Hence I decided to optimize the short growth assay conditions for the 
LXSN populations. To do this, I seeded 6x105 LXSN- and LXSN_E6-expressing cells. 
At day 1 I counted cells to check their seeding efficiency. At days 2, 4 and 6 I counted 
cells to assess their growth patterns (Fig 5.7Ai). These time-points should equate to 
days 5, 7 and 9, respectively, in my normal time-courses. A bar chart showing fold-
increase relative to the previous time-point is shown in Figure 5.7Aii. 
 
The data show that, as normal, control and E6-expressing cells start to diverge in terms 
of their growth from day 1 onwards. At the end of a normal growth assay, I generally 
see a 2-fold difference in cell number between LXSN- and E6-expressing cells. In this 
format, the difference is slightly less but still very big. The bar chart shows that at day 
2, cells with E6 have increased their numbers much more than the control cells. Same as 
wild type NIKS, NIKS with LXSN take longer to recover from the seeding process and 
therefore only start to grow rapidly from day 2 onwards. Hence, the increase in LXSN 
control cell numbers is bigger than for E6-expressing cells prior to the last time point, 
although overall the latter can grow to a much higher cell density. Between days 1 and 6 
LXSN have increased their total cell number 2.5-fold whilst E6-expressing cells have 
have done so 5-fold. This means that all in all, E6-expressing cells have reached a  
1.8-fold higher cell density than LXSN control cells. The data are an average of 7 
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individual experiments. Unpaired s were used to compare LXSN and E6 cell numbers at 
each time-point. There are significant differences between them at confluence at day 2 
and post-confluence at days 4 and 6 with p values of 0.0043, 0.0005 and 0.0002, 
respectively. 
 
I hypothesized that, if repression of Notch signaling by E6 is indeed involved in driving 
proliferation, then inhibition of the gamma secretase complex (by using DAPT) and the 
resulting low levels of NICD would promote faster cell growth. I expected this effect to 
be bigger in control cells without E6 as the NICD levels here are much higher to begin 
with. Hence, I predicted that DAPT would only have a minor positive effect on the 
growth of cells that express high levels of E6, such as LXSN_E6 and HSIL-like 1K 
cells. In contrast, the growth of cells expressing little or no E6, such as LSIL-like 2K 
and NIKS or LXSN cells, respectively, would be enhanced considerably. Based on this, 
I further hypothesized that use of DAPT would result in a collapse of the LSIL- and 
HSIL-like growth phenotypes as all cells would be able to grow to a high density due to 
the presence of DAPT. 
  
To test my theory I seeded LXSN- and LXSN_E6-expressing cells and in parallel 
NIKS, 1K and 2K in a short growth assay. From the day after seeding onwards cells 
were treated with 10 µM of DAPT or DMSO that was replaced every 24 hours. Cells 
are normally only given fresh FC medium (with EGF) every second day of the short 
growth assay (on days 2, 4, and 6). To allow me to change the medium every day, and 
thereby replace the DMSO or DAPT, I prepared conditioned medium for the changes at 
days 3 and 5 to ensure that the growth conditions, in terms of growth factor 
concentrations, throughout the experiment remained consistent. The cells were counted 
in duplicate at days 1, 2, 4 and 6 to assess their differential proliferation patterns. The 
results are shown in Figure 5.7B and C for LXSN and E6-expressing cell populations 
and NIKS, 1K, and 2K cell lines, respectively. 
 
Surprisingly, treating cells with DAPT has a huge negative impact on their growth. The 
effect of DAPT seems to be much bigger for the E6-expressing population as compared 
to the one without. Due to this, E6-expressing cells treated with the drug can grow at a 
comparable rate to untreated LXSN cells. DAPT works on the gamma secretase 
complex, which is involved in negatively regulating cell growth through Notch 
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signaling at a high cell density. Hence, this difference in the effect of the drug is 
presumably caused by the fact that E6 allows cells to proliferate rapidly and reach 
confluence more quickly. This means that while DMSO-treated E6-expressing cells 
grow to a density that is almost 2-fold higher than that of LXSN cells, this difference is 
only approximately 1.4-fold for DAPT-treated cells. For the clonal cell lines I see a 
similar negative effect on growth with DAPT. While untreated 1K and 2K diverge from 
day 2 onwards to give rise to their normal HSIL- and LSIL-like growth phenotypes, 
DAPT-treated 1K and 2K do not diverge significantly throughout the time-course. 
These cells now grow to an overall density that is only slightly higher than that of 
untreated NIKS. Similarly to the LXSN populations, the effect of DAPT is bigger for 
cells with higher levels of E6.  
 
The results of the DAPT growth assays are unexpected. My hypothesis that the 1K and 
2K growth phenotypes will collapse holds true. I also see a similar effect for LXSN and 
E6-expressing cells. However, I hypothesized that the effect of the drug may be smaller 
for cells with high levels of E6 as they have lower NICD levels to begin with; I have 
observed the opposite here. The biggest surprise is that according to my hypothesis 
DAPT-treated cells should grow to a higher, not lower, cell density than their untreated 
counterparts.  
 
Other members of my laboratory have found that DMSO has effects on the expression 
of viral proteins, such as E4, in NIKS (personal communication with Clare Davy and 
Qian Wang; NIMR, London, UK). I speculate that DMSO could be having effects on 
the expression levels of not only viral but also cellular proteins and that this may be 
causing these unforeseen effects. For this reason I have decided to re-optimize the 
conditions of this experiment.   
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Figure 5.7: Treating LSIL- and HSIL-like cells with DAPT results in a collapse of 
the differential growth phenotypes 
A) E6-expressing and LXSN control cells were seeded at a high density (6x105) in 
6-well plates and counted in duplicate at days 1, 2, 4 and 6 post‐seeding. Day 2 
corresponds to confluence at day 5 of a normal growth assay while days 4 and 6 
correspond to post-confluence at days 7 and 9. Cells were compared in terms of their 
growth phenotypes.  
i) The average number of cells per 6-well plate well was plotted against the time in 
days. The error bars represent +/- the standard error of 7 individual experiments. 
Unpaired t-tests were used to compare LXSN- and E6-expressing cell numbers at each 
time-point. The p values at day 2, 4 and 6 are 0.0043, 0.0005 and 0.0002, respectively. 
ii) Fold-increase relative to the previous time-point was calculated and plotted in a bar 
chart. The error bars represent +/- the standard error of 7 individual experiments. 
A short growth assay was done with LXSN- and E6-expressing cells (B) or NIKS, 1K 
and 2K (C). From day 1 onwards cells were treated with 10 µM of DAPT or DMSO 
that was replaced every 24 hours. Cells were counted in duplicate at days 1, 2, 4 and 6 
post-seeding and compared in terms of their growth phenotypes. The average number of 
cells per 6-well plate well was plotted against the time in days. The error bars represent 
+/- the standard deviation of the duplicate wells. 
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5.2.8 Treating cells with DAPT dissolved in ethanol brings about a negative effect 
on growth 
In the previous section I postulated that the growth inhibitory effect of DAPT on all my 
cells may be a brought about by the presence of DMSO as opposed to being a direct 
effect of the drug itself. To resolve the issue I decided to repeat the experiment using 
DAPT dissolved in ethanol.  
 
To this end I seeded LXSN- and E6-expressing cells and in parallel NIKS, 1K and 2K 
in a short growth assay. From the day after seeding onwards cells were treated with 
10 µM of DAPT or ethanol that was replaced every 24 hours. Similarly to the growth 
assays in the previous section I used conditioned media to feed cells on days 3 and 5 to 
ensure that the growth conditions throughout the experiment remained consistent. The 
cells were counted in duplicate at days 1, 2, 4 and 6 to assess their differential 
proliferation patterns. The results are shown in Figure 5.8A and B for LXSN and 
E6-expressing cell populations and NIKS, 1K, and 2K cell lines, respectively.  
 
Even when dissolved in ethanol, DAPT has a negative effect on the growth of all the 
cells. Once again, the effect of the drug is bigger for E6-expressing than LXSN cells 
due to the former being able to grow to a higher cell density. Hence, while DAPT-
treated LXSN cells show the same growth pattern as untreated cells, untreated E6-
expressing cells have increased their numbers 1.5-fold more than DAPT-treated ones. 
For 1K and 2K clones I see the normal HSIL- and LSIL-like growth phenotypes. After 
treatment with DAPT the difference between 1K and 2K is slightly diminished. As 
found previously, the growth effect of the drug is bigger for 1K than for 2K. 
 
The data here suggest that the growth inhibitory effect of DAPT is caused by the drug 
itself as opposed to what it is dissolved in. Looking through the literature I have found 
that DAPT does not specifically block the Notch receptor cleavage function of gamma 
secretase, but that it is an inhibitor of the complex on the whole. I speculate that DAPT 
may be inhibiting other functions of gamma secretase and that this is bringing about the 
unexpected growth effects observed in the growth assays.  
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Figure 5.8: Treating cells with DAPT dissolved in ethanol brings about a negative 
effect on growth 
A short growth assay was done with LXSN- and E6-expressing cells (A) or NIKS, 1K 
and 2K (B). From day 1 onwards cells were treated with 10 µM of DAPT or ethanol 
that was replaced every 24 hours. Cells were counted in duplicate at days 1, 2, 4 and 6 
post-seeding and compared in terms of their growth phenotypes. The average number of 
cells per 6-well plate well was plotted against the time in days. The error bars represent 
+/- the standard deviation of the duplicate wells. 
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5.2.9 Treating cells with R04929097 brings about a negative effect on growth 
My work using the gamma secretase inhibitor DAPT has shown that the drug has a 
growth inhibitory, as opposed to growth promoting effect on NIKS cells. DAPT is a 
general inhibitor of the gamma secretase complex, not just its Notch receptor cleavage 
function. A well-known substrate of gamma secretase is amyloid precursor protein 
(APP). In Alzheimer’s disease, cleaved amyloid beta (Aβ) is processed abnormally and 
its accumulation is associated with the amyloid plaques in the brain (Hardy and Allsop, 
1991). Furthermore, presenilin-1 (PS-1), one of the subunits of the gamma secretase 
complex, has been implicated in Wnt/β-catenin signaling. PS-1 can bind to β-catenin 
and bring about its phosphorylation and subsequent degradation (Kang et al., 2002). 
β-catenin is a transcription factor that is a key component of the Wnt pathway. 
Canonical Wnt pathway activation, which leads to the formation of the active β-catenin 
transcription complex, has been associated with HPV-dependent transformation of cells 
(Uren et al., 2005), with a more recent study showing that E6 alone can augment Wnt 
signaling (Lichtig et al., 2009). Additionally, PS-1 can control cleavage by gamma 
secretase of the E-cadherin receptor (Marambaud et al., 2002). E-cadherin, along with 
β-catenin, is a major component of adherens junctions that are found at cell-cell contact 
sites in the epithelium and play an important role in, amongst other things, contact 
inhibition. The cleavage of E-cadherin by gamma secretase leads to the disassembly of 
the adherens junction complex, and release of β-catenin into the cytoplasm that can 
then, as part of canonical Wnt signaling, activate transcription. Due to the variety of 
functions of the gamma secretase complex described here, and many others that have 
not been considered, I decided that it was important to use a GSI specific to Notch 
signaling during my experiments. I purchased an inhibitor called R04929097 that 
reduces Notch processing with a much higher affinity and at a much lower 
concentration than APP cleavage and other functions of gamma secretase.  
 
I seeded LXSN- and E6-expressing cells and in parallel NIKS, 1K and 2K in a short 
growth assay. From the day after seeding onwards cells were treated with 8 nM of 
R04929097 or DMSO that was replaced every 24 hours. I used conditioned media to 
feed cells on days 3 and 5 to ensure consistent growth conditions throughout the 
experiment. The cells were counted in duplicate at days 1, 2, 4 and 6 to assess their 
differential proliferation patterns. The results are shown in Figure 5.9A and B for LXSN 
and E6-expressing cell populations and NIKS, 1K, and 2K cell lines, respectively. 
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Much like DAPT, R04929097 reduces the growth potential of all the cells. Once again, 
the effect of the drug on E6-expressing cells is much bigger than for LXSN cells, with 
the former now growing to a lower density than untreated LXSN cells. For untreated 1K 
and 2K, I get the normal LSIL- and HSIL-like growth phenotype. The extent of the 
negative effect of R04929097 seems to be the same for NIKS, 1K and 2K, regardless of 
the levels of E6. This means that even in the presence of the drug, the normal LSIL- and 
HSIL-like proliferation patterns emerge. 
 
The results here indicate that blocking gamma secretase has a growth inhibitory effect 
on cells, regardless of whether the GSI specifically targets Notch processing or not. 
Additionally, due to the pleiotropic effects of gamma secretase, it is difficult to fully 
interpret my data. The issue of affecting both growth promoting and suppressing 
pathways should have been solved by using R04929097. However, the overall outcome 
of my experiment has not changed. Some studies have shown that Insulin-like growth 
factor 1 (IGF-1), EGFR and also ErbB4, a receptor tyrosine-protein kinase that is a 
member of the EGFR subfamily, are substrates of gamma secretase (Ni et al., 2001, Li 
et al., 2007, McElroy et al., 2007). My medium contains supplemented FBS (providing 
growth factors), EGF and also insulin. Therefore I speculate that this may be interfering 
with gamma secretase and causing, at least in part, the growth effects that I observe 
here. 
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Figure 5.9: Treating cells with R04929097 brings about a negative effect on growth 
A short growth assay was done with LXSN- and E6-expressing cells (A) or NIKS, 1K 
and 2K (B). From day 1 onwards cells were treated with 8 nM of R04929097 or DMSO 
that was replaced every 24 hours. Cells were counted in duplicate at days 1, 2, 4 and 6 
post-seeding and compared in terms of their growth phenotypes. The average number of 
cells per 6-well plate well was plotted against the time in days. The error bars represent 
+/- the standard deviation of the duplicate wells. 
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5.2.10 E6 up-regulates Notch signal transduction via RBPJ 
In the previous sections I manipulated Notch signaling to attempt to show that 
regulation of this pathway by E6 is essential for overcoming contact inhibition. 
Unfortunately my various approaches have not worked well and I do not have 
conclusive data. Therefore, I decided to use a completely different approach and 
measure the activity of the Notch promoter using a transcription transactivation assay. 
By using this technique I was hoping to directly monitor the activity of the Notch 
pathway. E6 from βHPVs, has recently been shown to bind MAML1, which forms part 
of the transcriptional activation complex with RBPJ and NICD, and thereby reduce 
Notch signaling (Brimer et al., 2012, Tan et al., 2012, Meyers et al., 2013). Based on 
this I speculated that Notch activation would be reduced in high level E6-expressing 
cells as compare to the LXSN control. 
 
To do this LXSN- and E6-expressing NIKS cells were electroporated in triplicate with 
the Topflash Photinus luciferase reporter plasmid containing either the specific RBPJ 
binding site of NICD (including the tandem repeats of the RBPJ transcriptional 
response element (TRE)) or a mutant version used as a negative control. This RBPJ-
responsive construct encodes the firefly luciferase reporter gene under the control of a 
minimal (m)CMV promoter. The Renilla luciferase reporter plasmid was 
co-electroporated and serves as an internal control for normalizing transfection 
efficiencies. Cells were seeded in 6-well plates and allowed to grow to confluence for 5 
days. To assess Notch activity, cells were lysed and the Photinus luciferase levels were 
quantified and normalized to the luminescence levels of the Renilla plasmid (Fig 
5.10A). My results show that the levels of RBPJ activity are approximately 2.6-fold 
higher in E6-expressing as compared to LXSN cells. This suggests that E6 can up-
regulate RBPJ activation. 
  
These data are surprising in that I was expecting Notch signaling to be reduced in the 
presence of high levels of E6, yet I have observed the opposite. To further confirm my 
results I decided to carry out some RT-qPCR analysis to establish whether HES1 
transcript levels correlate with RBPJ activation. HES1 is one of the main downstream 
effectors of the Notch pathway. Having seen more RBPJ-responsive promoter activity 
in E6-expressing cells, I also expected higher HES1 mRNA levels in these cells.  
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HSIL-like 1K and LSIL-like 2K cells were cultured in a growth assay format and 
harvested from duplicate wells at sub-confluence at day 3 and post-confluence at day 7. 
Subsequently I extracted RNA and performed RT-qPCR to assess HES1 transcript 
levels. Figure 5.10Bi and ii show that at both days 3 and 7, respectively, the levels of 
HES1 mRNA are higher for 1K than 2K cells.  
 
The results of the transactivation assay and the qPCR experiments are compatible with 
each other and show that Notch signaling via RBPJ is elevated in cells with high levels 
of E6 as compared to cells with lower levels. This suggests that high E6 levels correlate 
with Notch pathway activation. It is interesting that E6 is apparently having opposing 
effects; it can down-regulate NICD levels but at the same time increase activation of the 
Notch responsive promoter.  
Chapter	  5:	  Investigation	  of	  the	  Pathways	  Targeted	  by	  E6	  to	  Enhance	  Proliferation	  	  




B i.       ii. 
 
Figure 5.10: E6 up-regulates Notch signal transduction via RBPJ 
A) LXSN- and E6-expressing cells were electroporated in triplicate with the Topflash 
Photinus luciferase reporter plasmid containing the specific RBPJ binding site of NICD. 
The Renilla luciferase reporter plasmid was co-electroporated and used as an internal 
control. Cells were seeded in 6-well plates and allowed to grow to confluence for 5 
days. To assess Notch activity, cells were lysed and the Photinus luciferase levels were 
quantified and normalized to the luminescence levels of the Renilla plasmid (arbitrary 
units). The error bars represent the standard deviation of triplicate wells.  
B) 1K and 2K cells were cultured in a growth assay format and harvested in duplicate at 
sub-confluence at day 3 (i) and post-confluence at day 7 (ii). Subsequently RNA was 
extracted, RT-qPCR performed and the levels of HES1 mRNA assessed relative to 
ELF1. The error bars represent the standard deviation of duplicate wells. 
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5.2.11 E6-dependent growth correlates with the levels of a putative truncated form 
of NICD 
In Section 5.2.8 when I assessed the growth of my cells treated with DAPT dissolved in 
ethanol, I prepared cell pellets at each of the time points. I lysed cells with a RIPA 
buffer containing 6 % SDS and carried out some western blot analysis with the whole 
cell extracts from day 6 to test whether the levels of NICD were diminished in the 
presence of the GSI (data not shown). As part of these routine westerns I found that my 
NICD antibody can detect a small band of approximately 17 kDA with a much higher 
affinity than NICD. As NICD is a big protein that runs at 102 kDa, many of the low 
molecular weight proteins are routinely run off the bottom of low percentage gels and 
hence, I had never detected this other NICD species before. I hypothesized, based on the 
antibody’s specificity and the size of the fragment, that the small band is the RAM 
domain of NICD. When an active ligand binds to the Notch receptor on the cell surface, 
gamma secretase cleavage gives rise to active NICD that can translocate to the nucleus. 
Once there, it can associate with RBPJ through an interaction involving both the RAM 
(RBPJ Associated Molecule) and ANK domains of NICD (Johnson and Barrick, 2012), 
leading to transactivation of Notch target genes. Biochemical analysis has shown that 
the RAM domain is also involved in displacing co-repressor proteins from the 
promoters of target genes to give rise to the transcriptional activation complex of Notch 
(Johnson and Barrick, 2012). To the best of my knowledge a stand-alone RAM domain 
has not been described in vivo in other studies. Surprisingly, I found that the levels of 
this truncated form of NICD correlate with E6-dependent growth of cells (Fig. 5.11A). 
LXSN control cells have no E6, express high levels of NICD and low levels of the 
putative “RAM” domain. In contrast, E6-expressing cells have low levels of NICD and 
high levels of the proposed “RAM” at the time-point analyzed. In both LXSN and E6-
expressing cells, DAPT can reduce the levels of both full-length and “truncated NICD”. 
 
Leading on from this experiment I wanted to ensure that this stand-alone expression of 
the proposed “RAM” domain is not specific to NIKS cells. To do this I cultured primary 
cervical cells (PHKS) (isolated by Deborah Jackson in the laboratory) and also 1321 
keratinocytes (that contain β-actin promoter driven HPV16 E6/E7) to confluence and 
prepared cell pellets. Cells were lysed with a RIPA buffer containing 6 % SDS and 
whole cell extracts were used to assess the levels of “truncated NICD” (Fig. 5.11B). The 
western blot shows that both the primary cells and 1321s express “truncated NICD”. 
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Similarly to the patterns of expression observed in NIKS, E6- and E7-expressing1321 
cells have low levels of NICD and high levels of the putative “RAM” domain while 
PHKS, without the oncogenes, show the opposite. 
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Figure 5.11: E6-dependent growth correlates with the levels of a putative 
truncated form of NICD 
A) LXSN and E6-expressing cells were cultured in a short growth assay. From day 1 
onwards cells were treated with 10 µM of DAPT or ethanol that was replaced every 24 
hours. Cells were harvested in duplicate at day 6 post-seeding and lysed using a RIPA 
buffer containing 6 % SDS. Whole cell extracts were used to detect both full-length 
NICD and “truncated NICD” by western blot.  
B) Primary human cervical cells (PHKS) and 1321 keratinocytes (expressing both E6 
and E7) were cultured to confluence. Cells were harvested and lysed using a RIPA 
buffer containing 6 % SDS. Whole cell extracts were used to detect both full-length 
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5.3 Discussion 
In this chapter I have examined the underlying mechanism that is giving rise to the 
LSIL- and HSIL-like growth phenotypes. The different proliferation patterns of these 
cells correlate with high E6 levels in the latter from the point of confluence onwards. I 
first assessed whether degradation of p53 or PDZ proteins by E6 is involved in growth. 
I found that the PDZ motif seems to promote rapid proliferation but is not the sole 
contributor to cell growth. I then established that Notch signaling is involved in 
mediating growth in a high-density cell environment, though p21, a key effector of the 
pathway, is not activated in my cells in a Notch-dependent manner. Subsequently I 
moved on to show that use of a gamma secretase inhibitor (GSI) leads to a collapse of 
the phenotypic differences between HSIL-like 1K and LSIL-like 2K cells. Although the 
exact kinetics of the experiment appear wrong, this result shows that signaling through 
gamma secretase, which plays a crucial role in the Notch pathway, is involved in giving 
rise to the growth differences between these clonal cell lines. Further analysis of the 
Notch pathway showed, surprisingly, that high E6 levels are associated with increased 
RBPJ activation, as reflected in the transcript levels of HES1. This result is in 
accordance with a further experiment where I found that the putative “RAM” domain, 
may be expressed on its own in NIKS and also other keratinocytes, and that the levels of 
this small fragment of the protein correlate with E6-dependent proliferation. 
 
Some of my Notch-related results, and those of others are contradictory. It is 
unexpected that E6 can bring about such a big reduction in NICD levels but at the same 
increase transcriptional activation of Notch targets. I speculate that the two mechanisms 
work in tandem to bring about growth of cells. The main role of Notch in epithelial cells 
is to promote growth arrest and commitment to the cellular differentiation program 
(Dotto, 2008). However, Notch may also have tumorigenic, and hence growth 
promoting effects, as shown in a recent study focusing on AP-1, yet another effector of 
the pathway. AP-1 is a dimeric transcription factor complex consisting of one Jun 
family member (cJun, JunD or JunB) and also a Fos family member (Fra1, Fra2, cFos 
or FosB) (Eferl and Wagner, 2003). It was previously shown that cancer cells such as 
SiHa and HeLa contain primarily cJun/cFos dimers while non-tumorigenic HPV-
immortalized keratinocytes and other similar cells contain cJun/Fra1 dimers (Soto et al., 
2000, de Wilde et al., 2008). In the study at hand (Henken et al., 2012), two sets of SiHa 
cells expressing exogenous Notch were assessed, with increased AP-1 activity measured 
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in both. Moderate levels of Notch were associated with cJun/cFos dimers normally 
found in SiHa, whereas high levels of Notch lead to a change in AP-1 complex 
composition to cJun/Fra1, which is associated with non-tumorigenic cells. This suggests 
that the effects of Notch on transformation are dosage dependent. While I have not 
looked at AP-1 activation in my cells, or dimer composition for that matter, I speculate, 
based on the Henken et al. study, that I might also be seeing a dose dependent effect of 
Notch signal transduction. I postulate that in my cell line model, low levels of NICD 
and high transcriptional activation through RBPJ, associated with high E6 levels in the 
HSIL-like clone, contribute to increased proliferation. In contrast, high levels of NICD 
and lower levels of transcriptional activation in the LSIL-like cell line, with less E6, are 
associated with slow growth and reduced capacity to overcome contact inhibition. 
 
Furthermore, the growth effects I have observed in my cells, that seem to correlate with 
differential Notch signaling, could also be caused by the regulation of Notch 
transcriptional activation itself. NICD has the capacity to bind to thousands of gene 
promoters with only a small subset of these being fully activated in its presence 
(Margolin et al., 2009). Activation seems to be dependent on the cellular context, with 
RBPJ binding to DNA in a cell type specific manner (Meier-Stiegen et al., 2010). 
Moreover, activation is heavily regulated by histone acetylation (Mulligan et al., 2011) 
and DNA methylation (Deaton and Bird, 2011). Additionally, histone modifications like 
methylation and ubiquitinylation also play major roles in regulating Notch-dependent 
transcriptional activation (Borggrefe and Liefke, 2012).  
 
Yet another publication has shown that HES1 can interact with RBPJ and thereby 
reduce the transcriptional activation of Notch targets, including the HES1 gene itself 
(King et al., 2006). I have shown that HSIL-like cells have higher levels of HES1 
transcript than the LSIL-like cell line. Therefore I speculate that HES1 could be 
involved in down regulating those targets of Notch that can have growth inhibitory 
effects. 
 
The discovery that a peptide, that is recognized by the NICD antibody, and that is of a 
size consistent with the RAM domain of NICD, is present as a stand-alone fragment in 
my cells is unexpected. The finding that the levels of this putative truncated form of 
NICD correlate with the growth of cells is surprising and may suggest that this fragment 
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is involved in promoting cell growth. Johnson et al. from the Barrick laboratory at 
Johns Hopkins University in Baltimore, have shown that the main role of the RAM 
domain is to displace co-repressors from RBPJ upon NICD binding. This then enables 
the RBPJ/NICD complex (along with other co-activators such as MAML1 and p300) to 
activate Notch transcriptional targets (Borggrefe and Liefke, 2012). I propose that the 
stand-alone “RAM” domain could be removing repressors of RBPJ in my cells, more so 
in HSIL-like cells with high levels of “RAM” than in LSIL-like cells with low levels. 
This may lead to the activation of growth-promoting Notch targets (discussed above) 
and thereby allow cells to overcome contact inhibition. 
 
I also have a second “RAM”-related growth theory. While E6 can only reduce the levels 
of full-length NICD (and thereby increase levels of the truncated form), Figure 5.11A 
shows that DAPT decreases both full-length and “truncated NICD”. Based on this, I 
speculate that the growth effects observed in my cells may be dependent on the “RAM” 
vs. NICD ratio as opposed to the precise levels of each protein itself. However, this 
needs to be investigated further. 
 
In this chapter I have shown that the negative effect of E6 on NICD levels is very big, 
with an approximate 50 to 100-fold decrease in levels, while all the downstream targets 
are associated with much smaller effects. For instance, RBPJ promoter activity is 
enhanced 2.6-fold in the presence of E6 while HES1 mRNA levels, between LSIL- and 
HSIL-like cells, are even less different. These distinct results together might indicate 
that E6 is having other growth-promoting effects that I have not yet considered. Recent 
findings (Howie et al., 2011) have shown that E6 from primarily HPV5 and 8, but also 
type 16, can bring about degradation of the tumor suppressor p300. This is achieved by 
binding of E6 directly to the protein and inhibiting its interaction with AKT. AKT 
phosphorylates p300 and this is essential for maintaining the stability of the latter. As 
p300 is associated with various signaling pathways, including some that are involved in 
proliferation and cellular differentiation, even small changes in its levels are associated 
with profound effects on the whole cell. For instance, it has been shown in human 
foreskin keratinocytes, that loss of p300 is associated with delayed onset of 
differentiation, the ability of cells to re-enter the cell cycle and also increased growth 
potential (Wong et al., 2010). Another study has found that cell-cell adhesion is also 
lost (Krubasik et al., 2006). Furthermore, for 16E6 specifically, it has been proposed 
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that shRNA-mediated knock-down of p300 is associated with the transcription of 
hTERT and subsequent telomerase activity (James et al., 2006). Hence, based on this, it 
seems reasonable to test in my cell lines whether this specific effect of E6 is involved in 
giving rise to the distinct patterns of proliferation I have observed.  
 
All in all, the data have shown that high levels of E6 lead to rapid proliferation in the 
context of cell-cell contact. This is associated with up-regulation of RBPJ-dependent 
transcription and also down-regulation of NICD. I hypothesize that increased 
transcription arises because of the ability of the putative “RAM” domain to displace 
repressors from the RBPJ complex (Johnson and Barrick, 2012). This enables 
transcriptional activation of growth promoting Notch targets, such as AP-1, which may 
be involved in bringing about the differential proliferation phenotypes between LSIL-
like cells, with low E6 levels, and HSIL-like cells, with high E6 levels. 
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Chapter 6: Final Discussion 
 
6.1 Project background and rationale 
Previous work by Isaacson Wechsler et al. in 2012 showed that HPV16-containing 
episomal NIKS cell lines spontaneously present with two rafting phenotypes; one set of 
cell lines has a gene expression pattern that resembles a LSIL lesion while the others are 
reminiscent of an HSIL, according to the viral gene expression patterns which were 
previously characterized by Middleton et al. in 2003. The authors further showed that in 
monolayer culture, the HSIL-like cells have the capacity to grow faster than LSIL-like 
cells from the point of confluence onwards when cell-cell contact is abundant. The aim 
of my work was to further characterize these cell lines and to investigate the underlying 
mechanism causing the differences between them. I anticipated that this could provide a 
useful insight into neoplastic progression: the changes that occur as a lesion develops 
from a low-grade infection associated with a productive viral life cycle, to a high-grade 
one with an abortive life cycle. 
 
6.2 The HPV16 E6 protein on its own can drive keratinocytes to proliferate in a 
monolayer growth environment 
The first aim of this study was to determine whether differences in E6/E7 levels are 
responsible for the LSIL- and HSIL-like phenotypes. I show here, surprisingly, that E6 
on its own can cause the enhanced growth of keratinocytes, whilst E7 is unable to 
increase proliferation of my cells in normal culture conditions. E7 is the oncoprotein 
that is classically associated with driving cell cycle progression due to its well 
characterized ability to bind to and degrade the Rb protein (Dyson et al., 1989, Munger 
et al., 1989) and thereby bring about release of E2F (Boyer et al., 1996) and components 
required for G1/S transition (Zerfass et al., 1995). However in my model system, the 
levels of E7 protein are not different between the two types of cells that show different 
growth rates. In contrast, the levels of E6 are elevated in the HSIL-like cells compared 
to the LSIL-like cells, from confluence onwards. I further tested this growth-promoting 
function of E6 using cells expressing either one of the two oncoproteins individually in 
the absence of the viral genome. This confirmed that in my standard cell culture 
conditions, E6 on its own has the capacity to enhance proliferation. 
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To investigate the inability of E7 to drive proliferation of my cells, I considered the 
normal environment of HPV, the stratified epithelium. E7 generally fulfills its 
growth-promoting role in the suprabasal layers of the epithelium, where cells would 
normally be differentiating. In these cell layers the levels of growth factors are much 
lower than in the basal layer, where many cells are mitotically active even in the 
absence of the virus. During normal cell culture, cells are surrounded by a high 
concentration of growth factors due to the inclusion of FBS and EGF in my keratinocyte 
growth medium. EGF signals through the ERK1/2 pathway of the MAPK system 
(reviewed in (Shirakata, 2010)), which leads to cyclin D activation (Dhillon et al., 
2007). Cyclin D then interacts with both CDK4 and CDK6 to, bring about the release of 
E2F from Rb (reviewed in (Sherr, 1994)). E2F induces the expression of other S phase 
promoting genes, such as cyclin A and CDK2 (Soucek et al., 1997), leading to cell cycle 
progression (reviewed in (Woo and Poon, 2003)). Hence I hypothesized that in the 
normal monolayer environment, the high concentration of growth factors, reminiscent 
of the basal layer, makes the function of E7 largely redundant as E2F is already fully 
released. Based on this I showed that in a growth-factor diminished environment, which 
resembles the suprabasal layers, E7 can promote cell proliferation because in this 
situation the degradation of Rb, brought about by E7, leads to the release of E2F. 
Hence, I conclude that cell culture conditions have to mimic the normal environment of 
the virus in order for the normal growth-promoting function of E7 to be observed. 
Interestingly, the effects of E6 are independent of the presence of growth factors, 
suggesting that E6- and E7-induced growth effects occur through different mechanisms. 
 
While the role of aberrant E6 levels in promoting malignancy has been studied 
extensively, this has predominantly been done in transformed cells and non-
keratinocytes. In contrast, this study uses non-transformed keratinocytes, which can 
support the full viral life cycle in raft culture (Flores et al., 1999) and, importantly, 
contain viral episomes. This is in contrast to fibroblasts that cannot stratify into an 
epithelium, and also cervical cancer cell lines such as CaSki, SiHa and HeLa that are 
associated with integrated HPV genomes. This means that I could the cell line model to 
characterize the full productive life cycle and also early events during life 
cycle deregulation.  
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My data show that the induction of proliferation by E6 is associated with increased 
cyclin A levels, which is in accordance with published findings in fibroblasts by 
Malanchi et al. in 2002 and 2004. However, my work with the E6SAT mutant, which is 
unable to bring about the degradation of p53, has shown that cyclin A is not always 
found at high levels in E6-stimulated cells. While E6SAT-expressing cells have the 
same growth potential as wild type E6-expressing cells they do not express high levels 
of cyclin A. This suggests that whilst cyclin A activation may correlate with wild type 
E6-induced proliferation, it is not in itself causative of the increased proliferation. That 
cyclin A appears elevated in the presence of increased cell proliferation, is perhaps not 
surprising, as any mechanism that drives cells either to transit G1 faster, or have a 
greater propensity to enter S phase, will result in elevated cyclin A. It is not clear why 
cyclin A is not elevated by the E6SAT mutant, but may be due to suppression of cyclin 
A expression by p53 (Yamamoto et al., 1994). Since the different cyclins are known to 
be able to substitute for each other (Geng et al., 1999, Masamha and Benbrook, 2009), 
lack of cyclin A, per se, is not a problem for cell cycle progression, and this indeed 
appears to be the case in the NIKS SAT mutant.  
 
My work further shows that NIKS cells expressing only E6 and also HSIL-like cells, 
have lower levels of p21 than the empty vector LXSN control and the LSIL-like clone, 
respectively. This suggested initially that p21 levels might correlate with cell growth as 
shown by Malanchi et al. in 2004 and also Shai et al. in 2007. However, the E6SAT 
mutant showed not only that the expression of p21 is dependent on p53, but also that in 
these p53-degradation deficient cells, the levels of p21 are high. Again this suggests that 
whilst decreased p21 levels can appear to correlate with wild type E6-induced 
proliferation, the decrease in p21 levels is not necessarily causative of increased growth 
potential. While most work focusing on p21 has shown that it negatively regulates cell 
cycle progression and, hence, inhibits growth (reviewed in (Abbas and Dutta, 2009)), in 
certain situations it has been attributed oncogenic activities. The protein is over-
expressed in a variety of human cancers, including that of the cervix (Cheung et al., 
2001). Moreover, other studies suggest that p21 localization can have an effect on its 
precise function. While the growth-repressive role of p21 is carried out predominantly 
by its nuclear fraction, the cytoplasmic pool has oncogenic potential, for instance during 
breast carcinogenesis (Zhou et al., 2001, Winters et al., 2003). All these observations 
together are supportive of my data and show that even in the presence of high levels of 
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p21, proliferation of cells is possible in certain situations. Hence, the fact that E6SAT-
expressing cells are associated with both fast growth potential and high p21 levels does 
not pose a problem in that respect. 
 
My data are in accordance with previous work that showed almost 20 years ago, that E6 
can enhance cell growth (Ishiwatari et al., 1994, Inoue et al., 1994, Inoue et al., 1998, 
Song et al., 1999), and that various cell cycle proteins are affected, (Malanchi et al., 
2002, Malanchi et al., 2004, Shai et al., 2007). However my analysis has extended what 
is known by showing that it is not necessarily the effects on cyclin A and p21 that are 
responsible for E6-induced proliferation in keratinocytes.  
 
As discussed throughout this study, I believe that in my cell culture model a confluent 
monolayer resembles the basal layer of the epidermis in terms of cell density. This 
theory and the dependency of LSIL- and HSIL-like growth phenotypes on cell-cell 
contact add a great deal of significance to my model. I speculate that the effects of E6 
and E7 observed in the various monolayer conditions can be used to infer the functions 
of the oncoproteins in the epithelium. Hence, I hypothesize that in a stratified 
epithelium, E6 can induce rapid cell growth, and thus promote neoplasia in many cells 
layers, irrespective of the presence of extracellular growth factors, while the function of 
E7 may be limited to the upper layers where growth factors are sparse. My raft culture 
data with cells expressing only E6 seem to support this theory. Compared to empty 
vector control rafts, the number of MCM7-positive cells (delineating cells that are in 
S phase) in both the basal and suprabasal layers, is much higher for E6-expressing cells. 
 
6.3 The manipulation of E6 levels has a corresponding effect on proliferation 
Having shown that the underlying difference between the LSIL- and HSIL-like cells is 
the E6 level, I then wanted to move on to my second objective and test whether 
changing the levels of E6 would have the predicted effect on cell growth. To this end I 
transfected cells with a plasmid vector expressing high levels of E6 and showed that the 
resulting populations grew to a higher density than HSIL-like cells. While doing these 
experiments I also showed that, in accordance with a previously postulated hypothesis 
in my laboratory (Nicolaides, 2011), high levels of E6 seem to promote loss of the viral 
episomes. This observation has recently been reported in the literature (Kho et al., 
2013).  
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Subsequently, I used RNAi to knock-down E6 levels in HSIL-like cells and showed that 
when levels of E6 are very low, these cells do not have the capacity to grow 
significantly faster than NIKS cells treated with control siRNA. This line of work 
further confirmed that high E6 levels do not merely correlate with a high growth 
potential of cells but seem to be the underlying cause of the observed phenotypes.  
 
6.4 Notch signaling, as perturbed by E6, is involved in overcoming cell-cell contact 
inhibition 
The third and final aim of my work was to investigate which function of E6 is involved 
in promoting proliferation. I decided to assess the Notch pathway due to its known role 
in repressing epithelial cell growth and initiating differentiation (reviewed in (Watt et 
al., 2008)). 
 
I found that the high levels of E6 associated with the fast growing HSIL-like cells, 
correlate with low levels of NICD. An inhibitory effect of E6 proteins from other HPV 
types on Notch signaling has previously been found in several independent studies 
(Brimer et al., 2012, Tan et al., 2012, Meyers et al., 2013). Using gamma secretase 
inhibitors (GSIs), to block formation of NICD, I found that the precise kinetics of cell 
growth resulting from Notch inhibition are not as anticipated. However, the GSIs cause 
a reduction in the divergence between the LSIL- and HSIL-like growth phenotypes. 
Notch signaling, as regulated by gamma secretase, is involved in negatively controlling 
cell proliferation at a high cell density. Hence, the effects of both GSIs used seem to be 
greater in cells that, as a result of high E6 levels, grow more rapidly. These results 
confirm that low NICD levels correlate with high E6 levels in such a way that is 
conducive to rapid proliferation, though I have not yet shown that repressed Notch 
signaling is the underlying cause of cell growth.  
 
The work of the other groups that have assessed the effect of E6 on the Notch pathway 
(Brimer et al., 2012, Tan et al., 2012, Meyers et al., 2013) has shown that E6 from 
bovine papillomaviruses (BPV) and/or βHPV8 can bind MAML1 (one of the 
transcriptional co-activators of NICD) and thereby negatively affect activation of Notch 
target genes. None of these studies have found a direct association between NICD and 
E6. Additionally, one group (Tan et al., 2012) has carried out some preliminary analyses 
with 16E6 and shown that this protein is not associated with the same mechanism. 
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Based on this I decided to assess Notch promoter activity in the NIKS cells to determine 
whether 16E6 could regulate transcriptional activation of Notch targets by reducing 
NICD levels. Surprisingly, my results indicate that in HSIL-like cells Notch signaling 
through the RBPJ promoter is significantly enhanced by E6. Additionally, the levels of 
HES1 mRNA, one of the targets of the NICD transcriptional activation complex, are 
higher in HSIL-like cells with high levels of E6, than in LSIL-like cells that are 
associated with less E6. Hence, the results of my experiments to this point seem to be in 
direct conflict with each other. On the one hand, E6 can reduce NICD, which should 
repress Notch signaling, while on the other hand, E6 seems to augment Notch promoter 
activity. As discussed above, the lack of HPV16 E6-dependent repression of Notch 
transcriptional targets has previously been reported (Tan et al., 2012) and my data 
support this view. This suggests that 16E6 has evolved a different mechanism for 
disrupting the Notch pathway. 
 
The presence of an apparent truncated form of NICD, the putative “RAM” domain, may 
yet resolve the issue of my seemingly contradicting data. My results show that the 
levels of this putative “RAM” domain correlate with the growth of cells, in that high-
level E6-expressing cells are associated with more “RAM” than LXSN control cells. 
This suggests that in fast-growing cells, high E6 levels may promote degradation of 
NICD in favor of the stand-alone putative “RAM” domain. This then leads to increased 
transcriptional activation of Notch target genes, presumably due to the higher levels of 
“RAM”. There are several ways by which high levels of the “RAM” domain could 
theoretically promote transcription of Notch target genes. The first possibility, discussed 
briefly at the end of Chapter 5, is based on findings by Johnson et al. in 2012. In the 
absence of Notch, RBPJ is a repressor complex (Dou et al., 1994) and can inhibit 
transcription of its target genes through the recruitment of histone deacetylase HDAC1 
(Kao et al., 1998). The role of RAM is to bind with high affinity to RBPJ and displace 
co-repressors, to promote formation of the activator complex (Johnson and Barrick, 
2012). In this first scenario, the binding of “RAM” to RBPJ would not allow the full 
length NICD protein (containing both RAM and ANK domains necessary for promoting 
transcriptional activation) to bind to RBPJ. While the “RAM” domain alone may not 
actively drive transcription, it could still bring about de-repression of transcription of 
growth promoting Notch target genes, leading to proliferation. A second option is that 
the “RAM” domain, which I estimate to be approximately 50- to 100-fold more 
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abundant than full-length NICD, can bind to RBPJ and thereby inhibit NICD from 
binding and recruiting MAML1 and other co-activators to growth-repressing Notch 
target genes. Without further analysis, I cannot rule out the possibility that, as the 
putative “RAM” domain arises from cleavage of full-length NICD, it may actually be 
the other half of the NICD (i.e. the ANK domain, which my antibody does not detect) 
that is the active fragment. Based on my results to date I propose that the first option, in 
which “RAM” leads to de-repression of the activation of transcriptional targets, is most 
likely. It seems that in NIKS cells, Notch signaling can bring about expression of genes 
that actively promote growth. Growth promoting effects of the Notch pathway have 
been described through activation of AP-1 (Henken et al., 2012), histone 
methyltransferases (Hsu et al., 2012) and also by the activation of a subset of Notch 
targets through HES1 (Dudley et al., 2009).  
 
I also detected the putative “RAM” domain in another keratinocyte cell line and also in 
primary cervical cells, and I speculate that the fragment may play a significant role in 
Notch signaling in many other cell types. Hence, assessing the expression patterns of 
the putative “RAM” domain as part of all experiments investigating Notch signal 
transduction, may help shed light on the divide in the HPV field pertaining to the exact 
involvement of this pathway in cervical neoplasia.  
 
6.5 The role of adherens junctions in deregulating Notch signaling  
As explained in more detail in the Introduction, one of the main types of adhesive 
junctions, which are found at cell-cell contact sites, is the adherens junction, whose 
main component is the cell receptor E-cadherin (reviewed in (Balda and Matter, 2003)). 
Adherens junctions allow adjacent cells to bind to each other and are implicated in roles 
such as contact inhibition, cell polarity and adhesion. Both E6 and E7 can reduce the 
levels of E-cadherin (Matthews et al., 2003, Yuan et al., 2009, Laurson et al., 2010) and 
as such affect the overall formation and efficacy of the junction and hence downstream 
pathways. Two other components of the junctions are α- and β-catenin, with the latter 
also being an important cellular transcription factor. Both hDlg and hScrib, two PDZ 
proteins that high-risk E6 can associate with and target for degradation, localize to 
adherens junctions to stabilize the link between the catenins and E-cadherin (Qin et al., 
2005). Additionally, the PDZ protein MAGI-1 can also be found at the site of adherens 
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junctions (Dobrosotskaya and James, 2000, Ivanova et al., 2007). While I have not 
assessed the levels of E-cadherin in my cells in this study, I have done some work with 
an E6 mutant (E6∆PDZ) that lacks the PDZ motif and is unable to bind these proteins. 
During a growth assay with this cell population I found that it grows slower than wild 
type E6-expressing cells. Although this difference may result from the lower stability of 
the mutant E6 protein, it might also reflect a role for PDZ proteins in E6-induced 
proliferation. Reduced PDZ protein degradation by this E6 mutant could result in more 
intact cell polarity, adhesion and cell-cell contact inhibition pathways. As both hDlg and 
hScrib localize to adherens junctions and enable their correct formation, I speculate that 
degradation of these two proteins by E6 promotes abnormalities in junction formation 
and hence contact inhibition, thereby contributing to the ability of E6 to allow cells to 
proliferate to a high cell density. 
 
Additionally, based on the known effects of E6 on E-cadherin (Matthews et al., 2003), I 
hypothesize that this interaction further destabilizes adherens junctions. According to 
this theory and my observations with the E6∆PDZ mutant, I suggest that the presence of 
E6 prevents normal junction formation or, at the very least, significantly slows down 
the process. This has negative effects on cell adhesion, polarity and cell-cell contact 
recognition and hence the normal downstream pathways associated with high cell 
density. Hence I propose that the effects of E6 on Notch signaling that I have described 
here may not be brought about directly by the interaction of E6 with components of the 
Notch pathway, but as a downstream result of disrupted adherens junctions. A study 
showing that the Delta-like 1 ligand of Notch can localize to adherens junctions in a 
MAGI-1-dependent manner to activate Notch signaling in adjacent cells (Mizuhara et 
al., 2005) seems to be supportive of this theory. It would suggest that degradation of the 
MAGI-1 protein by E6 and subsequent lack of Delta-like 1 presentation on the cell 
surface can lead to reduced Notch activation and hence promote proliferation.  
 
6.6 Overall conclusions 
E6 is a viral protein that is necessary for the productive viral life cycle. When expressed 
aberrantly it can contribute to neoplastic progression and malignant transformation of 
cells. In this study I have used a unique monolayer cell line system to show that the 
HPV16 E6 oncoprotein on its own can promote keratinocyte cell growth and that high 
levels of E6 seem to be associated with the progression from a LSIL- to an HSIL-like 
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growth phenotype. My data also suggest that E6-dependent proliferation correlates with 
high levels of a putative truncated form of NICD and also augmented activity of Notch-
responsive promoters. Moreover, my experiments using gamma secretase inhibitors 
indicate that the gamma secretase complex itself, and downstream targets other than 
those involved in Notch signaling, have strong effects on cell proliferation. Hence, I 
propose that signaling through gamma secretase and the Notch pathway is involved, at 
least in part, in giving rise to the growth patterns, although I have not yet established 
whether it is the underlying cause.  
 
Based on my data and the known effects of E6 on adhesive junctions, I further 
hypothesize that the growth phenotypes may not only be brought about directly by the 
interaction of E6 with components of the Notch pathway, but as a downstream result of 
disrupted adherens junctions. According to this theory, HSIL-like clonal cell lines, due 
to the higher levels of E6 associated with these cells from confluence onwards, have a 
less intact apical junctional complex than LSIL-like cells, leading to their differential 
responses to contact inhibition. This is manifest through an effect on Notch signaling. 
According to this model, it is likely that deregulation of the Notch pathway directly by 
E6 is not the only underlying cause of high cell density proliferation. This means that, 
although not investigated here, other pathways involved in contact inhibition, for 
instance the Hippo pathway (discussed in the Introduction), may also be affected. This 
theory, if proven to be correct, may explain some of the more multi-faceted results 
associated with Notch signaling that I have not been able to explain in full so far.  
  
The monolayer experiments in high and low level growth factor environments seem to 
suggest that the role of HPV16 E7 is redundant in the presence of high concentrations 
of growth factors, as both E7 and growth factors target the same point in the cell cycle. 
However, in a growth factor diminished environment, which is reminiscent of the 
suprabasal layers of the epithelium, E7 is able to fulfill its normal function. Based on 
current literature, and the fact that in my experiments E6 can drive growth irrespective 
of the presence of growth factors, I hypothesize that E6 and E7 have distinct effects on 
proliferation. E6 can push cells through the cell cycle more quickly, via the pathways 
proposed above, to bring about enhanced proliferation while the role of E7 is to push 
quiescent cells into cycle, in an environment that is associated with low levels of growth 
factors, such as the suprabasal layers.  
Chapter	  6:	  Final	  Discussion	  	  
	   222	  
Due to the established role of aberrant E6 expression in promoting HPV-dependent 
malignancy, the E6 protein has been subject of considerable work. Moreover, a role of 
E6 in driving the proliferation of cells specifically has been described before. However, 
in most cases these observations have been made by overexpressing E6 alone either in 
cervical carcinoma cells, fibroblasts or transgenic mice. This study has uniquely 
modeled this function of E6 in episomal HPV16-expressing keratinocytes. The fact that 
I am using LSIL- and HSIL-like cell lines that consistently give rise to distinct growth 
patterns, due to differences in E6 protein levels, in a cell-cell contact dependent manner, 
means that they can be used to model neoplastic progression.  
 
6.7 Future work 
 
6.7.1 Investigating whether the pathways disturbed by E6 in monolayer are also 
increasingly deregulated during neoplastic progression 
The aim of my future work is to determine by which mechanism(s) E6 can drive cell 
growth in monolayer. Once that has been established, I want to show that the pathways 
disrupted in this environment are also affected in a similar way in a stratified epithelium 
and, hence, the site of HPV infection. This involves several different approaches: 
 
1) To show that the pathways deregulated by E6 to give rise to the LSIL- and HSIL-like 
growth patterns are also instrumental in driving the corresponding rafting phenotypes, I 
will use the LSIL- and HSIL-like rafts (Isaacson Wechsler et al., 2012) to stain for 
NICD levels and also adherens junction formation using E-cadherin. 
 
 
2) To ensure that the pathways affected by E6 in NIKS are not part of a cell-type 
specific effect, I will use other cells, including primary cervical keratinocytes, to show 
that the same pathways are similarly altered.  
 
This line of investigation is also important as it was shown recently that a specific 
population of cells at the squamo-columnar junction of the cervix, is associated with 
most, if not all, cervical carcinomas (Herfs et al., 2012). This suggests that neoplastic 
progression and HPV-associated malignancy may be dependent on the precise cellular 
environment. 
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3) I will test whether the same pathways perturbed in the monolayer environment, and 
presumably LSIL- and HSIL-like raft cultures, are also altered in real cervical biopsies. 
According to my model the level of deregulation should be higher in high-grade 
cervical lesions than in low-grade lesions.  
 
6.7.2 Gaining more insight into the role E7 
My results suggest that the ability of E7 to carry out its main role, of bringing about the 
release of E2F from Rb, is dependent on its precise extracellular environment. I want to 
test my hypothesis and confirm that the role of E7 is limited to suprabasal layers of the 
epithelium. The experiments to further my knowledge in this respect include:  
 
1) Attempting the knock-down of cyclin D by RNAi. This will allow me to test my 
theory that both E7 and growth factors bring about the expression of cyclin D by 
releasing E2F from Rb.  
 
2) I will try to establish which type of growth factor(s) is involved in mediating cell 
growth. I supplement my NIKS growth medium with pure EGF and IGF. However, 
FBS, that is also included, contains a variety of growth factors that could be involved in 
promoting proliferation. 
 
3) I speculate that the effect of growth factors is dose-dependent. Therefore I will use 
various different concentrations of EGF, IGF and/or FBS, mimicking the different cell 
layers of the epithelium that are associated with a growth factor gradient, to determine 
at which concentration E7 is able to fulfill its role, at least in part.  
 
4) To further assess whether the growth factors in the growth medium and E7 are in fact 
targeting the same downstream effectors, I will use an E7 mutant that is unable to bind 
to and bring about the degradation of Rb. If my hypothesis is correct then this mutant 
form of E7 should not be able to promote cell cycle entry even in a growth-factor 
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6.7.3 Characterization of the putative “truncated NICD” 
It remains important to conclusively establish whether the putative “RAM” domain, is a 
truncated form of NICD and whether it is pivotal in bringing about the LSIL- and 
HSIL-like growth phenotypes. Doing this involves a number of different experiments: 
 
1) To further characterize the putative “RAM” domain I will be challenging my western 
blots with other anti-NICD antibodies to different sites on the RAM domain, and using 
mass spectrometry to analyze the fragments immunoprecipitated by my antibody.  
 
2) To determine whether the “RAM” domain can enhance proliferation and/or 
transcription in cells, I will be expressing the RAM domain from a plasmid vector that I 
have obtained from Doug Barrick (Johns Hopkins University, Baltimore, USA). 
Initially this will be done in easily transfectable cells, but with the aim of eventually 
analyzing the effect in NIKS. 
 
3) The presence and levels of other truncated NICD species will also be assessed using 
antibodies to sites external to the RAM domain. In particular, as the ANK domain is the 
main player involved in binding to RBPJ, it is of interest to investigate whether this 
domain too is found on its own and the extent to which it correlates with E6-dependent 
cell growth. 
 
4) It has been shown that in certain situations the NICD can be cleaved at other 
proteolytic cleavage sites (Cohen et al., 2005, van Tetering et al., 2011), giving rise to 
various different species, and it is hypothesized that these may have different biological 
properties. It will be interesting to see if the apparent lack of NICD in the presence of 
E6 is in fact just a failure of my antibody, which is specific to a particular cleavage 
event, to recognize other forms of NICD that may be present.  
 
5) I have some additional preliminary observations (data not shown) that suggest that 
the levels of the putative “RAM” domain are affected by proteasome inhibition (with 
MG132), in an E6-dependent manner. This suggests that E6 may direct the NICD to the 
proteasome to bring about degradation of NICD and increase the levels of the “RAM” 
domain, and it will be important to further test this. 
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6) Additionally, if I can find a protease inhibitor that specifically blocks “RAM” 
formation without having any adverse effects on cells, this would be another way of 
assessing whether high levels of the putative “RAM” domain are causative in the rapid 
proliferation of high-level E6-expressing cells. I could start, for instance, by inhibiting 
the granzyme B (van Tetering et al., 2011) and caspase-3 and -6 (Cohen et al., 2005) 
proteolytic cleavage sites between the ANK and RAM domains. 
 
6.7.4 Dissecting the role of adherens junctions in mediating the effects of E6 on 
Notch signaling 
I hypothesized earlier that the effects of E6 on the Notch pathway may not be brought 
about by E6 directly affecting Notch signaling but actually as a consequence of 
disrupted adherens junctions. I now want to investigate this further and determine 
whether in the LSIL- and HSIL-like cells adherens junctions are differentially intact.  
 
1) To determine whether the junctions are disrupted I will stain confluent E6-expressing 
monolayer cells with antibodies to adherens junction proteins, starting with E-cadherin, 
as it has been shown to be affected by the presence of E6 in previously published 
studies. Additionally I will also assess β-catenin levels, as β-catenin signaling may be 
altered by the effects of E6 on E-cadherin or though Wnt signaling, via both PDZ-motif 
dependent (Matsumine et al., 1996, Ishidate et al., 2000, Takizawa et al., 2006, 
Nagasaka et al., 2006) and independent (Lichtig et al., 2009) mechanisms. 
 
Other targets for staining would include the PDZ proteins hDlg, hScrib and MAGI-1. 
Most studies looking at the effect of high-risk E6 on these PDZ proteins have been done 
in vitro or using over-expression systems. However, other work that has assessed the 
levels of endogenous PDZ proteins in response to HPV31 genome transfection has 
shown no effect on E6 (Lee and Laimins, 2004). Therefore, the function of the 
PDZ-binding motif of E6 in vivo remains unclear and hence interpreting the results of 
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2) I will also assess the levels of adherens junction proteins by western blot. If I find 
that E-cadherin levels are affected by E6 in my cells then I can increase them using 
drugs, such as Indole-3-carbinol and 5-Aza-2'-deoxycytidin. These have been shown to 
reinstate normal levels of E-cadherin (D'Costa et al., 2012a, D'Costa et al., 2012b) in 
response to HPV-dependent depletion. I expect that this would have a negative effect on 
the growth potential of cells.  
 
3) To determine whether E6-mediated disruption of the Notch pathway is indirectly 
caused by its effects on adherens junctions, I will activate the Notch pathway 
independently of cell-cell contact. To do this I will introduce active Jagged and/or Delta 
ligands to sub-confluent E6-expressing and control cells. If E6 is acting directly on the 
Notch pathway then I should find low levels of NICD, whilst if it is acting via effects on 
adherens junctions, and hence high cell density, then I should find high levels of NICD. 
 
4) The negative effect of E6 on E-cadherin (Matthews et al., 2003) seems to be 
mediated by DNA methyltransferase (DNMT) (D'Costa et al., 2012a). DNMT activity is 
elevated in cells expressing E6 (Au Yeung et al., 2010), and when repressed, normal 
E-cadherin transcription is restored (D'Costa et al., 2012a). Based on these findings, it 
seems worthwhile to assess DNMT levels in my NIKS cells to determine whether 
downstream effects of DNMT could be involved in modulating proliferation. 
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